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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative condition which is 
almost universally fatal. Some sufferers have an identifiable genetic mutation (<2%), but 
the majority of cases are sporadic (SALS). There is a body of evidence suggesting 
involvement of oxidative stress and mitochondrial abnormalities in the pathogenesis of 
ALS.
Mitochondrial function was assessed in remote tissues (muscle, cultured 
myoblasts, cultured fibroblasts) from patients with ALS and controls. Muscle tissue was 
examined for histological features consistent with a mitochondrial disorder. 
Mitochondrial respiratory chain function was measured in mitochondrial homogenates. 
Mitochondrial protein expression was determined using immunofluorescent antibodies to 
a mitochondrial DNA (mtDNA)-encoded respiratory chain enzyme subunit with image 
analysis. MtDNA quantity and quality was assessed using Southern blot and long-range 
PCR. Analysis of inheritance patterns was performed using a database of familial ALS 
cases. No mitochondrial abnormalities were identified using these techniques. There was 
no evidence of anticipation or a sex effect on inheritance.
In order to look for a difference in susceptibility to oxidative stress, cell cultures 
were examined for markers of oxidative damage and apoptosis, following growth with a 
free radical generating agent (paraquat). These studies demonstrated an increased 
susceptibility to oxidative damage in patient myoblasts and fibroblasts. This effect was 
not seen in cybrid studies combining mtDNA from patient platelets with experimental 
cells devoid of mtDNA (p° cells), where no difference in oxidative damage was seen, 
confirming the absence of a systemic mtDNA abnormality.
These results suggest that patients with SALS have an increased systemic 
sensitivity to oxidative stress which becomes pathological in tissues, such as motor 
neurons, which are considered to be vulnerable to such stress due to their metabolic 
activity and structure. This altered sensitivity is due to a factor other than a mitochondrial 
DNA abnormality, such as a nuclear DNA mutation or an unidentified environmental 
factor.
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1 Introduction
1.1 Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) was first described by Charcot in 1869, with a 
clinical description of 2 cases and pathological description of 5 post mortem 
examinations (1). ALS is also known as Motor Neuron Disease (MND) and, in America, 
as Lou Gehrig’s disease, after a well known baseball player who contracted the condition. 
ALS is a neurodegenerative disease of adult onset. In the UK, ALS has an incidence of 
around 2:100 000 annually and a prevalence of 6:100 000 (2). ALS occurs from the age 
of 20 with increasing prevalence with increasing age. The clinical pattern of ALS is that 
of a progressive disease affecting the lower (distal to the spinal cord) and upper (brain 
and spinal cord) motor neurons with sparing of the sensory system (figure 1.1). Weakness 
of the muscles occurs, along with spasticity. Immobiltity, loss of speech and swallowing 
may occur. Any muscle groups may be affected, and death most commonly comes about 
from respiratory involvement within 5 years of the onset of the disease (3). There has 
been, as yet, no specific environmental cause for ALS identified and the underlying 
pathogenesis of the sporadic disease remains to be identified.
Although there is a large degree of heterogeneity in the presentation of the motor 
neuron diseases, the presence of upper motor neuron signs and symptoms usually 
distinguishes ALS from the purely lower motor nerve disorders, such as spinal muscular 
atrophy. The diagnosis is usually made by finding the appropriate clinical features, and 
supported by the demonstration of denervation of muscle on electrophysiological testing
(4). Exclusion of other diseases, such as primary muscle disorders is sometimes required
(5).
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Figure 1.1- Upper and lower motor neurons
From The Muscular Dystrophy Association publications (1997)
- “ALS Care”
ALS may present with bulbar involvement (swallowing and speech abnormalities), 
limb weakness, which can often be asymmetrical, or with the fasciculations that are seen 
in denervated muscles. Degeneration o f  the motor neurons can produce spasticity, 
wasting and weakness o f the affected muscle group. Compromise o f the motor supply to 
the muscles o f  respiration means that for many patients, respiratory failure is the eventual 
cause o f death (2). Respiratory support, through artificial ventilation, may be employed 
with the aim o f prolonging life, although this may be a difficult decision in the overall 
context o f quality o f  life (6).
Pathologically, degeneration of the anterior horn cells within the spinal cord 
with subsequent distal motor neuron death occurs (1). The mechanism by which this 
process occurs is unknown, although a number of possible explanations have been 
suggested. Aberrant glutamate handling, with abnormal excitatory amino acid 
metabolism producing locally toxic agents has been suggested (7), and is considered in 
greater detail below (1.6). A subgroup of patients with familial ALS (FALS) have been 
shown to have a mutation in the superoxide dismutase 1 gene (SOD1) (see section 1.3). 
Protein aggregration within diseased motor neurons has been demonstrated in transgenic 
SOD1 mice to correspond to fragmentation of Golgi apparatus (8). The suggestion from 
this study is that there is a causal relationship between the aggregation of mutant SOD1 
and ubiquitin, fragmentation of the Golgi apparatus of motor neurons and 
neurodegeneration. Oxidative damage mediated by free radical damage (9) has been 
proposed as a mechanism of cell death and is considered in greater detail in the context of 
mitochondrial abnormalities (1.5.2). The local involvement of non-neuronal cells in 
mediation of the disease process has been identified, with non-neuronal cells that do not 
express mutant SOD1 delaying degeneration and significantly extending the survival of 
mutant-expressing motor neurons (10). This raises the possibility that extra-neuronal 
mechanisms may be involved in the disease process.
The involvement of abnormal neuronal protein transport mechanisms in the 
pathogenesis of ALS was suggested by the demonstration of polymorphisms in the C- 
terminal region (11) and deletions in the tail (12) of the human neurofilament heavy 
protein gene in a limited number of individuals with ALS. This is involved in neuronal 
transport mechanisms and, therefore, potentially a number of different neuronal 
preocesses. A frameshift mutation in the peripherin (a neuronal intermediate filament 
associated with inclusion bodies) gene in a small number of patients with ALS supports 
the involvement of disordered transport mechanisms (13). The assembly of the micro- 
tubular elements of the neuronal transport system has been shown to be abnormal in 
SOD1 mice (14), and adds more weight to the aberrant transport hypothesis.
Although there are differing theories as to the cause of motor neuron death in ALS, it 
seems difficult to delineate discrete mechanisms (15).
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At the present time, there is no curative treatment available for ALS. Riluzole is 
licenced for the treatment of the disease. It is thought to act by the inhibition of glutamate 
release (see 1.6) and may prolong life in patients with ALS for around 2 months when 
compared with a placebo (16).
1.1.1 Other Motor Neuron Diseases
ALS is a motor neuron disease with a clinical spectrum which includes primary 
lateral sclerosis (PLS) and progressive muscular atrophy (PMA). PLS is a purely upper 
motor neuron disease, PMA is a purely lower motor neuron disorder. There are rarer 
syndromes which may involve an ALS-type of clinical picture, with upper and lower 
motor neuron involvement, in association with more unusual features. Western Pacific 
ALS is a constellation of the classical motor neuron pattern of involvement seen in ALS 
with associated progressive dementia (17). The Parkinsonism-dementia complex found in 
Guam involves a disease phenotype which may contain elements of ALS along with 
Parkinsonian features and cognitive involvement (18). The genetic basis of this disease 
has yet to be elucidated (19). A combination of upper and lower motor neuron 
involvement with urinary incontinence, sensory disturbance and dementia is seen in 
polyglucosan body disease, due to the accumulation of PAS-positive polyglucosan bodies 
(PB) of various sizes and shapes in the cerebral hemispheres, brainstem, cerebellum, 
spinal cord, nerve roots and nerves (20). A syndrome of motor neuronopathy with 
cataracts and skeletal abnormalities has been described in a single 4-generation family 
(21). Although these diseases are relatively rare, when compared with ALS, their 
existence demonstrates that upper and lower motor neuron pathology can occur in 
conjunction within disease phenotypes other than ALS.
1.2 Mitochondria
Mitochondria are thought to have arisen from aerobic bacteria which colonised 
eukaryotic cells 108 years ago (22). This is known as the “endosymbiont hypothesis” and
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proposes that the mitochondria that populate eukaryotic cells were once free-living 
bacteria that formed a symbiotic relationship with the eukaryotic progenitor cells about 
20 x 108 years ago, when atmospheric oxygen concentration was increasing. These 
bacteria gradually lost their independence, becoming subservient to the nuclear genome. 
This is supported by the fact that mitochondria retain several “primitive” features that are 
also found in modem bacteria. However most of the original mitochondrial genome has 
long since been moved to the nuclear DNA. Mitochondria are dependent on numerous 
different proteins imported from the cytosol.
Mitochondria are composed of four compartments; an outer membrane, an inner 
membrane, the intermembrane space between the outer and inner membranes, and the 
matrix which is the region inside the inner membrane (23).
Mitochondria are organelles present in every cell in the body (including platelets). 
They are the major site of ATP production, through the five oxidative phosphorylation 
(OXPHOS) enzyme complexes located on the inner membrane of the mitochondrion. 
Mitochondria have their own genome. Mitochondrial DNA (mtDNA) is a double­
stranded DNA molecule of 16,569 base pairs (figure 1.2). This encodes 13 polypeptides 
of the OXPHOS system, with the remaining 73 polypeptides being encoded by the cell 
nucleus (figure 1.3) (24). Components of complex I (NADH ubiquinone reductase), III 
(ubiquinol cytochrome c reductase), IV (cytochrome c oxidase) and V (ATP synthase) are 
encoded for by the mtDNA, whereas complex II (succinate ubiquinone reductase) is 
entirely encoded by the nuclear DNA. Differences in base excision repair mechanisms 
mean that mtDNA is more vulnerable to oxidative stress than nuclear DNA (25). It is also 
thought that the proximity of the mtDNA molecule to the generative sites of reactive 
oxygen species (through the mitochondrial electron transfer system) means that the 
mtDNA is more vulnerable to damage from free radicals than nuclear DNA (26), which is 
located some distance from the point of ATP generation.
Cells contain many thousands of copies of the mtDNA molecule. A mutation of the 
mtDNA molecule may be present in only a portion of the mtDNA molecules present in 
any one cell. This is important in mitochondrial disease where disease expression only 
comes about where a threshold of mutated mtDNA is reached (see 1.2.1).
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Figure 1.2 The mtDNA molecule showing encoding regions for the different proteins. 
The outer circle represents the heavy (H) strand -  i t ’s origin o f replication (Oh)  is shown 
as is the origin o f replication (Oi) o f the inner, light strand. ND1, 2, 3, 4, 4L, 5 and 6 are 
the genes ecoding subunits o f NADH dehydrogenase; COI, II, III encode subunits o f  
cytochrome c oxidase; cyt b encodes the cytochrome b component o f ubiquinol 
cytochrome c reductase; MTERF=Mitochondrial transcription termination factor; 
ATPase6 and ATPase 8 are subunits o f complex V (ATP synthase). The tRNA genes are 
shown as black dots and are labelled with the single character for the Amino Acid the 
tRNA picks up and delivers to the Ribosome during protein synthesis (courtesy o f Dr JW 
Taanman).
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Apart from energy production and attendant free radical generation, the mitochondria 
have a role in intracellular calcium homeostasis. Calcium sequestration by the 
mitochondria is thought to stimulate and control the rate of oxidative phosphorylation, to 
regulate the opening of the mitochondrial permeability transition pore (MPTP) and
a  *
perhaps apoptotic cell death, and to modify the shape of cytosolic Ca pulses or 
transients (27) . The movement of calcium through the mitochondrial membrane is, 
therefore, thought to be related to regulation of ATP generation and apoptosis signaling.
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Figure 1.3 The mitochondrial respiratory chain complexes I-V on the inner 
mitochondrial membrane demonstrating the electron transfer system (complexes I  to IV), 
the proton cycle and the contribution o f mtDNA- and nuclear DNA-encoded components 
(shown in red and blue, repectively) to each complex. CoQ is co-enzyme Q; cyt c is 
cytochrome c. The generation o f reactive oxygen species (ROS) resulting from electron 
transfer is shown. ATP7B is ATPase, Cu2+ transporting, beta polypeptide.
From: Schon, E.A., Manfredi, G. 2003. Neuronal Degeneration and Mitochondrial 
Dysfunction. J. Clin. Invest. 111:303-312.
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MtDNA is transmitted through the female germ line (28). Although a single case of 
partial paternal transmission has been reported (29), inheritance of paternal mtDNA is 
considered exceptionally rare (30,31). Therefore, diseases associated with with mtDNA 
mutations generally display maternal inheritance.
1.2.1 Mitochondrial Diseases
There are a number of disorders associated with abnormalities of the mitochondrial 
organelle or the mtDNA contained therein. These are called “mitochondrial diseases”. 
Although many discrete diseases of this type have been described, they often share 
common features, such as deafness, seizures and short stature, with the phenotype not 
being readily associated with the genotype (32). Mitochondrial diseases may arise from 
mutations in the mitochondrial genome or mutations in the nuclear genome which 
encodes mitochondrial components. Specific point mutations of the mtDNA can cause 
disease. The most common mutations occur in the tRNA genes. The A3243G mutation in 
the 3 tRNAleu (UUR) gene accounts for 80% of cases of MELAS (33) (mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes), for example. Other diseases 
caused by mtDNA point mutations include maternally inherited Leigh’s syndrome (34), 
Leber’s hereditary optic neuropathy (35) and NARP (36) (neuropathy, ataxia and retinitis 
pigmentosa).
Diseases caused by deletions of mtDNA are usually due to large deletions involving 
both tRNA and protein encoding mitochondrial genes. Disorders caused by single 
deletions of mtDNA include Kearns-Sayre syndrome (37) and sporadic ocular myopathy 
(38). Multiple mtDNA deletions are found in patients with inclusion body myositis (39) 
and autosomal dominant progressive external ophthalmoplegia (40).
Mitochondrial genetic disorders may demonstrate a phenomenon whereby the 
phenotype changes when the threshold of mtDNA abnormalities in a previously 
unaffected tissue is surpassed (41). The threshold for the development of disease is lower 
in tissues highly dependent on oxidative metabolism such as the brain, heart, skeletal 
muscle, retina, renal tubules and endocrine glands.
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A mutation in one mitochondrial DNA molecule within a cell leads to a mixture of 
mutant and normal mtDNA molecules - this is termed heteroplasmy 
During mitosis it is a matter of chance which mtDNAs will be passed to each daughter 
cell.
Over many cell divisions the proportion of normal and mutant mtDNA molecules can 
drift towards either pure mutant or normal (homoplasmy). This can occur during the 
replication of somatic cells or during proliferation of female germinal cells. Hence the 
threshold for the development of a mtDNA disorder may be said to be reached when the 
mutant load of mtDNA copies is sufficiently high.
With ageing, there is an accumulation of somatic mtDNA mutations (42). It is 
hypothesised that this process produces alterations in the expression of the mitochondrial 
genome which may produce some of the “pathological” changes associated with the 
ageing process (43). A study looking at mtDNA analysis and respiratory chain function 
assessment in muscle (44) has demonstrated that increasing age produced deficiencies in 
respiratory chain function and increasing amounts of mtDNA deletions in some 
individuals. This study failed to correlate the enzyme activities and mtDNA deletions, 
directly, however, and could not prove that decline in respiratory chain function was due 
to mtDNA alterations, alone. A mouse model, utilising increased levels of mtDNA 
mutations through a proof reading deficiency, has been shown to develop early ageing in 
association with increased markers of apoptotic activity (45), but not an increase in 
markers of oxidative stress.
1.3 Familial and Sporadic ALS
Approximately 10% of all patients with ALS have a positive family history of the 
disease (46), although the majority of cases are sporadic. Mutations of the SOD1 gene, 
which encodes the enzyme copper/zinc superoxide dismutase, are found in approximately 
20% of familial patients (47). SOD1 mutations are found in 1-2% of all patients with 
ALS (ALS1) (48). The SOD1 gene is on the long arm of chromosome 21 (21q22.1). 
Many different mutations with predominantly dominant inheritance have been found in
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the 5 exons of this gene (49). No mutations coding for SOD2, a closely related compound 
which localizes to the mitochondria have been found in familial or sporadic ALS (FALS 
and SALS, respectively) (50). Mutations in the SOD1 gene have also been identified in a 
proven sporadic case of ALS (51), in apparently sporadic cases (46) as well as with 
recessive inheritance (52).
Other, rarer, genetic abnormalities have been detected in patients with ALS, 
including the alsin (53) and APEX (54) genes, but the significance of some of these is 
uncertain at the present time. Other genes have been identified which have been linked 
with particular phenotypes or with an increased susceptibility to the development of ALS 
(Table 1.1).
At the current time the vast majority of research into the pathogenesis of ALS has 
focused on SOD1 transgenic mice (see 1.4.1 below) and cell models, as these are felt to 
provide a good disease model of both FALS and SALS (55). Less work has been 
performed in comparing familial with non-familial, or SOD1 with non-SODl patients. 
Work on fibroblast cultures, showing differing sensitivities to oxidative stress in SALS 
and FALS (56) demonstrated that cells from sporadic patients were much more sensitive 
to oxidative stress than SOD1 FALS fibroblasts. Indeed, using serum withdrawal as a 
stressor induced no difference in stress between control and FALS SOD1 fibroblasts. Post 
mortem central nervous system tissue showed respiratory chain enzyme activity differing 
in the brains of SALS and FALS patients (57), with reduced SOD1 activity and increased 
complex I activity in FALS-1 patients and increased oxidative damage to proteins in 
SALS patients. These studies suggest that there may well be differences between the 
disease types in terms of cellular pathology, especially as regards possible mitochondrial 
involvement. There is great heterogeneity in phenotypic presentation both within and 
between the different SOD1 genotypes, and even more between the other genes that have 
been identified as causing ALS. This may suggest that particular transgenic mouse or cell 
models may only be good models for the genotypes involved, with a limited application 
to sporadic, or other familial forms.
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Table 1.1 The current known causative and susceptibility genes for ALS.
Name Gene / locus Epidemiology Inheritance Age Onset 
(years)
Clinical Features
ALS1 (47) SOD1 2 lq 10% of familial 
cases
Usually
Dominant
Adult
(mean=46)
Similar to SALS, 
homozygotes more 
severe phenotype.
ALS2 (58) Alsin 2q33 10 known 
families
Recessive Childhood
(mean=6.5)
Spasticity, very slowly 
progressive, no sensory 
or bladder involvement.
ALS3 (59) 18q21 Large French 
family
Dominant Adult
(Mean=45)
Upper and lower neuron 
involvement, mean 
progression=5 years.
ALS4 (60) Senataxin
9q34
England and 
Maryland
Dominant 2nd decade Early gait disorder and 
distal weakness, slowly 
progressive.
ALS5 (61) 15ql5 Europe and 
North Africa
Recessive Teens Predominantly lower 
motor neuron distal 
pattern of involvement.
ALS6 (62) 16q 4 known 
families
Dominant Mean 38 to 
67 years
Generalised involvent 
with variable 
progression.
ALS7 (62) 20pl3 1 family Dominant Adult
(mean=57)
Progression over 3 
years.
ALS8 (63) VAPB
20ql3.33
7 Brazillian 
families
Dominant Adult
(mean=35)
Heterogenous 
presentation between 
cases with variable 
progression.
ALSX Xpl l-ql2 1 family Dominant Adult, 40 - 
60
Bulbar dysfunction, 
slowly progressive.
Neurofilament 
heavy chain
(H)
22ql2 5 patients Dominant or 
sporadic
Variable Variable, may involve 
dementia and bulbar 
symptoms.
APEX (54) 14ql 1.2-12 4 patients Sporadic None consistent.
Peripherin (64) 12ql2-ql3 2 Patients Sporadic Asymetrical leg 
weakness, progresses 
over 5 years.
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One of the main difficulties that has been encountered in the study of the 
pathogenesis of SALS is that of trying to identify discrete phenotypes which may be of 
value in proteomic analysis (65) in an attempt to elucidate specific genetic causes of the 
disease.
The inheritance patterns of familial ALS cases have been analysed, and examples of 
autosomal dominant, autosomal recessive and X-linked kindreds have all been described 
(66), indicating that there are likely to be many potential genetic aetiologies.
1.4 Superoxide Dismutase
Of those patients with familial ALS, 5-10% have identifiable mutations in the gene 
which codes for superoxide dismutase 1 (SOD1) (47,66,67). SOD1 is an enzyme which 
removes reactive superoxide radicals (0 2 "') from cells by converting them to a harmless 
form (2H* + Of ” —► H2O2 + O2) The superoxide radicals, which are by products of 
normal cellular processes, can damage cells if their levels are not controlled by 
superoxide dismutase. The active form of SOD1 incorporates a zinc and copper ion into 
its 3-dimensional structure. Although primarily a cytosolic enzyme, it has been posited 
that a portion of the SOD1 localises to the intermembrane space of the mitochondrion 
with a metallochaperone, which protects the cell from mitochondrial oxidative damage 
(68). Subsequent work has questioned whether the toxic effect exerted by the mutant 
SOD1 is dependent upon copper handling abnormalities (69), demonstrated by ablating 
the gene encoding the copper chaperone for SOD1 (CCS) in a series of FALS-linked 
SOD1 mutant mice, and showing that this did not modify the onset and progression of 
motor neuron disease in SOD 1-mutant mice. Using dorfin, a ligase for mutant SOD1, 
accumulation of the mutant SOD1 in mitochondria was significantly reduced in a 
neuronal cell model, with resulting inhibition of cytochrome c release and caspase 
activation, thus reducing neuronal cell death (70). This would imply that inhibition of the 
toxic properties of mutant SOD1 would have a protective role for the cell.
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Crystal structure studies of mutant SOD1, using X-ray diffusion techniques have 
shown that mutations in the amino acid sequence at the surface of the molecule may 
cause significant conformational change and destabilisation of the enzyme (figure 1.4) 
(71). This would imply that point mutations in the sequence could produce a toxic gain of 
function through alterations in binding of the SOD 1 molecule.
Wild-type A4V I113T
Figure 1.4 Crystallographic scatter studies o f wild type and 2 mutant (A4V and II131) 
SOD1 molecules demonstrating conformational surface changes (72).
1.4.1 Transgenic SOD 1 Mice
The first SOD1 transgenic mice, carrying the G93A mutation, which is sometimes 
carried by FALS patients, were developed in 1994 (73). The actual site of the SOD1 
G93A transgene insertion site lies on distal mouse chromosome 12 (74). These mice 
become paralysed in one or more limbs and die by 4-5 months of age. It has been shown 
that the presence of the SOD1 mutation produces a toxic gain in function. These mice 
develop degeneration of the motor neurons. Extensive pathology develops within the 
spinal cord of these mice some time prior to the onset of clinically apparent disease. 
Golgi apparatus fragmentation precedes microvacuolar changes in the mitochondria of 
the spinal cord, with swelling of the mitochondrial intermembrane space. Further 
analysis of these mice revealed that ubiquinated cytoplasmic inclusion bodies containing
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the mutant S0D1 develop (75). These changes bear strong similarities to the pathological 
changes seen in the post mortem spinal cords of patients with ALS. The mutant SOD has 
been shown to colocalise to the mitochondria in the central nervous sytem of transgenic 
mice (76). Many therapeutic trials have been performed using the SOD1 mouse model 
and various neuroprotective agents, none have, as yet, translated into appropriate 
treatments for the human ALS disease (77).
To develop pathological changes, these mouse models over-express mutant SOD1 to 
produce very high levels intra-cellularly. While this may be important in manifesting the 
disease phenotype, there could be important differences between the disease mechanisms 
in the human disease and mouse models.
1.4.2 SOD1 Neuronal Cell Models
Neuronal cell models of the SOD1 mutation have been developed. Using micro-array 
techniques, an immortalized mouse motor neuronal cell line NSC34 was stably 
transfected with either normal or mutant (G37R, G93A, I113T) SOD1 cDNAs, and the 
effect of the presence of these proteins on gene expression was analysed (78). These 
experiments have demonstrated that the presence of the mutant SOD1 leads to a decrease 
in expression of kij3b, a kinesin-like protein, which forms part of the kif3 molecular 
motor. The expression of c-fes, a cytoplasmic protein-tyrosine kinase thought to be 
involved in intracellular vesicle transport was also decreased. In addition, a decrease in 
expression was confirmed for intracellular adhesion molecule 1 (ICAM1) in the presence 
of all three of the mutations studied (78). Further work with this cell model has 
demonstrated the development of ultrastructural mitochondrial abnormalities and 
diminished activity of respiratory chain complexes III and IV (79) in the presence of 
mutant SOD1. Molecular studies of this neuronal cell model of ALS have suggested that 
the mutant SOD1 may exert a toxic effect through the generation of reactive oxygen 
species (ROS) as well as direct inhibition of mitochondrial function (80). More recent 
work on the G93A neuronal cell model (81) using gene expression profiling, showed that 
a number of DNA transcripts were differentially expressed in the presence of mutant
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human S0D1, including the antioxidant response element genes encoding certain 
detoxifying enzymes and antioxidant response proteins.
Glutamate transport in a G93A human neuroblastoma SHSY-5Y cell model was more 
sensitive to oxidative stress as induced by growing cells in media supplemented with 0.3 
mM paraquat (82) than in non-transfected cells. This study did not show an attenuating 
effect of anti-oxidant treatment to the effects of the paraquat on glutamate uptake by the 
cell cultures.
There is evidence that the surrounding environment of non-neuronal cells can 
influence the toxicity of mutant SOD1 expressed in motor neurons; in chimeric 
transgenic SOD1 mice, the survival of SOD1 motor neurons was extended by the 
presence of wild type non-neuronal cells (83). This would suggest that while mutant 
SOD1 cell models can provide valuable information about changes gene expression, they 
may be less useful in modeling the disease state per se.
1.5 Evidence for the Involvement of Mitochondria in the Pathogenesis of ALS
1.5.1 Structural Studies
Electron microscopy of human motor neurons from patients with ALS has revealed 
similar mitochondrial abnormalities to those developing in SOD1 mutant mice. For 
example, mitochondrial structural abnormalities have been identified in the post mortem 
corticospinal tract (84) (axonal swellings were seen to consist of accumulations of 
neurofilaments and altered mitochondria) and ventral horn cells (85) (scattered 
mitochondria, vesicles and fragments of smooth endoplasmic reticulum were found 
among interwoven bundles of neurofilaments) of those affected. The mitochondria in 
each case were swollen with disrupted membrane abnormalities evident. Ultrastructural 
studies on remote tissues have shown similar patterns of mitochondrial abnormalities in 
patients with ALS, including the liver (86) and motor end plates (figure 1.6) (87).
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Figure 1.6 Motor end plates from a patient with a peripheral neuropathy (disease 
control) (A) and 2 patients with ALS (B,C) show a higher density o f larger mitochondria 
in the ALS patient samples. Sch =  Schwann cell envelope, m =  mitochondria, sv = 
synaptic vesicles, j f =junctional folds. Calcium precipitates are arrowed. Bar = 0.5 pm 
(From: Siklos et al. Ultrastructural evidence for altered calcium in motor nerve terminals 
in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:203-16).
1.5.2 Mitochondrial Mediation of Oxidative Damage
The role of mitochondria in the generation and homeostasis of free radicals within the 
cell, leads to the hypothesis that an abnormality of mitochondrial function will lead to 
oxidative damage through the action of ROS (88). Accordingly, markers of oxidative 
damage have been found to be increased in the brain (57) and spinal cord (89) of patients 
with ALS. Levels of oxidative damage have been shown to be elevated in the central 
nervous system DNA of the SOD1 G93A transgenic mouse model of ALS (90). A 
mitochondrial uncoupling protein (MUCP3) has been shown to be upregulated in the 
muscle of SOD 1 transgenic mice as well as the muscle of patients with sporadic ALS, but 
not in the spinal cord (91). MUCP are thought to have a role in the regulation of 
mitochondrial activity in situ, and changes in levels of expression may represent changes 
in intracellular mitochondrial function. These findings suggest that while the primary site
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of damage in ALS is the motor neurons, a more generalised metabolic abnormality may 
be implicated in the pathogenesis, or as a secondary effect.
Analysis of the central nervous system of transgenic SOD1 mice has also revealed 
increased levels of oxidative damage to DNA as measured by 8-hydroxy-2- 
deoxyguanosine (8-OHdG) (92). Staining for the immunoreactivity of 8-OHdG was not 
localized in the nucleus but in cytoplasm with small granular pattern, which may suggest 
that an oxidative damage to mtDNA is occuring in these mice.
A large prospective study of individuals using vitamin supplements identified that 
regular users of vitamin E, which acts as cellular antioxidant, were at a lower risk of 
dying of ALS than the population as a whole, including individuals taking vitamin C 
supplements or multi vitamin preparations (93). Although this study was controlled for 
age and smoking status, it was not blinded, and relied totally on self reporting.
1.5.3 Calcium Homeostasis
Abnormalities in the cellular homeostasis of calcium have been demonstrated in 
patients with ALS. Homogenised muscle biopsy samples of patients with ALS 
demonstrate elevated mitochondrial calcium levels (87). Peripheral blood lymphocytes 
show increased cytosolic calcium levels and impaired response (an increase in basal 
oxygen consumption rate) to inhibitors of oxidative phosphorylation (94). In a neuronal 
cell line expressing mutant SOD1, mitochondrial membrane potential was shown to be 
diminished and cytosolic calcium levels increased (95). Increased mitochondrial Ca2+ 
concentrations as a result of excitotoxicity (as for highly metabolically active cells such 
as neurons) has been associated with the generation of superoxide and may induce the 
release of proapoptotic mitochondrial proteins, proceeding through DNA 
fragmentation/condensation and culminating in cell demise by apoptosis and/or necrosis 
(96). This process has been implicated in the pathogenesis of many neurodegenerative 
diseases.
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1.5.4 Mitochondrial Enzyme Activity
The main role of mitochondria is energy production which is achieved through the 
generation of ATP through the oxidative phosphorylation complexes (I -  V) on the inner 
mitochondrial membrane (24) (figure 1.1). Direct assessment of mitochondrial function 
may be demonstrated through assaying the activity of these complexes. For example, a 
specific decrease in complex IV has been described in the spinal cord (97), muscle (98) 
and anterior horn cells (9) of patients with ALS. Obviously the central nervous system 
assays were performed on post mortem tissue. Corresponding complex II activity in the 
anterior horn cells was found to be normal (9). This finding is important, as complex II is 
entirely coded for by nuclear DNA, while complex IV is partly coded for by mtDNA. A 
single patient with an ALS type disorder has been described with a severe muscle 
complex IV deficiency due to an out of frame mutation in the mitochondrial gene for the 
major subunit of complex IV (99). G93A mice, transgenic for an SOD1 mutation 
associated with familial ALS, show evidence of generalised mitochondrial respiratory 
chain deficiency with impaired ATP synthesis in central nervous system tissue (100,101).
A neuronal SOD1 transgenic cell model was investigated for respiratory chain 
complex activity and cell death under oxidative stress. Complex II and IV activity was 
found to be diminished, and serum withdrawal from the growth medium, to generate 
oxidative stress, produced increased levels of cell death in the model relative to wild type 
SOD1 controls (102).
Although there is evidence of mitochondrial electron transfer chain abnormalities, 
the findings are not uniformly consistent between human tissue, mouse models and cell 
models. For example, complex I levels were found to be low (103) or normal (104) in the 
skeletal muscle of patients with SALS, increased in the brains of patients with FALS 
(105), low in the spines of transgenic SOD1 mice (101) and normal in a transgenic SOD1 
cell model (79). Although variations in respiratory chain enzyme activities may point to 
the involvement of mitochondria in the pathogenesis of ALS, a clearly defined 
relationship has yet to be proven.
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1.5.5 MtDNA Mutations
A wide range of degenerative conditions have been described in association with 
mtDNA (mtDNA) mutations (106). For instance, mtDNA abnormalities in association 
with electron transport chain deficiencies (107) have been described in neurodegenerative 
diseases such as Parkinson’s disease (108,109) and nuclear genetic abnormalities coding 
for mitochondrial proteins have been described in Huntington’s disease (110) and 
Friedreich’s ataxia (111).
Although abnormalities of mtDNA have been documented in ALS patients in 
some reports, other reports found no evidence of such an association. In one study, 
decreased levels of mtDNA have been demonstrated in the muscle of 14 out of 17 
patients with ALS (112). The absolute number of mitochondria was unaffected, as 
illustrated by the normal citrate synthase levels within the tissue concerned. Low levels of 
mtDNA were also found in the brains of patients with ALS (113). This study also 
measured levels of the 4977 base pair deletion of mtDNA. In patients with ALS, levels of 
the deletion were higher in the motor cortex than the temporal cortex in patients with 
ALS compared with normal controls. The 4977 base pair deletion has previously been 
shown to be elevated in the normal aged brain (114). Levels of this mutation have 
recently also been found to be elevated in skeletal muscle from a proportion of patients 
with ALS compared with the levels found in patients with other neuromuscular disorders 
(115) This would implicate mtDNA degeneration as a possible factor in the pathogenesis 
of SALS.
In contrast to the above studies which suggest the association of ALS with 
mtDNA abnormalities, single cell analysis of post mortem tissue demonstrated no 
difference in the levels of the common deletion of mtDNA in the motor neurons of 
patients with SALS and controls (116), The finding would suggest that significant 
accumulation of mtDNA deletions in the central nervous system is not the cause of 
SALS. This is supported by a study comparing mtDNA levels in the skeletal muscle of 
patients with SALS and neurogenic controls with normal controls (117). The study 
identified that there was only a minimal decline of mtDNA:nDNA ratios in SALS and 
disease control patients in comparison with healthy controls.
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Nevertheless, in some patients, specific mtDNA mutations have been identified 
that are considered to be involved in the pathogenesis of the disease. As mentioned above 
(1.6.4), a single patient with ALS has been described with low levels of muscle complex 
IV activity occuring secondary to a mtDNA mutation causing a deficiency in the 
expression of a subunit of complex IV (99). Furthermore, a single patient with a motor 
neuron disease associated with temporal lobe epilepsy was found to have a mutation in 
the mitochondrial tRNA gene (118). This was associated with mild complex I deficiency 
in skeletal muscle. Even so, the mutation was not identified in a cohort of 40 patients 
with SALS. The association of a disorder of the motor neurons with a mtDNA mutation 
and evidence of respiratory chain deficit in remote tissues supports the possibility of 
mtDNA abnormalities in the pathogenesis of SALS.
1.5.6 Cybrid Studies and Platelets
An important technique for determining whether mitochondrial or nuclear DNA is the 
source of observed pathological cellular abnormalities is provided by cybrid studies. 
These involve the fusion of patient platelets (which contain mtDNA, but do not have a 
nucleus, and therefore lack nuclear DNA) with experimental p° cells. p° cells are cells 
that have been depleted of mtDNA, but contain nuclear DNA. The fusion results in the 
patient mitochondria being presented in a control nuclear context (figure 1.7). Early work 
with cybrids, indicated a deficiency in platelet complex I activity of patients with 
Parkinson’s disease (119). A later study of cybrids derived from the platelets of ALS 
patients revealed several deficits in the cell line that were not present when control 
platelets were fused with the SH-SY5Yp° cells (120). These included a decrease in 
complex I activity as well as an increase in free radical scavenging activity and 
abnormalities of calcium homeostasis, similar to those described above. Other work 
performed at a later time (121) suggests that citrate synthase, glutamate dehydrogenase 
and and cytochrome oxidase activities are the same in platelets from patients with 
sporadic ALS and controls. More recent work suggests that the repopulation of 143B p° 
cells with mtDNA from the platelets of patients with ALS restores normal respiratory
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activity within those cells (122). Although different recipient cells were used in each 
case, respiration in intact SH-SY5Y and 143B cells has been shown to be similar (123). 
SH-SY5Y cells are a line derived from human neuroblastoma cells, while 143B cells are 
derived from a human osteosarcoma line (124). The differences in results may well be 
explained by the differences in experimental conditions between the two studies, rather 
than proving or disproving the existence o f  a mitochondrial abnormality in the platelets o f  
patients with ALS.
Fusion
Cybrids
Figure 1.7 Fusion o f anuclear platelets with p  cells lacking mtDNA. The donor mtDNA 
is obtained from platelets, and repopulates experimental cybrid cells.
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1.5.7 SOD1 and Mitochondria
A subcellular fractionation study o f  transgenic G93A mice and a single SALS 
patient (72) demonstrated the presence o f  mutant SOD1 in the spinal cord mitochondria, 
whereas virtually no wild type SOD1 localised to these organelles. Recruitment o f  
abnormal SOD1 occurred independently o f  copper chaperone or dismutase activity. A 
highly preferential association with spinal cord mitochondria in human ALS for a mutant 
SOD1 that accumulates only to trace cytoplasmic levels (72) has been shown. This 
provides a link between the observed mitochondrial abnormalities detailed above, and the
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production of disease causing SOD1 mutants in FALS. In a more recent study, it was 
demonstrated that, in addition to being in the mitochondrial outer membrane and 
intermembrane space, mutant SOD1 is also localised to the matrix (125). Aberrant SOD1 
macromolecular aggregates were found in the matrix of brain mitochondria, suggesting 
that mutant SOD1 in the brain mitochondrial matrix is misfolded and prone to 
aggregation. This may contribute to selective neuronal degeneration.
Further work has been performed demonstrating that the mutant SOD1 molecule 
binds to bcl-2, a mitochondrial anti apoptotic protein (126). While the wild-type protein is 
anti-apoptotic, mutant SOD1 promotes apoptosis. It was shown that both wild-type and 
mutant SOD1 bind bcl-2, providing evidence of a direct link between SOD1 and an 
apoptotic pathway. This interaction is evident in vitro and in vivo in mouse and human 
spinal cord and in the spinal cords of transgenic SOD1 mice (126) and suggests that wild 
type SOD1 may have a role in protecting the cell against programmed cell death. The 
proposed model involves the binding of bcl-2 by aggregates of mutant SOD1. This is 
supported by the finding that mutant SOD1 linked to the mitochondria promotes 
apoptosis more strongly than a cytososlic mutant SOD1 (127).
In contrast to these findings, another group has demonstrated that both wild type and 
mutant SOD1 are to be found in the intermembrane space of SOD1 G93A transgenic 
mice overexpressing mutant human SOD1 (100). This study identified evidence of 
morphological and functional abnormalities in mitochondria from the spinal cord of 
affected animals, including oxidative damage to mitochondrial proteins and lipids and 
deficiencies in the electron transfer chain, and ATP synthesis.
1.6 The Glutamate Hypothesis
Glutamate is the major excitatory neurotransmitter within the central nervous system. 
There are a number of different subtypes of glutamate receptors distributed thoughout the 
CNS. Abnormal activation of these receptors has been associated with neuronal death 
through the activation of a number of pro-apoptotic emzymatic pathways (128).
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Disturbances in calcium homeostasis and free radical mediation of neurotoxicity are also 
thought to depend on aberrant glutaminergic neurotransmission. (129).
Glutamate levels are found to be elevated in the serum (a mean increase of 100% in 
patients compared with controls) (130) and the CSF (a mean increase of 100 -  200% in 
patients compared with controls) (131) of patients with sporadic ALS. The involvement 
of glutamate transmission in the pathogenesis of the disease is further supported by the 
use of riluzole, a glutamate release inhibitor, in slowing the progression of the disease. 
Riluzole has been shown to have a modest effect in prolonging survival in ALS (132). 
Glutamate toxicity can occur both acutely, and in a chronic, irreversible, manner. (133) 
This would mirror the progressive nature of the disease in ALS patients.
In studies of another SOD1 transgenic model, cultured motor neurons from the G93A 
SOD1 transgenic rat showed increased sensitivity to the excitotoxic effects of glutamate 
relative to controls (134). These effects were attenuated by the antioxidant vitamin E, and 
survival time was increased in the animals by the use of riluzole and gabapentin, both 
glutmatate antagonists. Unlike riluzole, gabapentin has not been shown to be of 
therapeutic benefit in human ALS (135).
With regard to the role of mitochondria in glutamate toxicity, neuronal cells which 
are overstimulated by glutamate undergo excess calcium influx. Blocking the uptake of 
calcium by the mitochondria significantly reduced glutamate toxicity (136). This would 
imply that perturbed mitochondrial function results in changes in the flux of calcium 
through the cell which may mediate neurotoxicity by glutamate receptor activation.
1.7 Hypothesis
Following review of the pathogenesis of ALS and the mitochondrial pathology, as 
described above, the following hypothesis was proposed and tested in the series of 
experiments which are described:
Cumulative mtDNA (as opposed to nuclear DNA) mutations resulting from oxidative 
damage in mitochondria contribute to motor neuron death and the development o f motor
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neuron disease. These mutations are random with a threshold effect that would explain 
the selective late onset motor neuron death. Motor neurons are especially vulnerable to 
oxidative damage due to their structure and high metabolic turn over.
During the performing of these experiments, a further hypothesis was developed: 
ALS is the result o f a systemic hypersensitivity to oxidative stress.
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2 Methods and Materials
2.1 Patients and Controls
2.1.1 Patient information and Consent
Patients and control subjects were recruited from neurology outpatient clinics. 
Control subjects were also recruited from inpatients at the Royal Free Hospital who were 
undergoing muscle biopsy for other diagnostic purposes. Each subject was given a 
comprehensive information sheet and a full verbal explaination of the study was 
provided, with opportunities to discuss any issues arising or any questions that the subject 
may have had. Ethical approval was obtained from the Royal Free Hospital Local 
Research Ethics Committee.
Informed consent was obtained, seperately, for the muscle, blood (platelets) and 
skin samples. A record was made of the level of power in the limb that was being 
biopsied for the study. All patients had MRC grade power of 3 or greater.
Because all of the patients and controls had a muscle biopsy performed for 
diagnostic purposes, these biopsies were examined to ensure that “normal” controls did 
not, in fact, have demonstratable pathology on microscopy. Normal controls had a final 
clinical diagnosis of no muscle or other physical disease. The samples were also 
scrutinised to ensure that patients who fulfilled the diagnostic criteria for motor neuron 
disease did not have other muscle pathology.
None of the patients or controls smoked at the time of the study. Past smoking 
history was not recorded.
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2.1.2 Patients
There were 12 ALS patients enrolled in the study. Mean age was 57.3 years 
(range 33-70 years). The mean time from diagnosis was 5.25 years, (table 2.1) MRC 
Power score in the affected limb ranged from 3 to 5. At the time of writing, as far as can 
be ascertained, all of the patients in the study are still alive. One patient has familial ALS 
with an SOD1 mutation (figure 2.1) (see section 3). ALS was defined by the El Escorial 
criteria for the diagnosis (137).
Table 2.1 Patients
Name Sex Diagnosis Power in 
biopsied 
limb
Age at Study Time from 
Diagnosis 
(years)
PA1 M ALS 5 33 2
PA2 M ALS 5 61 8
PA3 F ALS 4 56 4
PA4 M ALS 4 68 11
PA5 M ALS 3 70 18
PA6 F ALS 3 43 4
PA7 F ALS 4 60 1
PA8 M ALS 5 57 2
PA9 M ALS 3 58 7
PA10 M ALS 3 53 1
PA11 F FALS 4 65 4
PA12 M ALS 4 64 1
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Figure 2.1 Pedigree for PA 11 (arrowed), patient with familial ALS. Filledfigures are 
affected individuals. The pedigree shown is incomplete for reasons o f confidentiality.
2.1.3 Disease Controls
There were 11 disease controls recruited to the study, with a mean age of 55.3 
years (range 18-71 years). These had peripheral neuropathies, benign fasciculations and 
hereditary spastic paraplegia (HSP) (table 2.2). Subsequent studies (138) demonstrated 
complex I respiratory chain enzyme mitochondrial abnormalities in the patients with HSP 
and, therefore, they were withdrawn from the study.
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Table 2.2 Disease Controls
Name Sex Diagnosis Age at Study
D1 M Motor Neuropathy 54
D3 M Peripheral Neuropathy 59
D4 M Benign Fasciculations 66
D5 M Peripheral Neuropathy 67
D6 M Peripheral Neuropathy 69
D7 F Progressive W eakness Unknown Cause 18
D8 M Benign Fasciculations 39
D9 F HSP 54
D10 M HSP 44
D11 M Benign Fasciculations 67
D12 M Post Polio Syndrome 71
2.1.4 Controls
Twenty one patients were recruited as controls. They had a mean age of 47.9 
years (range 26-82 years). These patients had a range of non-specific symptom defined 
conditions that were being investigated at the Department of Neurology, Royal Free 
Hospital. All of the controls had normal muscle biopsy histology and no evidence of 
neurological disease clinically. This group was not individually age- and sex- matched, 
but had a similar age range to the patient and disease control groups.
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Table 2.3 “Normal” controls
Name Sex Potential Diagnosis (reason 
referred for m uscle biopsy)
Ag
C1 F Myalgia 26
C2 F Myalgia 27
C3 F W eakness 60
C4 M ? Polymyositis 73
C5 M Myalgia 45
C6 M Myalgia 27
C7 M ?Myasthenia -  not proven 79
C8 F Muscle weakness and learning 
difficulties
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C9 F Proximal W eakness 82
C10 F Proximal W eakness 60
C11 M Muscle W eakness 20
C12 M Myalgia 37
C13 F W eakness 38
C14 F Generalised weakness 61
C15 F ?Dermatomyositis 44
C16 F ?Myasthenia -  not proven 31
C17 F ?Myalgic encephalomyelitis 30
C18 M Chronic fibrosing alveolitis 61
C19 F ?Myalgic encephalomyelitis 52
C20 M Myalgia 51
C21 F Generalised weakness 45
51
2.2 Materials
2.2.1 Equipment
Unless specified otherwise, the following equipment was used.
Tissue Culture -  ICN-Flow Automatic CO2 Incubator Model 320 (ICN-Flow Ltd., High 
Wycombe, Bucks, UK). Envair Class II Microbiological Safety Unidirectional Laminar 
Cabinet (Envair Ltd., Rossendale Lancashire, UK).
Homogenisation -  Uni-form 10ml glass/teflon homogeniser (Jencons Ltd., Leighton 
Buzzard, Bedfordshire, UK).
Spectrophotometers -  Hitachi U-3220 and Hitachi U-3210 (Hitachi Scientific Instruments 
Ltd., Wokingham, Berks, UK).
Centrifuges -  Beckman GPR bench top centrifuge equipped with a GH-3.7 horizontal 
rotor, Beckman 18 microfuge centrifuge (Beckman Ltd., High Wycombe, Bucks, UK). 
Kontron T-124 high speed centrifuge with a fixed angle Herolab A8.24 rotor (Kontron 
Instruments, Watford, Herts, UK).
Microscopy -  Zeiss axiophot fluoresence microscope with FITC and rhodamine filters 
(Carl Zeiss Microscope Division, Oberkochen, Germany), Zeiss axiophot microscope 
fitted with a computer controlled motorised stage and a triple band pass emission filter 
(Carl Zeiss Microscope Division, Oberkochen, Germany), Olympus CK2 contrast 
microscope (Southern Microscopes, Maidstl, Kent, UK).
DNA analysis -  Perkin Elmer PCR GeneAmp 2400 (Perkin Elmer, Wellesly, MA, USA), 
Beckman Coulter CEQ2000XL Sequencer (Beckman Ltd., High Wycombe, Bucks, UK), 
BioRad 200/2.0 constant voltage power packs (BioRad Lab Ltd., Hemel Hempstead, 
Herts, UK), UV transilluminator (GRI Ltd., Dunmow, Essex, UK), Horizontal Gel Tank 
model H5 (Gibco BRL, Gaithersberg, MD, USA).
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2.2.2 Chemicals
Unless otherwise stated, all chemicals were purchased from Sigma (Poole, Dorset, UK).
2.2.3 Antibodies
All antibodies were purchased from Cambridge Biosciences (Cambridge, 
Cambridgeshire, UK) apart from anti-cytochrome c which was purchased from BD 
Biosciences Ltd. (Cowley, Oxfordshire, UK).
2.2.4 Isotopes
Radioactive isotopes were obtained from ICN Biomedicals (High Wycombe, Bucks, UK)
2.3 Methods Overview
Mitochondria were studied in 12 patients with ALS (sporadic and familial) (table 
2.1), 21 controls of similar age (table 2.3), and 10 disease controls (table 2.2). 
Investigations were performed on muscle tissue, platelets, fibroblasts and myoblasts from 
each subject, where available. Cell cultures of each tissue type were initiated and grown. 
These cultures were assayed for respiratory chain enzymes. Platelets were fused with 
control p° cells (cells lacking mtDNA) (139), allowing investigation of the platelet 
mtDNA (124). The same investigations were performed on whole muscle homogenates 
from patients and controls.
Muscle tissue was analysed histologically, using a number of different stains to look 
for differences between control and patient samples.
MtDNA analysis was performed on DNA extracted from the muscle tissue. Southern 
blotting and long-range PCR techniques were employed to assess the total amounts of 
mtDNA in patients and controls as well as the number of deletions. The SOD1 status of
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all patients was analysed by direct sequencing of the PCR-amplified exons and intron- 
exon boundaries. Modes of inheritance of familial ALS were explored by the analysis of 
a database of families both with and without SOD1 mutations.
Mitochondrial function of cell and tissue homogenates was assessed by 
spectrophotometric assay of oxidative phosphorylation enzyme complexes (140-143). 
Cells for each tissue type were seeded onto glass coverslips, immunostained using 
antibodies against mtDNA encoded polypeptides, and analysed using a newly developed 
automated cytometric analysis system. This system allowed a mitochondrial deficit to be 
quantified in a way that avoids observer bias and can identify even a small proportion of 
cells not expressing the mtDNA-encoded protein. In addition to looking at the 
mitochondrial respiratory chain protein complexes, aconitase activity was assayed in 
whole tissue as a measure of oxidative stress in vivo.
In order to reveal a possible increased sensitivity to oxidative stress and analyse 
the possible relationship between cell death and oxidative stress, cell cultures were grown 
in paraquat of varying concentrations and tested for the extent of oxidative stress and 
apoptosis.
A database of familial ALS patients was created and analysed for evidence of 
anticipation or sex bias in inheritance of the disease. Given the known inheritance 
patterns of mitochondrial diseases, trends for unidentified mtDNA mutations were 
studied.
2.4 Sample Collection
2.4.1 Muscle
With appropriate surgical consent obtained prior to the procedure, open biopsy 
was performed on the quadriceps muscle, using local anaesthetic, under sterile operating 
theatre conditions. The sample collected was placed in tissue culture medium and was 
divided within 2 hours. Half of the piece was frozen at -80°C for whole tissue analysis the 
other half was used for myoblast generation.
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2.4.2 Skin
During the operative procedure for the muscle biopsy, a sliver of skin was taken 
from the edge of the incision. This was transported to the lab in tissue culture medium 
and processed for fibroblast generation within 2 hours.
2.4.3 Blood
Blood was collected in a 50 ml syringe using an 18 gauge needle. A tourniquet was 
applied for the minimum possible time. The blood sample was immediately transferred to 
a 50 ml container containing 3.8 ml of 10% trisodium citrate, in order to avoid clotting. 
The sample was transported to the laboratory and processed immediately for platelet 
collection.
2.5 Cell culture
2.5.1 Overview
Cells were grown on 10-cm culture dishes (Sarstedt). Fibroblasts, p° and cybrid 
fusion cells were grown on plain culture dishes using supplemented Dulbecco’s Modified 
Eagle Medium (DMEM) (Sigma) (see appendix 1). Myoblasts were grown on “Cell+” 
dishes (Sarstedt), in DMEM supplemented with additional foetal calf serum (BioLabs) 
(see appendix 1). All cell types were grown in an incubator utilising a humidified 
atmosphere with the CO2 concentration being maintained at 8% at a constant temperature 
of 37°C. The growth medium of cell cultures was changed every 3 days.
When cells reached confluence on a culture dish, they were split down. This 
involved washing the plate with phosphate-buffered saline and adding 1.2 ml of 0.01% 
trypsin solution (Gibco) in versene (1:5000) (Gibco). The plate was incubated at 37°C 
(appendix 1) for 1 minute followed by gentle agitation. The cells were then examined 
under the microscope to ensure that they had dislodged. Once this had taken place, the
55
trypsin on the plate was neutralised with culture medium. The cells could then either be 
divided onto other plates to grow further or frozen down.
When freezing cells down, the suspension resulting from trypsinisation was 
centrifuged at 1300 g  for 10 min. The supernatant would be discarded. The cells would 
then be resuspended in culture medium supplemented with 10% DMSO. In this form, the 
cells would initially be frozen at -80°C overnight in a polystyrene box to ensure slow 
refrigeration before being transferred to liquid nitrogen for long term storage.
2.5.2 Growing of human myoblasts in vitro starting from mononucleated satellite cells
The muscle biopsy specimen was transported to the laboratory in myoblast culture 
medium. On arrival it was transferred to a sterile 100-ml beaker. Ten ml of myoblast 
dissociation fluid (see appendix 1) was added. The muscle tissue was gently teased apart 
for about 3 min using two sterile needles on syringes. The biopsy suspension was 
transferred to a sterile capped tube and incubated in a water bath or incubator at 37°C for 
12 min, whilst shaken slowly (60 rpm).
The capped tube was removed and 10 ml of myoblast culture medium was added. 
The suspension was swirled gently and triturated by pipetting up and down the muscle 
fragments through a 10-ml wide bore pipette five times. If this was not possible, then the 
sterile needles were used again, to break up the fragments.
The muscle fragments were allowed to settle. Using a pipette, the supernatant was 
drawn off and filtered through a cell strainer (Sarstedt) into a 50-ml tube.
Another 10 ml of dissociation solution was added to the muscle tissue and 
incubated for a further 12 min.
In the mean time, the supernatant in the 50-ml tube was centrifuged for 10 min to 
sediment the cells. The supernatant was then aspirated off and the cells were resuspended 
in 0.5 ml of myoblast culture medium. The tube was subsequently placed in a humidified 
incubator (37°C and 8% CO2 in air) with the top slightly loose.
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The above process was repeated 2 to 3 times until the muscle tissue was 
completely dissociated or the 40 ml of dissociation fluid was used up.
The cell pellets resuspended in 0.5 ml of culture medium were combined and 
made up to 12 ml with myoblast culture medium and transferred to two collagen-coated 
6-cm culture dishes (Sarstedt).
The dishes were incubated overnight, humidified, at 37°C and 8% CO2 in air.
The next day, the medium was aspirated off and the plates rinsed twice with pre­
warmed myoblast culture medium to remove red blood cells and cell debris. Fresh 
medium was then added.
The medium was changed every 3 to 4 days until cells reached a 70% to 80% 
confluence. Myoblasts were then expanded to 10-cm “Cell+” dishes by trypsinisation. 
The myoblasts were grown and frozen down as outlined in the cell culture protocols 
(2.5.1).
2.5.3 Initiating fibroblast cultures
The piece of skin provided from the biopsy was transported to the laboratory in 
fibroblast cell culture medium. The piece of skin was removed from the transit medium 
onto a 10-cm culture plate (Sarstedt). Two ml of culture medium was placed onto the 
sample.
Using a sterile scalpel, the skin sample was divided into approximately 16 pieces 
on the culture plate. These pieces were equally distributed between two 6-cm culture 
plates (Sarstedt). A very small amount of medium was added to each plate, so that each 
piece of skin remained in contact with the base of the dish.
Every 2 days a few drops of medium were added to each plate in order to prevent 
the samples from drying out. The amount of medium was limited in order that the skin 
pieces remained in contact with the dish.
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Initially, epithelial cells were visible, these were shortly followed by fibroblasts. 
When the fibroblasts were becoming confluent, they were removed from the plate. This 
was done by the application of a small amount of trypsin solution (1 ml) (appendix 1) and 
gentle agitation of the plate. The trypsin was neutralized with the addition of 4 ml of 
fibroblast medium and the cells were transferred to a 10-cm plate.
From this stage, the fibroblasts were grown and frozen down as for the cell culture 
protocol.
2.5.4 Platelet fusion to p°cells
Thirty ml of blood was taken from the subject, using an 18-gauge needle, and 
avoiding the use of a tourniquet. The blood was immediately transferred to a 50-ml tube 
containing 3.3 ml of 3.8% trisodium citrate. The sample was centrifuged, as quickly as 
possible, at 200 g. The top two thirds of the supernatant was drawn off and transferred to 
a separate container. The remaining pellet was stored for subsequent DNA extraction. 
Prostacyclin I (Sigma) was added to this supernatant to a concentration of 70 pM. The 
sample was centrifuged at 1000 g  for 30 min.
The supernatant was discarded. The platelet pellet was resuspended in the original 
volume (supernatant) of Tyrode’s buffer (see appendix 1).
Further centrifugation at 1000 g  for 10 min was performed. This procedure was 
repeated twice, with the supernatant being aspirated off, resuspended in Tyrode’s buffer 
and centrifuged at the same speed. Following the third spin, the sample was left to stand 
for 20 min.
A549 p° cells were grown on 10-cm culture plates using standard fibroblast 
growth medium (appendix 1). When these were confluent on a culture plate, they were 
harvested, as outlined (2.5.1), by trypsinisation and centrifugation, and resuspended in 2 
ml of Dulbecco’s modified Eagle medium without calcium (Sigma).
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After 20 min, the platelet suspension was centrifuged at 1000 g  for 10 min. The 
supernatant was discarded, and the A549 p° cells were added to the platelet pellet. This 
mixture was centrifuged for 5 min at 250 g. The supernatant was aspirated off.
Five g of polyethylene glycol 8000 (Sigma) were dissolved in 100 ul of DMSO 
and 2 ml of calcium free medium, this was added to the cell / platelet pellet and gently 
agitated for exactly 1 minute. After this minute, 10 ml of medium were added. The 
suspension was divided between two 10-cm plates and placed in the incubator at 37°C, 
with a CO2 concentration of 8%.
The plates were fed regularly, with selective culture (cybrid) medium which lacks 
uridine and pyruvate and is made up with dialysed foetal calf serum (see appendix 1). 
This was done to select against cells that had not taken up platelet mtDNA, and hence 
would be unable to grow without using oxidative metabolism. The cells were grown and 
harvested according to the cell culture protocol, above (2.5.1).
2.5.5 Mitochondrial Pellet Preparation
A total of 20 confluent plates of the cells being examined were used. The plates 
were divided into batches of 5. The old media was aspirated off from the first batch, the 
cells were washed in phosphate buffered saline and trypsinised for 3 min at 37°C. The 
suspension was then neutralised with fresh media.
The suspended cells from the first batch (5 x 1 0  ml) were combined in a Falcon 
tube and spun down at 1300 g  for 10 min. Whilst spinning, trypsinisation was performed 
on the second batch.
Upon completion of the spin, the supernatant of batch 1 was discarded. The now 
pelleted cells were resuspended in the dilute cell suspension from batch 2. This was spun 
again at 1300 g  for 10 min.
The process was repeated with successive batches, thereby increasing the 
concentration of the cells in the suspension each time, until the required number of plates
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had been used.
The cells were washed by resuspending the final pellet in 10 ml of PBS, retrieving 
the cells by centrifugation at 1300 g  for 10 min. This process was repeated a further two 
times.
After the third wash, the PBS was discarded and the pelleted cells were frozen 
(still in the Falcon tube) at -80°C for a minumum of 1 hour.
The second stage of the procedure was performed in the human handling lab in a 
Class I hood.
The pelleted cells were thawed and resuspended in 2 ml of pre-chilled 
homogenisation buffer (see appendix 1). All used pipette tips were soaked in vircon for 
20 min prior to disposal.
The cells were homogenised in a 2-ml glass homogeniser with a plastic pestle 
(VWR) for 20 strokes at 1000 rpm.
The homogenised cell suspension was pipetted into a clean (pre-chilled) 
universal container and spun at 4°C for 10 min at 1500 g. The "nuclear fraction" was 
pelleted as a result of this spin. It contained liberated cell nuclei and membranes in 
conjunction with (as yet) unbroken cells. The supernatant, known as the post nuclear 
supernatant contained the cell cytosol, mitochondria and microsomes.
The post nuclear supernatant was carefully removed and stored, on ice, in a clean 
universal container. The pellet was then resuspended in a fresh 2 ml of pre-chilled 
homogenisation buffer, the suspension transferred to the homogeniser and the process 
repeated a further two times in order to harvest the maximum number of mitochondria, 
combining the post nuclear supernatant from all three spins. The remaining pellet from 
the third spin was discarded.
The combined post nuclear supernatant was then spun at the same speed once 
again to pellet any inadvertantly transferred contaminating nuclear fraction.
The post nuclear supernatant was transfered to a fresh (pre-chilled) high speed
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Kontron centrifuge tube; the pellet (if any) being discarded.
The post nuclear supernatant was then spun in the Kontron tubes at 4°C for 12 
min at 11500 g. The post-mitochondrial supernatant was discarded and the crude 
mitochondrial pellet re-suspended in 500 pi of homogenisation buffer. This was 
aliquoted into cryotubes (200 pi per tube) and snap frozen in liquid nitrogen. It was 
stored at -80°C. Enzyme activity was assayed within 5 days.
2.5.6 DNA Extraction from Cultured Cells
The cells required were grown to confluence on two 10 cm cell culture plates. 
These plates were trypsinised to release the cells, which were collected by centrifugation 
at 1300 g  for 10 min. The resulting cell pellet was frozen overnight at -20°C. The 
procedure for DNA extraction utilised the Nucleon Extraction Kit (Nucleon). One ml of 
solution B from this kit was added to the defrosted cell pellet and subsequently, the 
protocol as described below for DNA extraction from blood (2.7.1) was followed.
2.5.7 Confirming Platelet mtDNA Incorporation into Cybrids
An Alul (Promega) restriction enzyme digest was performed on DNA extracted 
from the cultured cybrids in order to assess whether platelet mtDNA had been 
successfully incorporated. A PCR was performed on the extracted DNA utilising the 
following reaction conditions;
10 x PCR Buffer (Sigma) 5 pi
DNA 100 ng(lpl)
M60 Primer 50 pmol CTA ACA CCA GCC TAA CCA GA
M61 Primer 50 pmol GGT TAG CAG CGG TGT GTG AG
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MgCl2 1.5 mM
dNTP 200 pM
Red Taq (Sigma) (lunit/pl) 2.5 Units
ddH20  to 50 pi volume
Reaction Conditions
4 min 94°C
30 s 94°C }
30 s 55°C repeated 30 times
30 s 72°C }
5 min 72°C
A restriction enzyme digest was performed using 17.5 pi of these PCR products 
with Alul. Five units of the enzyme, along with acetylated BSA, to a final concentration 
of 0.1 mg/ml, made up to a volume of 70 pi with the supplied restriction enzyme buffer, 
were incubated with the products of the PCR reaction for 150 min at 37°C. The resulting 
digest was run on a high resolution agarose (Sigma) gel of 4% in TAE buffer (appendix 
1) with 1 pi ethidium bromide (5.25 mg/ml in H20 ) per 10 ml of gel. The voltage across 
the electrophoresis tank was set at 25 V for 15 min in order to ensure that the polarity was 
correct and the marker dye was migrating appropriately. The voltage was subsequently 
increased to 60 V, and the gel was run for a further 90 min. The gel was examined on an 
ultraviolet transilluminator. Appropriate Polaroid pictures were taken. The buffer,
containing ethidium bromide was poured into an appropriate disposal device. The digest
was run with a <|>X174 DNAJHinfl marker (Invitrogen).
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2.6 Cell Staining
2.6.1 5-Bromo-2’-deoxy-uridine (BrdU) Labelling in Cybrid Cells
The cybrids were grown on glass cover slips to a confluence of around 50%. 
Staining was performed with a commercially available kit (Roche). Cells were grown for 
1 h in fibroblast growth medium supplemented with 15 pM BrdU at 37°C and 8% CO2.
The cells were removed from the incubator and the labeling medium was 
removed. The cells were then washed 3 times in beakers containing 25 ml of PBS. The 
coverslips were drained between washes on tissue paper. Fixation of the coverslips was 
carried out in 70% ethanol with, 50 mM glycine.HCl (pH 2.0) at -20°C for 30 min. The 
coverslips were then incubated with 80 pi of anti-Brdu working solution (i.e. anti-Brdu 
solution (bottle 4 of Roche kit), 10 times diluted in PBS) for 30 min at 37°C in a 
humidified atmosphere. Having been washed three times in PBS, the cover slips were 
ncubated with secondary antibody (anti-mouse-Ig-Alexa 488) (Molecular Probes) at a 
dilution of 1:100 in PBS for 30 min at 37°C in a humidified atmosphere.
The cover slips were washed again 3 times in PBS, before being mounted on glass 
slides (Agar) with Citifluor (Agar). Examination of the cover slips was perofrmed using a 
Zeiss axiophot fluoresence microscope equipped with FITC and rhodamine filters. The 
poportion of cells which demonstrated nuclear staining without extra-nuclear staining 
were compared with the proportion of cells which demonstrated extra-nuclear staining.
2.6.2 Mitochondrial protein immunofluorescence staining of cultured cells
The cultured cells to be examined were seeded onto coverslips for 24 h in 
appropriate growth medium (appendix 1). This was replaced with prewarmed medium 
containing 4 pM (50 pg per 35 ml of medium) Mitotracker® Red CM-H2XRos 
(Molecular Probes, Inc.) for 45 min. A stock of 50 pg Mitotracker dye in 200pl of DMSO 
was made up beforehand. The cells were then cultured for 30 min in plain prewarmed 
medium.
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The coverslips were washed three times in beakers containing 25 ml of PBS (not 
supplemented with MgCh and CaCh). The coverslips were drained between washes on 
tissue paper.
The coverslips were fixed in fresh, pre-warmed, 4% paraformaldehyde in PBS for 
20 min. The coverslips were washed three times in beakers containing 25 ml of PBS. 
Between washes, the coverslips were drained on tissue paper. The coverslips were placed 
in a rack in a container with PBS.
The rack was then transferred with coverslips to a container containing methanol 
at -20°C for 15 min. The coverslips on the rack were then placed in a container 
containing PBS.
The coverslips were further washed three times in beakers containing 25 ml of 
PBS, draining the coverslips between washes on tissue paper. Blockage of non-specific 
protein binding sites on the coverslips was performed with 300 pi of 10% normal goat 
serum (Sigma) in PBS for 30 min at 37°C in a humidified atmosphere.
The coverslips were drained and incubated with 80 pi of anti-COXl antibody 
(Molecular Probes) at a dilution of 15 pg IgG/ml in PBS, 2% normal goat serum for 45 
min at 37°C in a humidified atmosphere.
Coverslips were washed a further three times in beakers containing approximately 
25 ml of PBS. Between washes the coverslips were drained on tissue paper.
The coverslips were incubated with 80 pi of 100 x diluted goat anti-mouse IgG 
Alexa® 488 (Molecular Probes, Inc.) in PBS, 2% normal goat serum for 45 min at 37°C 
in a humidified atmosphere.
The coverslips were washed 3 times in beakers containing approximately 25 ml of 
PBS, draining the slips between washes on tissue paper. The coverslips were placed in a 
rack in a container containing PBS.
The coverslips were mounted on glass slides in Citifluor/PBS/glycerol (Agar) 
supplemented with 1 pg/ml of DAPI (Sigma) and sealed with nail polish.
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The slides were stored at 4°C in the dark until examination under fluorescence 
microscope could take place.
2.7 Superoxide Dismutase 1 Mutation Analysis
2.7.1 DNA Extraction from Whole Blood - Using Nucleon BACC2 kit (Amersham 
Biosciences)
The blood from which the DNA was to be extracted was placed in a 50-ml 
centrifuge tube. Four volumes of reagent A from the Nucleon BACC2 kit were added to 
the blood. The tubes were agitated for 4 min at room temperature. The tubes were spun at 
1300 g  for 5 min. The supernatant was removed from each tube. Two ml of reagent B 
from the Nucleon BACC2 kit was added to each pellet. The pellets were vortexed briefly 
in order to disperse them within the reagent. The suspension was transferred to a clean 
15-ml tube. Fifteen pi of RNAase were added to each tube, and they were incubated at 
37°C for 30 min.
Five hundred pi of 5 M sodium percholate was added to each tube, and they were 
inverted twelve times. Two ml of chloroform was added to each tube and they were 
inverted. Without further mixing, 300 pi of separation-suspension was added to each 
tube. The tubes were spun at 1300 g  for 3 min.
The upper phase from each tube was removed and transferred to a clean 15-ml 
tube. Two volumes of cold absolute ethanol was added to the upper phase and the tubes 
were inverted twelve times. The DNA precipitated out, allowing its removal. The DNA 
was carefully transferred to a 1.5-ml Eppendorf tube, containing 1 ml of 70% ethanol.
The Eppendorf tubes were spun at maximum speed (11500 g) for 5 min. The 
ethanol was poured off, and the Eppendorf tubes were left on a drying block for 
evaporation of the remaining ethanol. One ml of TE buffer (appendix 1) was added to 
each tube, and the tubes were left overnight for the DNA pellet to dissolve.
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2.7.2 Spectrophotometric Assay of DNA Solutions
The Hitachi U-3220 spectrophotometer was set up in order to measure the 
absorption between wavelengths of 210 nm and 310 nm. Scanning speed was set at 120 
nm per minute. A baseline was obtained by measuring the absorption of 480 pi of 
distilled water in a 500 pi quartz cuvette (Sigma). Twenty pi of the DNA sample, 
obtained by the extraction protocol was added to the cuvette and mixed thoroughly. 
Absorption was then measured. To determine the concentration from this reading in g/1, 
the absorption at 260 nm was divided by 20 (extinction co-efficient for DNA) and 
multiplied by 25 (volume in cuvette / volume of DNA added),
2.7.3 PCR for SOD1 Exon 1
Primers : G107 -  5’ CCC CTT GGC CCG CCC CAG TCA TTC 3’
G108 -  5’ TCG GGA GCG GCC TCG CAA CAC AAG 3’
Master Mix (for 25 pi); (all in pi)
h 2o 11.65
10 X Buffer (Sigma) 2.5
50 mM MgCl2 0.75
dNTP (200 mM) 0.5
G107 (50 pM) 2.0
G108 (50 pM) 2.0
Red Taq (Sigma) (lunit/pl) 2.0
DMSO 2.6
DNA (1 pg/pl) 1.0
Reaction Conditions:
94°C 5 min
94°C 30 s }
52°C 30 s repeated 30 times
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72°C
72°C
30 s } 
7 min
2.7.4 PCR for SOD1 Exon 2
Primers : G109 -  5’ AAG TGG TCA GCC TGG GAT TTC 3’
G110 -  5’ AGG GGC TAC TCT ACT GTT TAT 3’ 
Master Mix (for 25 p.1); (all in pi)
H20  11.65
10 X Buffer 2.5
50 mM MgCl2 0.75
dNTP (200 mM) 0.5
G109 (50 pM) 2.0
G110 (50 pM) 2.0
Red Taq (1 unit/pl) 2.0
DMSO 2.6
DNA (lug/p l) 1.0
Reaction Conditions:
94°C 5 min
94°C 30 s }
51°C 30 s repeated 30 times
72°C 30 s }
72°C 7 min
2.7.5 PCR for SOD1 Exon 3
Primers : G105 -  5’ TTG TTT CTG TTC CCT TCT CAC TGT 3’
G106 -  5’ GTT CCC CTT TGG CAC TTG TAT T 3’
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Master Mix (Tor 25 pB: tall in uB
H20 14.25
10 X Buffer 2.5
50mM MgCl2 0.75
dNTP (200mM) 0.5
G105 (50 pM) 2.0
G106 (50 pM) 2.0
Red Taq (1 unit/pl) 2.0
DNA (1 pg/pl) 1.0
Reaction Conditions:
94°C 4 min
94°C 30 s }
52°C 30 s repeated 30 times
72°C 30 s }
72°C 7 min
2.7.6 PCR for SOD1 Exon 4
Primers : G97 -  5’ TGT TTG CAA ATT TGT GTC TAC TCA 3’
G98 -  5’ GAA TTC GCG ACT AAC AAT CAA AGT 3’ 
Master Mix (for 25 pi); (all in pi)
H20 16.6
10 X Buffer 2.5
50 mM MgCl2 1.5
dNTP (200 mM) 0.5
G97 (50 pM) 0.3
G98 (50 pM) 0.6
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Red Taq (1 unit/pl) 2.0
DNA (1 pg/pl) 1.0
Reaction Conditions:
94°C 5 min
94°C 30 s }
50°C 30 s } repeated 30 times
72°C 30 s }
72°C 7 min
2.7.7 PCR for SOD1 Exon 5
Primers : G103 -  5’ TTT CTG CTT TTA AAC TAC TAA 3’
G 1 0 4 -5 ’ TTT AAG TCTGGC AAA ATA CAG 3’
Master Mix (for 25 uD: (all in uD
H20 13.65
10 X Buffer 2.5
50 mM MgCh 0.75
dNTP (200 mM) 0.5
G103 (50 pM) 0.8
G104 (50 pM) 1.2
Red Taq (1 unit/pl) 2.0
DMSO 2.6
DNA (1 pg/pl) 1.0
Reaction Conditions:
94°C 5 min
94°C 30 s }
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48°C
74°C
74°C
30 s repeated 30 times
30 s }
7 min
2.7.8 Agarose Gel Electrophoresis of SOD 1 PCR Products
A 100ml Agarose gel was made up at 1.5%, using TAE buffer (see appendix 1). 
The gel was left to cool until around 60°C. Ethidium bromide (5 pi of 10 mg/ml) was 
added to the gel, and it was poured into a horizontal plastic gel tank containing a comb 
and left to set.
TAE buffer was poured into the gel tank, covering the surface of the gel. The 
plastic comb was removed and the gel loaded with 5 pi of PCR product mixed well with 
1 pi of loading dye (Promega). One well was loaded with 3 pi of 100 bp DNA standard 
ladder (Promega) which had been mixed with 1 pi of loading dye.
The voltage across the electrophoresis tank was set at 25 V for 15 min in order to 
ensure that the polarity was correct and the marker dye was migrating appropriately. The 
voltage was subsequently increased to 60 V, and the gel was run for a further 90 min. The 
gel was examined on an ultraviolet transillmuinator. Appropriate Polaroid pictures were 
taken. The buffer, containing ethidium bromide was poured into an appropriate disposal 
device.
2.7.9 DNA Sequencing
The PCR product was cleaned using the Qiaquick Qiagen© clean-up kit. The 
DNA concentration was then determined by spectrographic analysis using the DNA 
spectrophotometric protocol, as outlined above (2.7.2). The sample was sequenced in 
both directions, using the primers that were used in the initial PCR process. Samples were 
sent for sequencing to the Wolfson Institute, University College London. A Beckman 
Coulter CEQ 8000 genetic analysis systems was used. The raw data was analysed using
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the Seqman programme and compared with available SOD1 sequence data (human 
chromosome 21 sequence segment 31953890 -  31963107 with accession number 
NC_000021).
2.8 Biochemical Assay of Mitochondrial Respiratory Chain Complexes
2.8.1 Spectrophotometry Overview
Assays to determine mitochondrial respiratory chain activity were performed 
using spectrophotometric methods. Separate assays were performed for complex I 
(NADH-ubiquinone Q reductase), complex II/III (succinate cytochrome c reductase) and 
complex IV (cytochrome c oxidase) activity (140-143). The samples were assayed for 
citrate synthase activity, and the final enzyme activity was expressed as a ratio of activity 
per citrate synthase activity. In addition, tissue samples were also analysed for protein, so 
that this could be controlled for.
The assays were performed blind. After preparation from cell pellets, the 
mitochondrial aliquots were assigned numbers by a third party, with the assignation of 
the individual aliquots not being revealed until after the assays and activity calculations 
had been performed. Assays for each complex were performed on three separate samples, 
with an average taken of the results to be used in calculating the enzyme activity, as 
described below. For the purposes of standardization, two patient samples and two age- 
and sex-matched controls were grown, harvested and analysed at the same time. All the 
samples were assayed using the same reagents on the same spectrophotometer (Hitachi).
\
2.8.2 Complex I Activity
This assay was performed using ubiquinone (Qi) (Eisai Corporation. Tokyo, 
Japan). A working solution of 1 in 50 dilution was made from a stock sample. The 
required amount of working solution for the assay was calculated by loading two quartz 
cuvettes with 990 pi of ethanol and adding 10 pi of the ubiquinone working solution.
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Both cuvettes were placed in the spectrophotometer, set to measure absorbance at 275 nm 
wavelength. A granule of sodium borohydride was added to the reference (back) cuvette, 
in order to reduce the ubiquinone to a non-absorbing ubiquinol state. The final 
absorbance change was measured and used to calculate the amount of ubiquinone 
required (see the spectrophotometry calculation section, below).
The mitochondrial enzymes were exposed by freeze-thawing the mitochondrial 
preparations (which were prepared as described above) three times in liquid nitrogen and 
a water bath set at 30 °C.
The spectrophotometer was set to perform a time scan at a wavelength of 340 nm 
at a temperature maintained at 30°C, with sampling set to a frequency interval of 10 s and 
total scan time at 8 min.
Three reference and three test cuvettes were set up with 800 pi of 25 mM 
phosphate buffer (pH 7.2) (containing 10 mM MgCb), 30 pi of 5 mM NADH, 10 pi of 
100 mM potassium cyanide and 50 pi of bovine serum albumin. One hundred pi of 
distilled water was added to the reference cuvettes. The test cuvettes were given 100 pi of 
distilled water minus the volume of ubiquinone (amount derived as above) and the 
volume of the mitochondrial preparation to be used. Mitochondrial preparation was then 
added to the test cuvettes. Both sets were loaded into the spectrophotometer (the test 
cuvette at the back, the reference cuvette at the front) which was auto-zeroed. The assay 
was then started and left for around 30 s for the absorbance to stabilise. The calculated 
volume of ubiquinone was added to the test cuvette, and the assay left to run for 2 to 3 
min. At this point 10 pi of rotenone (10 pM stock solution in ethanol) was added to both 
cuvettes. The rotenone-sensitive cellular NADH dehydrogenase activity was, therefore, 
inhibited. The rate was followed for a further 2 to 3 min, and the rotenone-sensitive rate 
of reaction was then calculated as described below. Three assays were performed for each 
sample.
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2.8.3 Complex II/III activity
The mitochondrial enzymes were exposed by freeze-thawing the mitochondrial 
preparations (which were prepared as described above) 3 times in liquid nitrogen and a 
water bath set at 30°C.
The spectrophotometer was set to perform a time scan at a wavelength of 550 nm 
at a temperature maintained at 30°C, with sampling set to a frequency interval of 10 s and 
total scan time of 8 min.
Six cuvettes (three test and three reference) were loaded with 600 pi of 166 mM 
phosphate buffer (pH 7.4), 20 pi of 15 mM EDTA and 50 pi of 2 mM horse cytochrome 
c (Roche). The three reference cuvettes were loaded with 320 pi of distilled water. Test 
cuvettes were loaded with 320 pi less the volume of mitochondrial preparation to be used 
plus 40 pi (for the volume of succinate required). Three Eppendorf tubes were loaded 
with 10 pi of 100 mM potassium cyanide and 40 pi of 500 mM sodium succinate. In 
order to activate the mitochondrial enzyme complex, the previously freeze-thawed 
samples were aliquoted at the required amount into the Eppendorf tubes 5 min before the 
start of the assay. At 1 min prior to the start of the assay, 10 pi of 100 mM potassium 
cyanide was added to the reference cuvette. The assay was started and auto-zeroed. After 
the baseline had stabilized, the contents of the pre-warmed Eppendorf tube was added to 
the test cuvette and mixed thoroughly. After spectrophotometric measurement running for 
3 to 4 min, 10 pi of 500 mM antimycin A were added to both cuvettes. The trace was 
then checked for an absence of antimycin A -  insensitive activity.
For each subsequent assay, the mitochondrial preparations were added to the 
Eppendorf tubes in a water bath set at 30°C at 5 min prior to the start of the assay, while 
the potassium cyanide was not added to the reference cuvette until 1 min prior to the start 
of the assay. The rate of reaction, and enzyme activities were calculated as described 
below. Three assays were performed for each sample.
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2.8.4 Complex IV (cytochrome c oxidase) activity
The mitochondrial enzymes were exposed by freeze-thawing the mitochondrial 
preparations (which were prepared as described above) three times in liquid nitrogen and 
a water bath set at 30°C.
The spectrophotometer was set to perform a time scan at a wavelength of 550 nm 
at a temperature maintained at 30°C, with sampling set to a frequency 10 s and total scan 
time of 8 min.
Initially the volume of stock reduced horse cytochrome c was calculated. The 
method of reduction is described below (2.8.5). Two cuvettes were identically loaded 
with 100 pi of 0.1 M phosphate buffer (pH 7.0) and 850 pi of distilled water. Fifty pi of 
the reduced cytochrome c was added to both cuvettes. Ten pi of 0.1 M potassium 
ferricyanide were added to the back (reference) cuvette. The change in absorbance was 
recorded and used to calculate the volume of reduced cytochrome c (50 pM) required for 
the assay, using the calculation described below.
Three reference and three test cuvettes were loaded with the previously calculated 
amount of reduced cytochrome c and 900 pi of 0.1 M phosphate buffer (pH 7.0), less the 
volume of cytochrome c to be used and the volume of mitochondrial preparation (for the 
test cuvettes), or the 10 pi (of ferricyanide) for the reference cuvettes. The reference 
cuvettes were loaded into the back of the spectrophotometer, while the test cuvettes were 
loaded into the front. Autozeroing was carried out, before 10 pi of ferricyanide was added 
to the reference cuvette in order to completely oxidise the cytochrome c. At this point, the 
absorbance read around 0.96 and the assay was started. The extinction coefficient for
i  1
reduced cytochrome c is 19.2 x 10 M' 550 nM. Thus, an absorbance of 0.96 implies a 
reduced cytochrome concentration of 50 pM.
After 30 s, the mitochondrial preparation was added, as rapidly as possible, to the 
test cuvette without removing the cuvette from the spectrophotometer. The assay was 
then left to run for 5 min. Data were taken from time point zero (at the addition of the 
mitochondrial preparation), and then again at 1 min intervals. The rate of reaction
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constant (K) was calculated using a logarithmic scale (see paragraph 2.8.7.6). This figure 
was then used to calculate the enzyme activity as described below.
2.8.5 Reduction of Cytochrome c
Cytochrome c was reduced in order to carry out the complex IV assays, using 
ascorbate and subsequent dialysis.
Five ml of ascorbate, at a concentration of 12 mg in 100 ml was added to 100 ml 
of horse cytochrome c (Roche) at a concentration of 10 mg/ml and was mixed thoroughly 
for an hour. The sample was then placed in a dialysis membrane and dialysed against 
0.01 M phosphate buffer (pH 7.0) at 4°C for 2 h. After this time, the buffer was changed, 
and dialysis continued for a further hour.
In order to check that the cytochrome c was fully reduced, two cuvettes were 
loaded with 850 pi of distilled water, 100 pi of phosphate buffer (pH 7.0) and 50 pi of the 
cytochrome c solution. They were loaded into the spectrophotometer, with wavelength 
measurement set to 550 nm. Ten pi of the ascorbate solution (50 ml/ml) was then added 
to the back cuvette. No change in absorbance indicated that full reduction had taken 
place.
In order to ensure that there was no ascorbate in the reduced cytochrome c 
samples, two cuvettes were loaded in a similar way to that described above. Instead of 
ferricyanide, oxidized cytochrome c was added to the back cuvette. The principle was 
that the absorbance would change if this was reduced by any residual ascorbate. On the 
basis of these analyses, a decision was made regarding the need for further dialysis, 
further ascorbate, or preparedness for use in the assay, proper. If ascorbate was present in 
the sample, further dialysis was performed. If the sample was shown to have undergone 
oxidation, further ascorbate was added, and the dialysis repeated.
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2.8.6 Citrate Synthase Activity
Citrate synthase is an enzyme of the mitochondrial matrix, and, as such, may be 
used to establish the concentration of mitochondria within a sample. The enzyme rates 
that were derived from the assay were expressed as ratios to the same sample’s citrate 
synthase activity.
The spectrophotometer was set to perform a time scan at a wavelength of 412 nm 
at a temperature maintained at 30°C, with sampling set to a frequency interval of 10 s and 
total scan time at 8 min. Because the citrate synthase is not a membrane-bound complex, 
Triton-XlOO was used to solubilise the membranes and release the enzyme.
One reference cuvette and three test cuvettes (per sample) were loaded with 500 
pi of 50mM Tris buffer (pH 8.0) (see appendix 1), 20 pi of 10 mM acetyl CoA, 20 pi of 
10 mM DTNB and 10% (volume) of Triton-XlOO. Four hundred and forty pi of distilled 
water was added to the reference cuvette. Four hundred and forty pi of distilled water less 
the volume of mitochondrial preparation to be used and 10 pi (for the oxaloacetic acid to 
be added) were added to the test cuvette. Both cuvettes were loaded into the 
spectrophotometer (test at the front and reference at the back). The required volume of 
mitochondrial preparation was added to the test cuvette and the assay started. When the 
baseline had stabilized, 10 pi of 10 mM oxaloacetic acid were added to the test cuvette. 
The assay was allowed to run for a further 5 min. Enzyme activity was calculated as 
described below.
2.8.7 Spectrophotometry Calculations
2.8.7.1 Calculation of volume of working solution of ubiquinone
A 1 M solution of ubiquinone will produce an absorbance change at 275 nM of 
12.25 x 103. Therefore, if volume V of ubiquinone produces absorbance change A, the 
molarity of the stock solution is A /12.25 (in mM). The required molar concentration
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within the cuvette is 50 pM. Therefore, 50 x 10 3 / ((absorbance change/12.25)/V) is the 
new volume of ubiquinone stock that needs to be added to the assay.
2.8.7.2 Complex I (NADH-Ubiquinonel reductase):
The complex I activity was calculated by dividing the change in absorbance at 
440 nM over time before and after the addition of rotenone to the reaction (fig 2.2) to 
determine the rate of reaction. This rotenone sensitive rate can be used to calculate 
enzyme activity, by knowing that the molar extinction coefficient of NADH is 6.81 x 103 
M. The rotenone sensitive rate of NADH reduction is:
{[(Ab-Aa)/(Tb-Ta)-(Ae-Ae)/(Te-Tb)]/6.81 x  103} x  1000/v x  1/1000 
Where A is the absorption at a given time point, T is the time at a given point and v is the 
volume of the mitochondrial sample added to the cuvette (in pi). The rate is given in 
mol.min*1.mrI.
time (min)
Figure 2.2 The rate o f reaction o f mitochondrial respiratory chain complex 1 
Where C represents the point o f addition o f rotenone.
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2.8.7.3 Complex II (succinate cytochrome c reductase)
Follows the basic principle of the above calculation, but the molar extinction 
coefficient of cytochrome c at 550 nm is 19.2 x 103 M '.cm '1. There is one rate to use (fig 
2.3) and the formula changes:
{[(Ab-Aa) /(Tb-Ta)]/19.2 x 10s}* . 1000/v  x  1/1000 
Where A is the absorption at a given time point, T is the time at a given point and v is the 
volume of the mitochondrial sample added to the cuvette (in pi). The rate is given in 
mol.min'.mr1.
0)o
§
time (min)
Figure 2.3 The rate o f reaction o f mitochondrial respiratory chain complex //////
2.8.7.4 Citrate Synthase
The equation is for above, but the extinction coefficient of DTNB at 412nm is
13.6 x 103 M '.cm '1
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2.8.7.5 Volume of reduced cytochrome c to use in complex IV assay.
Spectrophotometry was performed as above. The difference in absorbance 
between the cuvettes was recorded. As the molar extinction coefficient for cytochrome c 
at 550 nm is 19.2 x 103, it can be calculated that 50 pM of reduced cytochrome c will 
produce an absorbance change of 0.96. Because the amount of reduced cytochrome c in 
each batch varies, it is appropriate to calculate the volume required for each batch that is 
used. As 50 pM of reduced cytochrome c is required for the assay, the volume of reduced 
cytochrome c to be added to the cuvette: (0.96/A) x V (where A is the observed 
absorbance and V is the volume of reduced cytochrome c used).
2.8.7.6 Complex IV (cytochrome c oxidase) activity.
The rate of reaction is first-order (fig 2.4), therefore, the pseudo-first rate 
constant, K, was calculated (13g). This was done by noting the absorbance values at 1 
minute intervals following the initial reading (at the point of addition of the mitochondrial 
preparation). A plot was then made of lnAt=o -  In (At=o -  At=n) against time:
K = lnAt=o - In (At=o - At=n) per minute
The results were expressed as K. min'1.mg'1 or K. min'1.(citrate synthase activity)'1. 
Taking into account the dilution of the sample in the cuvette and the protein 
concentration or citrate synthase activity of the sample.
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0 2 3
time (min)
Figure 2.4 The rate o f change in absorbance o f  cytochrome c in the calculation o f the 
activity o f the mitochondrial respiratory chain enzyme IV
2.9 Muscle Analysis
In addition to the biochemical assays carried out on myoblasts, fibroblasts and cybrid 
cells, whole muscle taken from the open biopsy was homogenised and analysed for the 
respiratory chain enzymes and aconitase, a marker of oxidative damage. Respiratory 
chain enzyme assays were performed on muscle homogenate as described for cell 
mitochondrial preparations (2.6).
2.9.1 Muscle Homogenisation
Following biopsy, a piece of muscle tissue, stored at -80°C was taken from the 
freezer and snap frozen in a 2-ml cryotube in liquid nitrogen. This was done because
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fragmentation of the muscle was more complete from a solid state. The sample was then 
placed in a homogenisation tube with 75 pi of homogenisation buffer (appendix 1). Using 
the homogenisation pestle at 200 rpm, the sample was homogenised for 20 complete 
strokes. In order to clarify the sample, the muscle homogenate was spun at 450 g  for 1 
min. The resulting supernatant was distributed between two 2-ml cryo-tubes and placed 
on ice for subsequent respiratory complex assays, performed as described for cell 
homogenates (2.8).
2.9.2 Aconitase Assay
The mitochondrial enzymes in the sample were exposed by freeze-thawing three 
times in liquid nitrogen. The spectrophotometer was set to record at a wavelength of 340 
nm with a run time of 35 min. Sampling was set at a frequency interval of 10 s. Three test 
and one reference cuvettes were loaded with 600 pi of 83.3 mM tris buffer (pH 7.4), 100 
pi of 4 mM NADP, 50 pi of 100 mM sodium citrate, 10 pi of 60 mM MgCU, 10 pi of 
Triton X-100 and 2 units of citrate dehydrogenase. The required amount of homogenate 
was added to the test cuvettes, and the volume of each cuvette was made up to 1 ml with 
distilled water. The cuvettes were left in a water bath for 30 min at 30°C for the enzyme 
to become activated. The samples were loaded into the spectrophotometer and the assay 
run for 30 min. The reaction rate was calculated as for the respiratory chain enzymes 
(2.8.7), with a molar extinction coefficient of NADPH of 6.2 x 103.M'1.cm'1 being used.
2.9.3 Protein Determination
As well as being corrected for citrate synthase activity, the muscle homogenate 
enzyme activities were also corrected for protein concentration. This was done using a 
commercially available kit (Bio-Rad). The principle of this technique is that coomassie 
blue dye binds to protein under acidic conditions and a shift in light absorbance from 465 
nm to 565 nm occurs. The same technique for protein estimation was used for the cell 
aconitase assays.
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One ml of the standard coomassie dye in phosphoric acid and methanol solution 
(Bio-rad Laboratories) was diluted with 4 ml of water. On a 96-well plate (flat bottomed), 
200 pi of this solution were plated into 8 standard wells and an appropriate number of 
sample wells (4 per sample being analysed). A standard of bovine serum albumin at 2 
mg/ml was diluted 1:10 to give a working solution of 200 pg per ml. Standard 
concentrations of 0, 3, 6, 9, 12, 15, 18, 21 and 24 pg/ml were obtained by removing the 
required amount of dye solution from the standard wells and adding the same amount of 
protein solution. In a similar way, the sample was added to the sample wells at at least 
two different concentrations. The samples were mixed within their wells, and the plate 
was placed onto an ELISA plate reader (Hitachi), set to measure at 600 nm. The standard 
solutions gave a curve of absorbance against concentration, from which the protein 
concentration of the sample wells could be calculated from their absorbance.
2.9.4 Light Microscopy
A portion of the muscle sample obtained at biopsy was divided in theatre by the 
pathology technician (Ms J Workman), and snap frozen in isopentane cooled with liquid 
nitrogen. The sample was transported to the laboratory where the same technician 
performed standard lactate dehydrogenase, haematoxylin and eosin, succinate 
dehydrogenase, cytochrome oxidase, Gomori trichome stains for fibre size, type and 
distribution on each sample. The slides were then placed into storage. The slides were 
viewed using a 40x objective lens on a Zeiss light microscope. Any abnormal features 
present on each slide were noted. Comparison was made between the muscle biopsy 
samples taken from the patient group, controls and disease controls to determine whether 
there were features more common or exclusive to the patient group. The slides were also 
viewed and reported by Professor AHV Schapira; these reports were compared with the 
data obtained by the author in order to confirm that any abnormal features present had 
been correctly identified.
Electron microscopy was performed by Dr R King on the sample from the patient 
with familial disease, and reported verbally. The muscle biopsies were all prepared and
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stained using standard protocols in the Department of Clinical Neurosciences, Royal Free 
and University College Hospital Medical School.
2.10 MtDNA analysis
2.10.1 DNA extraction from whole muscle
The muscle tissue (approximately 100 mg) was macerated with two scalpels on a 
microscope slide in the Class 1 hood. The tissue was transfered to a 1.5-ml Eppendorf 
tube containing:
600 pi of 0.1 M sodium EDTA, 0.01 M Tris*HCl (pH 8.0)
40 pi of 10%SDS
100 pi of 20 mg proteinase K per ml.
The mixture was digested for 3 h at 56°C, rotating in an incubator. When the 
material was fully digested, the tubes were stored at -20°C until further processing could 
take place. Subsequently, the sample was thawed and 750 pi of liquefied phenol, washed 
in Tris buffer (Fisher Scientific) were added in a Class 1 hood. Extraction with phenol 
took place by rotation at room temperature for 15 min. The mixture was then micro­
centrifuged at 1.14 x 104 g  for 15 min (room temperature), and the (upper) aqueous phase 
was transfered very carefully to a new 1.5-ml Eppendorf tube. Extraction was then 
performed with 700 pi of phenol-solution/bromo-chloropropane/isoamyl alcohol 
(25:24:1) by rotation at room temperature for 15 min. The mixture was micro-centrifuged 
at 1.14 x 104 g for 10 min (room temperature), transferring the aqueous phase carefully to 
a new 1.5ml Eppendorf tube. This extraction step was repeated a further three times. 
Extraction with 650 pi of bromo-chloropropane/isoamyl alcohol (24:1) was then 
performed by rotation at room temperature for 15 min. After micro-centrifuging the 
sample at 1.14 x 104 g  for 5 min (room temperature), 500 pi of the aqueous phase was 
transferred to a new 1.5-ml Eppendorf tube. Fifty pi of 3 M NaOAC (pH 4.8) and 1.1 ml 
of ethanol (room temperature) were added and mixed thoroughly. The DNA precipitate
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was collected by centrifugation at 1.14 x 104 g  for 10 min (room temperature), the 
supernatant was removed and 1 ml of 70% ethanol was added to the tube. The pellet was 
collected by centrifugation at 1.14 x 104 g  for 10 min (4°C), and the supernatant 
removed. Having been briefly (5 min) dried at 37°C in the heat block, the pellet was 
dissolved in 30-100 pi of TE buffer (appendix 1) (i.e at room temperature for several 
hours). Once the DNA was fully dissolved, the quantity and quality were assessed with 
spectrophotometric assay (2.7.2).
2.10.2 Restriction Enzyme Digest
The DNA samples obtained as described were pipetted into 8-pg aliquots. 
Three pi of PvuII restriction enzyme (Promega) and 6 pi of lOx restriction enzyme buffer 
were added to each sample. The aliquots were made up to 60 pi, mixed throughly and 
briefly spun at 1.14 x 104 g  in a centrifuge before being incubated at 37°C for 2 hours.
2.10.3 Southern Blotting
The genomic samples obtained from the restriction digest were mixed with 0.2 
volumes of loading dye and run, along with a //mdll I-digested X DNA marker on a 0.7% 
agarose gel in 1 x TAE (appendix 1), 0.5 pg/ml ethidium bromide using the Pharmacia 
GNA 200 gel tank. The samples were resolved at 135 V on the gel, until the bromophenol 
blue band marker was running off the end of the gel. The gel was then transferred to a 
shallow container and depurinated in 330 ml of 0.2 M HC1 for 10 min whilst being 
agitated.
The depurinating solution was carefully poured off and the DNA was denatured in 
330 ml of 0.5 M NaOH, 1.5 M NaCl, for 30 min whilst being agitated. The denaturing 
solution was changed after 15 min. The denaturing solution was poured off and the gel 
neutralised in 330ml of 1 M Tris-HCl (pH 7.4) and 1.5 M NaCl for 40 min whilst being 
agitated. The neutralising solution was changed after 20 min.
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During neutralisation of the gel, the Optiblot Blotting Unit (Scotlab) was prepared 
for blotting. The unit, including the wick, was soaked for 10 min in an excess of single 
distilled water. The water was changed once during this period. Finally, the unit was 
rinsed with 10 x SSC buffer (appendix 1). Six hundred ml of 10 x SSC was poured into 
the base of blotting unit. A wet sheet of 3 MM paper (Whatmann) (in 10 x SSC) was 
transferred to the middle of the wick of the blotting unit. The gel was rinsed briefly in 10 
x SSC and transferred onto the wetted 3 MM filter paper. A Hybond-N membrane 
(Amersham Biosciences) was soaked, first in ddfUO, then in 10 x SSC, and placed on top 
of the gel. Three 3MM filter papers were soaked in 10 x SSC and placed in succession on 
to the top of the membrane.
The edges of the gel-membrane were covered with long strips of parafilm to 
prevent leakage. Fifteen absorbant dry towels were placed onto the gel-membrane and, 
finally, the top of the blotting unit. After 18 hours, the blotting unit was disassembled. 
The Southern blot DNA was cross-linked with UV light by placing on a UV- 
transilluminator (GRI) for exactly 2.5 min. The blot was dried between a thick paper 
towel and stored at room temperature until use.
Prehybridisation of the blot was carried out in 10 ml of 6 x SSC, 5 x Denhardt’s 
solution (appendix 1), 0.5 % SDS, 10 pg/ml heat-denatured, sonicated salmon sperm DNA 
(Sigma) at 65°C in an incubator (Hybaid) for 1 h. Because of local safety guidelines, all 
work involving radioactive materials was performed by Dr Taanman. 32P-labelled heat- 
denatured 18S RNA gene DNA and/or mtDNA probes, prepared by Dr Taanman using a 
commercially available labelling kit (Amersham) were added to the tube and left to 
hybridise overnight at 65°C. The blot was washed in 50 ml of pre-warmed 2 x SSC in the 
tube at 65°C for 15 min. The blot was then washed in 400 ml of pre-warmed 2 x SSC in a 
large container in a water bath at 65°C for 15 min. The blot was then washed in 250 ml of 
pre-warmed 2 x SSC, 0.1 % SDS in the large container at 65°C for 15 min. The blot was 
washed once more in 250ml of pre-warmed 2 x SSC, 0.1% SDS in the large container at 
65°C for 15 min. Finally the blot was washed in 500 ml of prewarmed 0.1 x SSC, in a large 
container at 65°C for exactly 10 min.
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The amount of radioactivity present was assessed with a Geiger counter. All 
radioactive products and waste were disposed of in accordance with local protocols and 
regulations.
The blot was initially exposed in a Phosphorlmager cassette (Amersham) and the 
levels of bound probe were quantified using ImageQuant software (Amersham). 
Student’s t-test was peformed on the results in order to detect a difference in the mean 
quantities of DNA.
2.10.4 Long-range PCR
DNA, extracted from skeletal muscle (see 2.10.1) was used for long-range PCR 
analysis of mtDNA. This technique utilised the Expand Long Template PCR System 
(Roche, Mannheim, Germany). A forward primer corresponding to the mtDNA 
nucleotide positions 6222-6236 and a reverse primer corresponding to the mtDNA 
nucleotide positions 16133-16153 were used (5’-CCC TCT CTC TCG CAT and 5’-CAG 
GTG GTC AAG TAT TTA TGG).
In order to determine the optimal concentration of primers and DNA template to 
use with the kit, a number of trial PCRs of control and patient DNA were performed 
using differing amounts of reagent.
The optimum amounts of reagent were determined to be (for 50 pi reaction):
DNA (1 pg/pl) 
dNTP (100 nM/pl)
Forward primer (100 nM/pl) 
Reverse primer (100 nM/pl) 
10 x buffer 
Enzyme mix 
H20-
0.2 pi
2 pi
3 pi 
3 pi 
5 pi
0.75 pi 
36.05 pi
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The PCR was carried out with a 1 min initial denaturation period at 93°C followed 
by 10 cycles of 10 s of denaturation at 93°C, 30 s annealing at 55°C and 6 min elongation 
at 68°C. This was followed by 20 cycles of 15 s denaturation at 93°C, 30 s annealing at 
55°C and elongation at 68°C, with each elongation period being 20 s longer than the one 
that preceded it in the cycle. Final elongation was carried out for 7 min at 68°C.
The samples were then run on a 0.8% agarose gel in 1 x TAE buffer for 5 hours at 
100 V, and visualised on a UV transilluminator.
2.11 Cellular Response to Oxidative Stress
2.11.1 Cell Apoptosis Assays
Capase-3 is a protease which is activated during the process of programmed cell 
death (apoptosis) (144). Apoptosis was measured in cell cultures. A commercially 
available kit (PhiPhiLux™ (Calbiochem)) was used for the assay of intracellular caspase- 
3 activity in response to a model of oxidative stress. The assay is based on the reaction of 
the enzyme with the cell-permeable PhiPhiLux® G1D2 substrate. Each substrate molecule 
contains two fluorophores and the cleaved substrate fluoresces green.
Cells of the experimental cultures at an equivalent passage number were grown on 
16-mm glass cover slips to a similar cell density. Cells were analysed at baseline and 
following 24 hour incubation in growth medium supplemented with a stock solution of 
ImM paraquat (25.7 g/1) to make up 0.1 pM (0.1 ml paraquat stock in 1000 ml cell 
growth medium) and 1 pM (1 ml paraquat stock in 1000 ml cell growth medium) 
solutions. The cover slips were washed once in PBS and then 40 pi of 10 pM of substrate 
peptide from the kit was added to each cover slip. The coverslips were incubated at 37°C 
for 30 mins and washed again with PBS. Without delay, the coverslips were examined 
under a fluorescence microscope using a fluorescein filter at 40 x 10 magnification. The 
number of fluorescent cells in one field was counted. The lamp of the microscope was 
then turned on, allowing a count to be made of all the cells in the field using phase 
contrast. Three randomly selected fields, progressing from left to right across the cover
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slip to avoid counting any cells twice, were analysed in this way. Caspase activation was 
recorded as the number of fluorescent cells per total cell population. For each culture 
performed this process was carried out on three different cover slips, with an average 
being taken of the total number of fields analysed.
2.11.2 Oxidative damage assay
As already described (2.9), aconitase was utilised as a measure of oxidative 
damage. In order to assess the level of oxidative damage in response to oxidative stress, 
aconitase levels were measured in cell cultures exposed to 0.05 pM 0.1 pM or 1 pM 
paraquat solutions in growth medium for 24 hours. The cell suspensions were harvested 
by trypsinisation of two confluent 10-cm plates of the cells followed by centrifugation at 
1300 g for 10 min and resuspension of the pellet in 70 pi of PBS. Twenty pi of 
suspension of cells were used for each assay. The method of assay is decribed in the 
section above (2.9.2). Values for aconitase activity were corrected for protein 
concentration of the cell suspension being analysed.
2.12 Data Analysis
All data were entered and stored in Microsoft Excel and Word Programmes. 
Subsequent statistical analysis of the data was carried out using SPSS© (version 12.0) 
software application. Individual statistical tests that were used are indicated in the 
methodology for each experiment, where appropriate. Statistical significance was taken 
as a calculated p value of less than 0.05 in all cases.
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3 Analysis of Nuclear DNA from Controls and Patients with ALS to 
Determine the Presence of Superoxide Dismutase 1 Mutations
3.1 Aims
To analyse the nDNA of the ALS patients, normal controls and disease controls to 
determine the presence or absence of mutations of the Superoxide Dismutase 1 (SOD1) 
gene.
3.2 Introduction
Sporadic and familial forms of ALS exist. The pattern of inheritance is usually 
dominant with variable penetrance (67). Mutations of the SOD1 gene, which encodes the 
enzyme copper/zinc superoxide dismutase, are found in approximately 20% of familial 
patients and occasionally, apparently sporadic, patients (67). SOD1 mutations account 
for 1-2% of all patients with ALS (ALS1) (48). Other, rarer, genetic abnormalities have 
been detected in patients with ALS, including the alsin (ALS2) (53) and senataxin 
(ALS4) (60) genes, along with linkage data for undefined genes (ALS3 (59), ALS5 (61), 
ALS6 (145), ALS7 (62) and ALS8 (63)) but the significance of these is uncertain at the 
present time (table 1.1). All 12 of the patients in this study (table 2.1) were screened for 
mutations of the SOD1 gene. One of the patients (PA11) was known to have familial 
ALS.
3.3 Approach
In order to screen for SOD1 mutations, total genomic DNA was extracted from 
whole blood (2.7.1), and the concentration determined by spectrophotometric methods 
(2.7.2). This DNA was subjected to PCR for the 5 exons of the SOD1 gene using the 
primers, reagents and conditions detailed (2.7.3). The samples were sent for sequencing
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at the Wolfson Institute for Biomedical Research, UCL. The sequence data was analysed 
using DNA STAR software package.
3.4 Results
There were no mutations in any o f  the SALS patients, disease controls or normal 
controls for the 5 exons o f  SOD1. The familial ALS patient was found to have a 
heterozygous 1147 T->C mutation in exon 4. This mutation is predicted to result in a 
lie 113Thr amino acid substitution in the protein (Figure 3.1).
i
v/y/vw aaa MvwvA-vcomroi(c8)
T G C T C . T T G G C C G C \  C
j  \ /
v'WYVv W ^ / W W v W W  PMienl(PAll)
T G C T C T/C T G G C C G C C 
Cys He lie Gly Arg Thr 
Thr
Figure 3.1 Heterozygous 1147 T—>C mutation in SOD1 exon 4 (arrowed) producing a 
Ile/Thr substitution.
3.5 Discussion
As none o f  the sporadic ALS patients in this study had a family history o f  
neurological disease, it is not surprising that there were no SOD1 mutations detected in 
this cohort. Although mutations in SOD1 o f  apparently sporadic cases are recognised (51)
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these are relatively rare. The familial patient studied showed no distinctive results in any 
of the investigations carried out into mitochondrial function.
The mutation identified (1147 T>C) on SOD1 exon 4 is a well recognised 
mutation in FALS and was first reported in 1993 (47). The patient’s mother died of ALS 
in her fifties, and genetic studies were never performed on her. None of the patient’s 
siblings has developed ALS as yet.
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4 Histological Features of Skeletal Muscle in ALS
4.1 Aims
To examine muscle tissue taken from patients with ALS, comparing it with 
normal control and disease control muscle to determine whether there are any histological 
features specific to ALS, and what these abnormalities may be.
4.2 Introduction
ALS is primarily a disorder of the motor neurons. As a part of the diagnostic 
workup, patients may have muscle biopsy with light microscopy of the samples obtained 
(146). This can be especially important where there is some doubt about the diagnosis or 
where there are a number of atypical features of ALS present (147). Some authors have 
reported abnormal metabolic activity (148) and ultrastructural abnormalities of the 
mitochondria in the skeletal muscle of patients with ALS (149). Skeletal muscle 
fasciculation and wasting are prominent clinical features of ALS. In view of the evidence, 
as outlined above, that there may be abnormal mitochondrial function and ultrastructure 
of skeletal muscle in ALS, features of mitochondrial diseases, as well as more general 
denervating conditions were looked for in the skeletal muscle samples which were 
obtained for biopsy.
Muscle biopsies are generally performed for diagnostic purposes, where the 
histological appearance of the muscle may provide additional information toward the 
management of the patient. Different histochemical stains are used to look for different 
pathological features. Haematoxylin and eosin (H+E) stains are used to look at fibre 
architecture and morphology (figures 4.1 -  4.4). Localisation of the nuclei and invasion 
of inflammatory cells are also seen with this stain. The presence of mitochondrial 
pathology may be looked for with cytochrome oxidase (for COX negative) or succinate 
dehydrogenase stains as well as Gomori trichome stains looking for the presence of
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ragged-red fibres which are indicative of mitochondrial accumulations. The absence of 
activity of these enzymes due to mitochondrial abnormalities can be seen in individual 
fibres of the muscle tissue (figure 4.8). ATPase stains, performed at different pH levels 
differentiate between type I and type II muscle fibres. These fibres perform different 
functions in the skeletal muscle. Type 1 fibres are slow contracting and predominantly 
aerobic in their metabolism whereas type II fibres are short acting, predominantly 
anaerobic in their metabolism. Different disease states can influence the distribution and 
relative densities of the two fibre types. Sudan black stains lipid present in the muscle 
whilst acid phosphatase demonstrates the presence of macrophages. There are a number 
of different conditions for which muscle histology analysis is important. Investigation of 
the muscular dystrophies, inflammatory disorders, storage disorders and mitochondrial 
diseases may involve the processing and analysis of a muscle biopsy.
4.3 Approach
Skeletal muscle biopsies of 12 patients with clinically definite ALS were 
examined and compared with skeletal muscle samples from a number of other conditions. 
Muscle biopsy specimens from 9 individuals with denervating conditions and benign 
fasciculation syndromes (table 2.2) were analysed along with muscle biopsy samples 
from 10 normal individuals. The same range of stains was carried out for each sample. 
ATPase, acid phosphatase, cytochrome oxidase, haematoxylin and eosin, Sudan black 
and also Gomori trichrome stains were performed according to standard laboratory 
protocols by Mrs Jane Workman. The samples were analysed, for each stain performed, 
in blinded fashion, and all of the positive features which were identified were confirmed 
as being present on another independent histological assessment.
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The positive features identified and quantified for each sample were :
Variation in fibre size (figure 4.1)
Internal nuclei (figure 4.2)
Fibre atrophy (figure 4.3)
Vacuolation (figure 4.4)
Grouping o f  all fibres (figure 4.5)
Grouping o f  type 1 fibres (figure 4.6)
Grouping o f  type 2 fibres (figure 4.7)
Lysosomal activity
COX negative fibres (figure 4.8)
Ragged-Red fibres (figure 4.9)
Inflammatory infiltrate (figure 4.10)
Increased lipid content (figure 4.11)
Figure 4.1 -  Variation in fibre size for sample C7 on H and E staining
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Figure 4.2- Numerous internal nuclei seen for sample C7 on H and E staining
Figure 4.3 -  Fibre atrophy seen on sample C l 1 with H and E staining
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Figure 4 .4 -  Vacuolation seen on sample C l 1 with H and E staining
Figure 4.5 -  Grouping o f type I (light) and type II (dark) fibres seen on sample PA2 with 
A TPase staining at pH  4.6
96
Figure 4.6 -  Grouping o f type I (light) fibres seen for sample D3 with ATPase staining at 
pH  4.6
Figure 4.7 -  Grouping o f type II (dark) fibres from sample D l with ATPase staining at 
pH  4.6
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Figure 4.8 -  COX negative fibre (arrowed) on sample PA4 with cytochrome oxidase 
staining
Figure 4.9 -  Red-ragged fibre (arrowed) seen on sample D5 with Gomori trichrome 
staining
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Figure 4.10 —  Inflammatory infiltrate (arrowed) seen on sample PA1 using acid 
phosphatase staining.
Figure 4.11 -  Increased lipid content in sample C9 seen with Sudan black staining
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4.4 Results
The samples from patients with ALS demonstrated a number o f  different 
abnormalities associated with denervation, such as fibre atrophy, angulation and variation 
in size. Statistical analysis using a three-way yy test revealed that these were not 
distinctive or diagnostic (figure 4.12 /  table 4.1). Grouping o f  all fibre types, occurred 
with a greater frequency amongst patient muscle samples than in control or disease 
control samples, although this did not quite reach significance (p=0.063).
The muscle biopsy specimen from the FALS patient was subject to electron 
microscopy by Dr R King. This was reported as demonstrating no significant 
abnormalities. There were no distinguishing features on immunocytochemical analysis.
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Figure 4.12 Bar chart showing the rates o f  occurrence o f  each histological feature in the 
control, disease control and patient groups, a = variation in fibre size, b = internal 
nuclei, c = fibre atrophy /  angulation, d  = vacuoles, e=  grouping o f  all fibre types, f  = 
grouping o f type 1 fibres, g  = grouping o f  type 2 fibres, h = lysosomal activity, i = COX  
negative fibres, j  = ragged red fibres, k =  inflammatory infiltrate, I =  increased lipid  
content
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Table 4.1 -  Features seen in diagnostic muscle biopsy as % o f total samples with 
statistical analysis.
Feature Controls
(No)
Controls
(%)
Disease
Controls
(No)
Disease
Controls
(%)
Patients
(No)
Patients
(%)
3-way Chi 
squared* 
(p value)
Variation in 
fibre size
5 50 6 75 9 75 0.69
Internal nuclei 1 10 0 0 1 8.33 1
Fibre atrophy / 
angulation
5 50 7 87.5 10 83.33 0.42
Vacuoles 2 20 0 0 0 0 0.5
Grouping of all 
fibres
3 30 1 12.5 7 58.33 0.063
Grouping of 
type 1 fibres
4 40 4 50 2 16.67 0.24
Grouping of 
type 2 fibres
0 0 2 25 0 0 0.5
Lysosomal
activity
4 40 5 62.5 7 58.33 0.72
COX -ve fibres 3 30 2 25 3 25 1
Ragged red 
fibres
2 20 2 25 1 8.33 0.62
Inflammatory
infiltrate
1 10 0 0 2 16.67 0.55
Increased lipid 
content
* Fisher's exact te
2
st used
20 1 12.5 2 16.67 1
4.5 Discussion
While muscle biopsy is important in excluding other conditions, where these are 
suspected, there are no histopathological abnormalities which, alone, would be diagnostic 
of ALS. Although grouping of all fibre types occurs with a greater frequency in muscle 
from patients with ALS, this feature is not specific enough to be regarded as having 
diagnostic value per se, as it is more a function of a denervation-reinervation pattern as 
recognised in previous studies (150,151). The disease control group, which included 
patients with known peripheral neuropathies, demonstrated a higher rate of type I or type
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II fibre grouping whereas the samples from ALS patients showed a higher rate of 
grouping of both fibre types. This suggests that the peripheral neuropathy patients 
develop a different pattern of denervation without reinervation, which may be why the 
muscle biopsy appearances of these patients are sometimes distinct from those with ALS.
There are cases where a muscle biopsy may be of diagnostic value in 
differentiating motor neuron disorders from primary muscle disorders (152). This is 
especially important in view of the potential for therapeutic intervention in the 
management of primary muscle disease, where immunomodulatory therapies may be 
appropriate.
Although some investigators have identified ultrastructural abnormalities of 
mitochondria in skeletal muscle of patients with ALS (including giant mitochondria, 
paracrystalline inclusions, and abnormal cristae) (149), there do not appear to be 
histological characteristics which allow ALS to be differentiated from other degenerative 
neuropathic conditions. As well as mitochondrial function in muscle tissue, which will be 
described in greater detail in following sections, work has been performed on muscle 
fibre function. A study looking at specific force and maximum unloaded shortening 
velocity in muscle from ALS patients and healthy controls demonstrated that ALS 
patients had decreased whole muscle specific force but normal single fiber function 
(153). This would appear to demonstrate that the rate of progression of disease can affect 
muscle fibre size and function, rather than the presence of ALS, per se. This may, 
however, also be secondary to the denervation that accompanies the disease. A study 
comparing muscle tissue from patients with ALS and other neurogenic atrophies with 
normal controls demonstrated increased levels of focal mitochondrial diminution in both 
disease groups (117). They used the appearance of core-like lesions on NADH staining. 
This was not looked for specifically in the present study, but the finding concurs with the 
appearance of certain abnormalities (fibre size variation and fibre angulation in disease 
and disease control groups compared with normal controls) which have been 
demonstrated, here. This supports the suggestion that muscle histological changes in ALS 
are secondary to denervation rather than mitochondrial pathology per se.
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It is also interesting to note that work has been performed on skeletal muscle 
energetics, which suggests that an energy imbalance in the muscles of transgenic SOD1 
mice may contribute toward a hypermetabolic state, with decreased adipose tissue and 
elevated metabolic rates (154). Again, difficulties arise in controlling for the pattern of 
denervation produced by the disease in delineating this as a secondary or primary 
phenomenon.
The features of muscle biopsy which would strongly suggest mitochondrial 
disease, such as ragged-red fibres and COX negative fibres (155) were not consistently 
present in muscle biopsies taken from patients with ALS. This would suggest that while 
there may be a mitochondrial component to the pathogenesis of ALS, this is not manifest 
at levels which would affect the structure or function of skeletal muscle tissue.
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5 Analysis of Mitochondrial Respiratory Chain Function and Oxidative 
Damage of Skeletal Muscle from Controls and Patients with ALS
5.1 Aims
To compare the activity of the mitochondrial respiratory chain enzymes in whole 
muscle tissue taken ffom patients, controls and disease controls. To compare oxidative 
damage in muscle tissue by the measurement of aconitase activity in whole muscle 
homogenates.
5.2 Introduction
Although the primary sites of pathology in ALS are the motor neurons in the 
spine and brain, a number of investigators have looked at mitochondrial abnormalities in 
skeletal muscle. As well as the ultrastructural abnormalities, which were dealt with in the 
preceeding chapter, biochemical mitochondrial function has been assessed.
Mouse models of ALS, that are transgenic for SOD1 mutations, have been used in
this field of study. Maximal oxygen consumption and apparent Km for ADP were
decreased in mitochondria from transgenic soleus (an oxidative muscle) (156). SOD 
activity was demonstrated to be lower in the nervous tissue than the muscle for these 
mice.
Human skeletal muscle has been investigated for biochemical activity. Response
of patient muscle to exercise was found to be abnormal, with increased lactate
production, possibly indicative of a respiratory chain disorder (148). The metabolic 
homeostasis of mice transgenic for SOD1 has been shown to be abnormal with increased 
energy expenditure and concomitant skeletal muscle hypermetabolism, suggesting that a 
primary muscle problem may be contributing to the development of the disease (154).
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The mitochondrial respiratory chain complex activities have been measured in patients in 
comparison with controls with spinal muscular atrophy (103). This revealed a decrease in 
muscle complex I activity in patient samples compared with controls. This was then 
confirmed using confocal laser-scanning microscopy and video fluorescence microscopy 
of NAD(P)H and fluorescent flavoproteins (98). Later studies appear to contradict these 
findings, suggesting that the respiratory function of saponin permeabilised muscle fibres 
from patients with sporadic ALS is entirely normal (104).
Aconitase has an iron-sulphur cluster (4FeS)2+ which is converted to the oxidised 
form (3FeS)+ by superoxide, allowing aconitase activity levels to be used as a secondary 
assessment of oxidative stress (157). Aconitase activity has been used as a measure of 
oxidative damage in tissues (158). If the abnormalities in mtDNA which have been 
identified in patients with ALS (112) are due to an increased level of oxidative damage, 
then the aconitase levels of the tissue may be affected. In the assessment of aconitase 
activity ffom muscle tissue, the aim is to determine whether patients with ALS undergo a 
greater degree of oxidative damage to all tissues, or whether they are more susceptible to 
this damage.
In order to establish mitochondrial function in the muscle of ALS patients, the 
activities of the mitochondrial respiratory chain complexes were measured in 
mitochondrial fractions and compared with controls. The values were calculated as a ratio 
to citrate synthase activity. Tissue aconitase activities and respiratory chain complex (I- 
IV) activities were related to age to determine whether age would affect these values in 
our sample.
5.3 Approach
Muscle samples were taken ffom the vastus lateralis muscle as described (section 
2.4.1). All samples were taken under a local anaesthetic, transferred to the laboratory in 
cell culture medium, and frozen down at -80 °C.
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For the purposes of analysis, muscle samples were homogenised as described 
(section 2.9.1). In order to minimise bias and inter-experimental variation, batches of 
patient, control and disease control samples were processed at the same. The samples 
were then assigned a code during the analysis which meant that the experiment and 
subsequent data analysis was performed with blinding to the sample origin. The samples 
were fractionated as described, and aliquots of the muscle mitochondrial-enriched 
fraction were snap frozen in liquid nitrogen and stored at -80 °C, until the biochemical 
analyses were performed.
For the aconitase assays, the spectrophotometric tests were performed on frozen 
homogenate, and the aliquots were used directly after homogenization and fractionation, 
without being frozen down, again.
Each assay was performed in triplicate, with an average of the results being used. 
Protein assays were performed on the aliquots, using the BioRad method (see section 
2.9.3). Values for the aconitase assays were calculated as per mg of protein. In order to 
correct for variations in mitochondrial number, values for the respiratory chain enzyme 
complexes were calculated as a ratio to total citrate synthase activity (which provides an 
index of mitochondrial mass) and protein.
A three way ANOVA test was performed on the data to determine whether there 
was any statistically significant difference between respiratory chain enzyme activities, 
aconitase activities or citrate synthase activites in control, disease control and patient 
whole muscle.
5.4 Results
5.4.1 Respiratory Chain Complexes
Spectrophotometric assay of the mitochondrial respiratory chain complexes 
revealed no significant difference between patients, disease controls and controls in 
muscle tissue homogenate for any of the enzyme complexes when controlled for citrate
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synthase concentration (table 5.1, figure 5.1) and for protein concentration (table 5.2, 
figure 5.2).
Table 5.1 Average enzyme complex activities in skeletal muscle as a ratio o f citrate 
synthase activity (mean ± SD)
I ll/lll IV
Controls (n=17) 0.17 + 0.1 0.17 + 0.07 0.04 + 0.016
Disease Controls (n=11) 0.2 ±  0.06 0.2 + 0.07 0.034 + 0.014
Patients (n»12) 0.23 + 0.11 0.19 + 0.07 0.044 + 0.014
Table 5.2 Average enzyme complex activities in skeletal muscle as a ratio o f  sample 
protein content (mg/ml) (mean ± SD)
I (mol.min^.ml1) ll/lll (mol.min'1.mr1) IV (mol.iniii'1.nir1)
Controls (n=14) 33.10 ±14.12 33.20 ±12.59 11.77 ± 4 .33
Disease Controls (n=11) 33.60 +16.24 33.37 ±15.14 10.96 ± 4 .48
Patients (n=12) 36.53 + 11.57 33.82 + 16.04 10.53 + 5.71
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Figure 5.1 -  Respiratory chain complex activity per  citrate synthase (CS) activity in 
mitochondrial fractions o f whole muscle showing result spread, mean values and SD. The 
SOD1 mutant sample result (PA11) is indicated (closed arrow). Complex IV results are 
multiplied by 5 fo r comparative purposes.
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Figure 5.2 -  Respiratory chain complex activity expressed per nmoles per minute per  
amount ofprotein (mg) in mitochondrial fractions o f  whole muscle showing result 
spread, mean values and SD. The SOD1 mutant sample result (PA 11) is indicated 
(closed arrow). Complex IV values are multiplied by 3 fo r  comparative purposes.
5.4.2 Aconitase levels
There was no statistically significant difference in aconitase levels between 
patient, control and disease control muscle tissue homogenate (table 5.3, figure 5.3).
Table 5.3 Aconitase activity in whole muscle /  mg protein
Mean aconitase Activity / mg protein 
(U/mg) ± SD
Controls (n=13) 12.96 ± 9 .7 9
Disease Controls (n=7) 16.01 ±  13.00
Patients (n=10) 13.52 ±  10.41
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Figure 5.3 -Aconitase activity activity expressed per  nmoles per minute per  amount o f  
protein (mg) in whole muscle with spread o f  values, mean and SD. The SOD1 mutant 
sample result (PA11) is indicated (closed arrow).
5.4.3 Variation in mitochondrial function with age
In order to determine the effect o f  patient age on mitochondrial respiratory chain 
function, linear regression analysis was performed for each respiratory chain complex 
against the age o f  the patient or control. Because no difference was found between 
groups, the samples were all pooled to look for variations in complex activity with age 
per se. A trend for increasing activity with age was found for complex I (figure 5.4) 
(p=0.07), but not complex 1I/III (figure 5.5) (p=0.54) or for complex IV (figure 5.6) 
(p=0.54).
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Figure 5.4 -  The variation o f  complex I activity in normal controls, disease controls and 
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Figure 5.5 -  The variation o f  complex 11/III activity in normal controls, disease controls 
and patients wih age. There is no association.
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Figure 5.6 -  The variation o f  complex IV activity in normal controls, disease controls 
and patients wih age. There is no association.
5.4.4 Variation in aconitase activity with age
In order to determine whether age exerted an independent effect on tissue 
aconitase activity, linear regression analysis was performed for each sample comparing 
age with tissue aconitase activity. No significant difference in association between 
sample groups was identified. Analysed as pooled samples, no association was found, 
indicating similar levels o f  oxidative damage (p=0.26) (figure 5.7).
5.4.5 Citrate synthase activity
There was no difference in mean citrate synthase activities between the patient, 
control and disease control muscle samples (p=0.38) (table 5.4, figure 5.8).
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Figure 5.7  -  The variation o f  muscle aconitase activity expressed p er  nmoles per minute 
per amount ofprotein (mg) with age in controls, disease controls and patient samples.
Table 5.4 Citrate synthase activity in whole muscle /  mg protein
Mean aconitase Activity / mg protein 
(U/mg) ± SD
Controls (n=16) 218.2 ± 8 4 .4
Disease Controls (n=ll) 170.9 ± 9 4 .7
Patients (n= ll) 173.9 ± 6 3 .3
♦ Control n=13 
■ Disease control n=7 
Patients n=10
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Figure 5 .8 -  Citrate synthase activity in control, disease control and patient muscle 
samples per mg ofprotein showing the spread o f values, mean and SD. The SOD1 mutant 
sample result (PA 11) is arrowed.
5.5 Discussion
The study demonstrated that there are no statistically significant functional 
deficits in skeletal muscle mitochondrial respiratory chain complex activity in patients 
with ALS compared with normal controls and disease controls.
This finding contradicts that o f other work in this field (98), where a specific 
decrease in complex I activity in the muscle o f  patients with ALS has been described, 
although these assays were not controlled for citrate synthase activity and, therefore, the 
variations in function may represent a variation in the number o f  functional mitochondria 
present in the tissue being analysed. This would raise the possibilty that the number or 
concentration o f  mitochondria becomes different in muscle tissue from patients with ALS 
and controls. There is no significant difference between patient and control groups when 
the samples are controlled for protein content. This would indicate that there is not a 
general proliferation or decrease in mitochondria secondary to changes in respiratory 
chain acivity. Taken together, these results suggest that mitochondrial concentration is 
similar in muscle tissue from patients and controls. This is confirmed by the finding that
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citrate synthase activity per mg of protein is the same in patients, controls and disease 
controls.
Detailed single fibre studies of mitochondrial mediated adenosine diphosphate 
stimulated respiration rates (104) have also demonstrated that there is no difference in 
mitochondrial function between patients and controls, however. The data shown here 
supports these findings. Another criticism raised in this second paper (104) was that the 
original work (98) had failed to control for differences in physical activity levels between 
patient and control populations. This study aimed to address this by using a disease 
control group with similar levels of activity to the patient group. Furthermore, patients 
and disease controls with similar power in the affected muscles were selected.
A recent study confirms the absence of mitochondrial respiratory chain enzyme 
abnormalities in muscle tissue taken from patients with ALS when compared with 
neurogenic (disease) and normal control groups (117). This study looked at enzyme 
activities relative to sample non-collagen protein content. As a separate finding, mean 
levels of citrate synthase activity were higher in muscle tissue from ALS patients and 
disease controls. This implies that enzyme activities controlled for citrate synthase may, 
in fact, be diminished in ALS and disease control groups. Such an assertion is not 
supported by our experimental work on citrate synthase activity.
There was no significant difference between aconitase levels in patient and 
control muscle tissue samples. Aconitase, as a surrogate marker of oxidative damage, 
may have been affected by the conditions in which the muscle tissue was collected or 
processed. There was a degree of variability in the time taken from the first incision taken 
of the muscle, to the time of freezing the sample down in liquid nitrogen, although was 
within a 2 min period. As it can be assumed that oxidative damage occurs in whole 
muscle tissue following removal, this may have introduced differences in the aconitase 
levels which did not accurately affect levels in vivo. A similar process may have affected 
the mitochondrial complex chain activities, although until the muscle biopsy process can 
be absolutely standardised, it would seem difficult to adequately eliminate this variable.
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In view of the fact that the pathological basis of ALS involves damage to the 
motor neurons, it is perhaps not surprising that there is no difference in levels of 
oxidative damage seen in peripheral tissues, as there is no reason why patients with ALS 
would have been exposed to different levels of oxidative stress, and therefore subject to a 
greater degree of damage, in the remote tissues. If oxidative damage were occuring as a 
secondary effect of the denervation of the muscle, this was not borne out on analysis of 
the disease control group, which included patients with peripheral neuropathies and 
benign fasciculation syndromes. In view of their morphology and function, motor 
neurons may be subject to greater levels of oxidative stress, and therefore oxidative 
damage. This would not necessarily result in damage to remote tissues, however. This 
issue is addressed in a later chapter (9).
The present study identified no relationship between age and respiratory chain 
activity in muscle mitochondrial fractions. This would appear to contradict some of the 
earlier studies into the relationship between mitochondrial activity and age. For example, 
a specific decrease in complexes I and IV (159) and a generalised diminution of all 
respiratory chain enzymes (160) have been demonstrated in skeletal muscle 
mitochondria in association with age. However, these early studies have been 
contradicted by more recent work which demonstrates that when mitochondrial function 
is controlled for physical activity (such as hand grip strength) rather than age, alone, no 
relationship between the decline in respiratory chain function and age is seen (161). 
Smoking status and physical activity, rather than age, were found to correlate with the 
decline of mitochondrial function in skeletal muscle in another study (162). As none of 
the patients or controls smoked at the time of our investigation, and as the levels of 
physical activity were assumed to be similar in the patient and disease control groups, it 
is, perhaps, not surprising that no clear decline in mitochondrial function in skeletal 
muscle with age was demonstrated.
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6 Analysis of Mitochondrial Respiratory Chain Function in Primary 
Cultured Cells and Platelet-derived Cybrids from Controls and Patients 
with ALS
6.1 Aims
To initiate primary myoblast and fibroblast cell cultures and platelet-derived 
cybrid cell lines from patients with ALS, disease controls with related conditions, and 
normal controls. To prepare a mitochondrial fraction from these cell lines. To perform 
biochemical assays in order to establish the presence or absence of a mitochondrial 
respiratory chain defect in the patient cell cultures.
6.2 Introduction
Mitochondrial dysfunction has been suggested as a significant factor in the 
aetiology of ALS (102,163,164). There is, for obvious practical reasons, difficulty in 
obtaining central nervous tissue from patients in the early stages of their disease. The 
studies that have been carried out on central nervous tissue have, therefore, either been on 
post mortem tissue (84,97) or on SOD1 mouse models of ALS (165,166). Other 
researchers have looked at peripheral tissues and cell types including whole muscle 
(98,117), lymphoblasts (142) and platelets (120-122) in an effort to characterise more 
general deficits in mitochondrial function that may occur in ALS. Analysis of the activity 
of the respiratory chain enzymes (figure 1.1) allows an assessment of the primary 
function of mitochondria to be made, as it is through these metabolic pathways that ATP, 
and hence cellular energy, is generated.
The assessment of the individual respiratory enzyme complex activities was 
performed rather than a more generalised “overall” assessment of mitochondrial 
respiratory function. Different levels of abnormalities of the different complex activities 
may be able to provide evidence regarding the aetiology of the deficit. This is because 
while complexes I, III, IV have components coded for by both the mitochondrial and
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nuclear DNA, complex II proteins are entirely encoded by the nuclear DNA molecule, 
with no mitochondrial contribution. While the assessment does provide some evidence 
regarding the possible aetiology of any deficit that is detected, it should be borne in mind 
that the assay techniques rely upon the mean mitochondrial activity of thousands of cells, 
with little information about the intercellular variation of mitochondrial activities within a 
culture, itself. This problem is adressed in a later chapter.
When reviewing the available evidence for mitochondrial respiratory chain 
deficiency in remote tissues of patients with ALS, the results are often contradictory. 
Deficits in fibroblast complex IV activity have been demonstrated in a small number of 
ALS patient fibroblast cultures (98) (n=3), with normal complex I and complex V 
activities. Other studies on cultured fibroblasts have shown abnormal superoxide 
production in mitochondrial fractions and elevated levels of MnSOD (167). Abnormal 
calcium homeostasis has been demonstrated in the peripheral blood lymphocytes of ALS 
patients (94). Although this study failed to demonstrate respiratory chain enzyme 
dysfunction, rate of respiration was demonstrated to be less sensitive to uncouplers in 
patient lymphocytes.
Human platelets contain mtDNA but no nuclear DNA. Fusion of patient platelets 
with control cells lacking mtDNA (p° cells) therefore allows a cell model to be created 
where the influence of the patient mtDNA can be analysed independently of the context 
of nuclear expression (124). Using the knowledge that complexes I, III and IV of the 
mitochondrial respiratory chain have components coded for by the mtDNA, allows 
conclusions about the aetiology of particular deficits to be drawn from the analysis of 
cybrid culture enzyme activity. Initial studies suggested that cybrids formed in this way, 
using the mtDNA of patients with ALS demonstrated deficiencies of complex I activity 
(120). Subsequent studies have failed to validate this finding, however (121,122). 
Possible reasons for this discrepancy include the use of different recipient cell lines in the 
three experiments. The first study utilized SHSY-5Y (neuroblastoma) cells, while one of 
the subsequent studies used 143B human lung carcinoma lines. These cells are thymidine 
kinase negative and, therefore, able to survive in BrdU supplemented medium, while 
nucleated donor cells would be selected against. This raises the possibility that the
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original study (120) results may have been distorted by nucleated cell contamination. The 
levels of oxidative metabolism undergone by the two cell lines have been shown to be 
similar (123), implying that the difference in respiratory chain activity was not due to 
differences in the recipient cell metabolic profiles.
6.3 Approach
6.3.1 Sample Generation
Primary cultures of myoblasts, fibroblasts and platelet-derived cybrids were 
initiated as described (section 2.2). These cultures were grown up on 10-cm plates in 
order to obtain a sufficient number for production of a mitochondrial fraction appropriate 
for functional assays. For myoblasts and fibroblasts, 20 confluent 10-cm plates of cells 
were harvested. For cybrid cultures, 8 confluent 10-cm plates were harvested. 
Mitochondrial fractions were prepared from the cell cultures as described (section 2.5.5). 
The passage number of all cell cultures at harvesting was between 4 and 6. Unfortunately 
a number of primary myoblast and fibroblast were lost to fungal infection. Some 
fibroblast cultures failed to seed from the initial skin sample (table 6.1). Although this 
may have been due to the agents used to clean the skin prior to biopsy, the surgeons all 
maintained that they used an equivalent amount of betadine for this purpose.
In order that samples with oxidative deficits were not selected against, the growth 
medium was supplemented with pyruvate and uridine, as described (124).
6.3.2 Cybrid Analysis
Experimental A549 (human lung carcinoma) p° cells were used to make the 
platelet-derived cybrids. In order to determine successful cybrid formation, 
immunocytochemical staining was performed on the cells labelled with BrdU. This is a 
thymine nucleoside analogue which is actively incorporated into replicating DNA and 
can be detected with a fluorescent labeled antibody to reveal areas of replicating DNA.
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Therefore in cells without mtDNA, only nuclear staining should be visible, whereas in p° 
cells repleted with mtDNA, there should be staining outside the nucleus within the 
cytoplasm (168). This was confirmed for each cybrid culture (figure 6.4).
In a further confirmation of the successful incorporation of wild type platelet 
DNA into the experimental cybrid cultures, a restriction enzyme digest was performed on 
a PCR-amplified mtDNA fragment from the cybrid cultures in order to exclude the 
persistence of the A549 mtDNA in cultures. Alul is a restriction enzyme which cuts 
TC/GA sites. A549 mtDNA has a 2 bp deletion of a CA repeat compared with wild type 
mtDNA (figure 6.1) at position 514-523. By using a forward primer (M60 -  see 2.5.7) 
and a specific mismatch reverse primer in a PCR of this section of mtDNA, a Taq I site 
was generated when A549 mtDNA was amplified, but not when wild-type mtDNA was 
amplified (figure 6.1).
Nucleotide position: 509 535
Wild type mt DNA: 5 ’-CCCAGCACACACACACCGCTGCTAACC-3’
Primer (M61): GAGTGTGTGGCGACGATTGG-5’
A549 mtDNA: 5 ’-CCCAGCACACACACCGCTGCTAACC-3’
....after amplification: CCCAGCTCACACACCGCTGCTAACC-3’
Figure 6.1 Mismatch PCR o f mtDNA to generate an Alul digest site in mtDNA from A549 
mtDNA. The mismatching nucleotide o f primer M61 and Taq I  restriction sites are 
underlined.
The products containing the polymorphism should generate a 146-bp digestion 
product, whereas the wild type should remain at 164-bp, as it should lack the Taq I 
cleavage site. The products of the digest were run on a 4% agarose gel with a <j>X174 
DNA/Hinfr marker. Again, this was confirmed for each culture (figure 6.5).
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6.3.3 Assays
In order to minimise error due to variability in experimental conditions between 
assays, cultures of control and patient-derived cells were grown and harvested at the same 
time. The mitochondrial fraction was prepared from each at the same time. In order to 
minimise experimental bias, the mitochondrial fractions were assigned a code by an 
independent observer, so that the assays would be performed “blind” as to the origin of 
the mitochondrial fraction. The samples were subsequently decoded when the assays and 
post-experimental data processing had been carried out.
Separate assays were performed for complex I (NADH-Coenzyme Q reductase), 
complex II/III (succinate cytochrome c reductase) and complex IV (cytochrome c 
oxidase) activity (140-142,169). In order to control for variations in mitochondrial 
concentration between samples, the samples were also assayed for citrate synthase 
activity, and the final enzyme activity was expressed as a ratio of activity per citrate 
synthase activity. All assays were performed at 30°C. Three assays were performed for 
each complex on each sample, and the final activity was given as an average of the three 
values.
Enzyme activities in muscle and cultured myoblasts were compared using linear 
regression analysis to determine whether there was a correlation, and hence persistence of 
possible mitochondrial deficits in cultured cells.
A three way ANOVA test was performed on the data from the patient, normal 
control and disease control samples to detect any statistically significant difference in 
enzyme activity.
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6.4 Results
Assays were performed on mitochondrial fractions from ALS patients, normal 
controls and disease controls as described (section 2.8). The numbers of fractions 
available are given for each cell type (table 6.1)
Table 6.1 Cell culture numbers assayed for respiratory chain enzyme complex activity
Control / patient Cell type Number of sam ples
Controls Myoblasts 10
Fibroblasts 8
Cybrids 6
Disease Controls Myoblasts 7
Fibroblasts 5
Cybrids 3
Patients Myoblasts 10
Fibroblasts 8
Cybrids 6
6.4.1 Myoblasts
There was no significant difference in respiratory chain complex activity between 
patient, control and disease control cultured myoblasts. Although the mean complex IV 
activity appeared markedly lower in the patient samples compared to the control samples, 
this difference was not significant (p=0.23). (Table 6.2, Figure 6.2).
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Table 6.2 Mean respiratory chain assay activities relative to citrate synthase activities for  
myoblasts ± SD
Cell Culture Type Complex I Complex II/III Complex IV*
Control 0.17 ±0.07 0.29 ±0.1 0.048 ± 0.020
Patient 0.15 ±0.07 0.26 ±0.11 0.032 ±0.016
Disease Control 0.17 ±0.08 0.29 ± 0.05 0.036 ± 0.028
6.4.2 Fibroblasts
There was no significant difference in any of the respiratory chain enzyme complex 
activities measured for patient, disease control and normal control fibroblasts (table 6.3, 
figure 6.3).
Table 6.3 Mean respiratory chain assay activities relative to citrate synthase activities for  
fibroblasts ± SD
Cell Culture Type Complex I Complex II/III Complex IV
Control 0.16 ±0.08 0.23 ± 0.08 0.042 ± 0.020
Patient 0.13 ±0.06 0.25 ± 0.07 0.052 ± 0 .0 18
Disease Control 0.23 ± 0.09 0.25 ± 0.04 0.038 ± 0.024
6.4.3 Cybrids
The successful incorporation of platelet DNA from patients and controls to 
generate experimental cybrids was confirmed by BrdU staining (figure 6.4) on the cybrid 
cell lines generated. PCR of cybrid DNA followed by Alul digestion and agarose gel 
electrophoresis was performed on the cybrid cultures, and confirmed that the mtDNA 
incorporated into the cybrids was wild type (figure 6.5). Only 3 disease control cultures 
of platelet cybrids were successfully grown. Complex IV activity was found to be lower
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in disease controls than in patient cybrids (p=0.084). Otherwise, there was no significant 
difference in respiratory complex activity between patient, control and disease control 
cultured cybrids (table 6.4, figure 6.6).
Table 6.4 Mean respiratory chain assay activities relative to citrate synthase activities for 
platelet-derived cybrids ±  SD
Cell Culture Type Complex I Complex II/III Complex IV
Control 0.31 ±0.11 0.3 ±  0.07 0.064 ±  0.026
Patient 0.31 ± 0 .1 7 0.36 ± 0 .1 1 0.060 ±  0.020
Disease Control 0.36 ±  0.19 0.29 ± 0 .0 6 0.036 ±  0.006
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Figure 6.2 Mitochondrial respiratory chain activities relative to citrate synthase 
(CS) activity in cultured human myoblasts showing spread o f values, mean and SD. 
The SOD1 mtant sample result (PAl 1) is arrowed. Complex IVactivities are 
multiplied by 5 for comparative purposes
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Figure 6.3 Mitochondrial respiratory chain activities relative to citrate synthase 
(CS) activity in cultured human fibroblasts showing spread o f  values, mean and 
SD. Complex IV activities are multiplied by 5 fo r  comparative purposes.
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Figure 6.4 Bromodeoxyuridine staining o f  replicating DNA. Staining o f  p° A549 cells (a) 
and platelet fusion cybrids from control subject C l l  (b) demonstrates the absence o f  
mtDNA in the p  cells, and the presence ofmtDNA in the cybrid cells. Bar-2 0 pm.
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Figure 6.5 Ethidium bromide stained agarose gels showing Alul digested PCR products 
o f  the mtDNA o f cybrids and parental A549 cells. The experimental cybrids lack the 
digestion site, indicating an absence o f  parental A549 mtDNA. No PCR product was 
detected with DNA extracted from A549 p° cells.
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Figure 6.6 Mitochondrial respiratory> chain activities relative to citrate 
synthase(CS) activity in platelet-derived cybrids showing spread o f  values, 
mean and SD. The SOD1 mutant sample result (PA 11) is arrowed. Complex 
IV values are multiplied by 5 for comparative purposes.
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6.4.4 Variation o f  mitochondrial function with age
In order to determine the effect o f  age on mitochondrial respiratory chain 
function, linear regression analysis was performed for pooled cell samples’ respiratory 
chain complex activity against the age o f  the patient or control. Fibroblast complex IV 
results showed a negative association with increasing age, although this did not quite 
reach significance. There was no other relationship between biological age and 
respiratory chain function demonstrated.
Table 6.5 The statistical significance o f the association between age and mitochondrial 
respiratory complex activity relative to CS activity for different cell cultures.
Cell culture complex analysed P value
Myoblast complex I 0.13
Myoblast complex II/III 0.43
Myoblast complex IV 0.46
Fibroblast complex I 0.56
Fibroblast complex II/III 0.23
Fibroblast complex IV 0.05
Cybrids complex I 0.54
Cybrids complex II/III 0.90
Cybrids complex IV 0.41
6.4.5 Correlation o f  muscle tissue and myoblast assays
Linear regression analysis was performed on the different sample results to 
determine the relationhips between respiratory chain complex activity (controlled for 
citrate synthase activity) in the different tissue and cell types for the same (pooled) 
samples.
There was a strong correlation between the muscle samples and the myoblast cultures 
derived from a particular sample for complex I (p=0.03) (figure 6.7).
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Figure 6.7  Complex I activity (aciivity/CS) in whole muscle tissue and cultured Myoblasts 
derived from the muscle. The SOD1 mutant sample result (PA 11) is arrowed.
Complex II/III showed no correlation (p=0.6) between activity in muscle tissue and 
cultured myoblasts, while complex IV showed a trend but no statistical correlation 
(p = 0 .14).
6.5 D iscussion
The initiation o f  primary cell cultures from tissue and the generation o f  platelet- 
derived cybrids was not always successful. Around half o f  the attempted cybrid fusions 
o f  mtDNA from platelets with p° cells failed. A significant proportion (around half) o f  
fibroblast cultures failed to seed from the initial skin biopsy specimens, while some 
myoblast samples were lost to fungal infection and incubator break down during the cell 
culture process (15 out o f  44). The amount and type o f  skin disinfectant used in the 
surgical excision o f  the skin biopsy may have influenced the ability o f  fibroblast cultures 
to seed from the primary tissue, although this was generally felt to be consistent. The
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orientation o f the pieces o f  tissue on the 10-cm culture plates may also have influenced 
the success o f the culture initiation.
The spectrophotometric assays themselves produced a wide spread o f  results 
around the mean for each sample. This is, perhaps, surprising given that the assays 
involve the analysis o f a cell homogenate. However, this phenomenon has been seen in 
previous studies o f respiratory chain activity assays in cultured cells using similar 
techniques (103,122,170).
Although differences in respiratory chain activity between patients with ALS and 
controls have been identified by others in muscle tissue (98,103), these studies have not 
been previously performed on cultured myoblasts. The present study identified no 
differences in activity between cultures taken from patients with ALS, normal controls 
and disease controls. There are a number o f  possible explainations for this. It may suggest 
there are, indeed, no differences or that mitochondrial function in the muscle o f  ALS 
patients is affected by the disease process itself, rather than as the consequence o f  an 
intrinsic abnormality o f the mitochondria. Alternatively, if  qualitative mitochondrial 
deficiencies occur as the result o f  random intercellular mosaicism, these effects may be 
attenuated in succeeding generations o f cultured cells. This would not appear to be a 
significant factor in the assessments performed, because the cell cultures were all 
analysed at the same passage numbers. To address this issue, the same biochemical 
assays were performed on whole muscle tissue. These experiments are detailed above 
(chapter 4). It is also worth pointing out that the findings o f  mitochondrial abnormalities 
from published studies on mitochondrial respiratory chain function in patients with ALS 
are often conflicting. In one o f  the first papers to identify a difference in mitochondrial 
respiratory chain activity (98), complex IV was determined to be normal in muscle tissue 
taken from patients, and attenuated in fibroblasts from the patient group. Complex I 
activity, however, was diminished in patient muscle tissue, but normal in cultured 
fibroblasts. These results would suggest that a process o f  greater complexity than primary 
deficits in mitochondrial expression may be occuring. It may be that a greater number o f  
samples utilised in the current study would have been able to demonstrate small
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differences between ALS patients and control groups in terms of mitochondrial 
respiratory chain activity.
The results of the assays performed suggest that age-related changes in 
mitochondrial function are not of sufficient magnitude to produce a decrement in the 
levels of activity of the mitochondrial respiratory chain enzymes in cultured cells. A 
number of studies have found that ageing is associated with impairment in oxidative 
phosphorylation and damage to the mtDNA (43,171,172). There are no consistent 
discrete complex abnormalities associated with ageing, however (160), and this is borne 
out by the results of these biochemical assays. Fibroblasts have been shown to develop 
abnormalities of mtDNA with ageing (173), and the presence of a negative association 
between complex IV activity (with mtDNA coded components) and age suggests that 
some functional impairment may occur as a result of acquired abnormalities of the 
mtDNA. A decline in complex IV function with age has been described by one study, 
although this used skeletal muscle (44). As this association was not seen in myoblasts or 
cybrids and it would be interesting to speculate as to whether acquired mtDNA 
abnormalities in fibroblasts occur as the result of solar damage to the skin (174). Indeed, 
mtDNA deletion levels have been described as a biomarker for sun exposure in normal 
skin (175).
The normal results for platelet respiratory chain activity found in SALS patients 
were also seen in a previous cybrid study which utilised platelets (122), while direct 
analyis of platelets from patients with SALS revealed no abnormalities in cytochrome 
oxidase activity or glutamate metabolism (121). Platelet incorporation, from patients into 
p° cells does not, therefore, seem to produce consistent deficits in mitochondrial function. 
These results do seem to conflict with the results of another group (120), but as alluded to 
in the introduction, contamination with nucleated cells cannot be excluded in this study.
It is interesting that there is a strong correlation in enzyme complex activities 
between muscle and myoblasts for complex I and less so for the other complexes studied. 
This would imply that whereas expression of these complexes may change over time in 
cell cultures, the expression of complex I appears to be relatively preserved.
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7 Immunocytochemical Assessment of Mitochondrial Protein 
Expression in Cell Cultures from Controls and Patients with ALS
7.1 Aims
To determine whether the intercellular expression of the mtDNA-encoded subunit 
I of cytochrome c oxidase (complex IV) protein is different in cultured cells from patients 
with ALS compared to controls.
7.2 Introduction
Subunit I of complex IV of the electron transport chain (COX I) is encoded for by 
mtDNA (figure 1.1). Quantification of the expression of this protein allows an assessment 
to be made of the integrity of mtDNA expression. It would be predicted that significant 
abnormalities of mtDNA would produce abnormalities in the expression of mtDNA- 
encoded proteins. In a population of cells where mtDNA abnormalities may vary between 
cells it is important to be able to look at the protein expression of individual cells, as a 
population assay would mask intercellular differences. A threshold effect whereby a 
cumulative number of mutated mtDNA molecules would need to be present to produce a 
generalised abnormality of mitochondrial function applies. Many mitochondrial disorders 
demonstrate mtDNA heteroplasmy (the presence of more than one type of mtDNA within 
cells) at a cellular level (176), with a large degree of intercellular variation in mtDNA 
abnormalities. The biochemical assays used to measure specific enzyme complex 
activities look at the gross average for a population of cells. If there were discrete random 
mtDNA abnormalities throughout the sample that were present in only a few cells, then it 
would be expected that these would not contribute to a demonstrable abnormality in an 
assay of a pooled cell sample. Furthermore, the spread of results in the cellular 
biochemical assays was large (chapter 6), implying that there is much variation between 
samples, even before consideration of any potential heteroplasmy of mtDNA.
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Acquired abnormalities of the mtDNA molecule may only be present in a small 
proportion of the cultured cells being studied. Even with appropriately supplemented 
(pyruvate and uridine) growth medium (124) this may become less pronounced with 
increasing passage number, whereby lines of cells which have developed mtDNA 
abnormalities are selected against and become depleted. For this reason, it is important to 
compare control and patient cell lines at equivalent passage numbers for phenotypic 
analyses.
7.3 Approach
The presence of a green fluorescent anti-COX I antibody was used as an indicator 
of COX I expression in the cell. The amount of COX I per cell will be dependent upon 
the number of mitochondria present within the cell. In order to control for variations in 
the number of mitochondria per cell, cells were treated with a red fluorescent dye 
(Mitotracker), which is selectively taken up by the mitochondria. The ratio of the signals 
of the antibody and the Mitotracker were measured for each cell and the ratios found in 
patient cells were compared with those found in control cultures.
Cultures of fibroblasts and myoblasts were initiated from primary tissue samples 
as described (section 2.3). At the same passage number (between 2 and 5), the cells were 
put onto glass cover slips at a medium density and left to grow for 24 hours. The cells 
were stained with Mitotracker dye (see paragraph 2.6.2).
The cells were then fixed and stained. The method involved incubation of the 
fixed cell culture on the cover slip with a mouse monoclonal antibody against subunit I of 
complex IV (COX I), followed by immunofluorescent detection of the primary antibody 
with green fluorescent (Alexa 488) labelled secondary antibody. The cell nuclei were 
stained blue with 4',6-diamidino-2-phenylindole (DAPI). Mr J Muddle carried out the 
cellular analysis of the stained cells; the slides were examined with a Zeiss Axiophot 
microscope fitted with a computer controlled motorised stage and a triple band pass 
emission filter. The three separate fluorescent images, red, green and blue, were captured 
using an automatic integrated camera system (figure 7.1). The system scanned 100 fields
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in a 10 x 10 matrix. The three integrated images (green, red and blue) were recorded for 
each field position. The fluorescent blue nuclear image (DAPI) was used to define the 
location of each cell, while the integrated images defined cell boundaries and produced a 
binary mask image of each of the mitochondria. Deficiencies in expression of the 
respiratory chain complex would be reflected in decreased green immunostaining with 
the red Mitotracker staining level remaining constant. Densitometric measurements of 
grey levels made for red and green images allowed the proportion of cells deficient in a 
particular complex to be quantified (figure 7.2).
Myoblasts were analysed in experiments where one patient would be matched 
with a disease control and a normal control, stained and fixed and analysed at the same 
time. Fibroblasts were pooled, so that all patient, control and disease control samples 
were stained, fixed and analysed at the same time. This allowed the total cell populations 
of the samples to be compared.
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Figure 7.1 Cultured myoblasts stained with (clockwise from top left), Mitotracker, green 
labelled anti-COX I and colocalisation with DAPI staining o f  the nucleus.
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Figure 7.2 Levels o f  complex IV subunit I per cell plotted against mean Mitotracker 
levels in the fibroblasts o f  a control subject (yellow dots) and a patient with known 
mtDNA depletion (red dots). There is a small sub-population o f  patient cells which are 
seen to demonstrate low levels o f  subunit I expression (arrowed).
7.4 R esults
Myoblasts were initially analysed on an individual age- and sex-matched basis to 
look for diifferences in distribution o f  COX I staining relative to Mitotracker between the 
cells o f  individual samples. Because o f  technical considerations and inter-experimental 
variation, the results for single patient / control analyses were not completed sufficiently 
to provide useful data. Because the cells were being looked at on an individual basis, the 
cell cultures samples were pooled into patient and control groups. Fibroblast samples C5, 
C6, C7, C8, C 14, C 17, C 18, C 21, D3, D4, D6, D7, D8, PA 1, PA2, PA3, PA4, PA6, PA8. 
PA9, PA 10, PA11, PA 12 were analysed together. For fibroblast cultures, there was no 
difference between pooled patient and pooled disease control and control cells in terms o f  
levels o f  COX1 expression (figure 7.3), Mitotracker expression (figure 7.4) or in the ratio 
o f  subunit I expression to Mitotracker (figure 7.5). It is important to note that the uptake
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o f Mitotracker is the same in the control and patient cell populations. If there was a major 
difference in Mitotracker staining between the cell populations, then it would be 
impossible to form conclusions about the expression o f  COX subunit I, as this forms the 
basis for the ratios.
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Figure 7.3 Line graph demonstrating the mean levels o f  COX I expression per cell 
(fibroblasts) fo r the total cell population analysed. Total number o f  cells is 100%. 
Disease control and control cells are pooled. (Total patient cells n=8 x 103, total control 
cells n=10 x 10s).
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Figure 7.4 Line graph demonstrating the mean levels o f  Mitoracker expression per cell 
(fibroblasts) for the total cell population analysed. Total number o f  cells is 100%. 
Disease control and control cells are pooled. (Total patient cells n=8 x 103, total control 
cells n=10x 103).
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Figure 7.5 Line graph demonstrating the ratio o f  COX 1 expression over Mitotracker 
expression per cell (fibroblasts) fo r the total cell population analysed. Total number o f  
cells is 100%. Disease control and control cells are pooled. (Total patient cells n=8 x 
10s, total control cells n=10 x 10s).
When looking at each cell individually, there was not an apparent sub-group o f  cells 
amongst the patient population which were seen to be deficient in COX1 expression 
relative to Mitotracker (figure 7.6).
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Figure 7.6 A cloud diagram o f  the ratios o f  COX 1:Mitotracker fo r patient (a) and 
control (b) fibroblast cell cultures. (Total patient cells n=8 x 103, total control cells n=10 
x lO 3).
COX subunit I negative cells, if present, would be visualised, as for figure 7.2, 
with a distinct sub-population below the main body o f  cells on the scatter plot. When 
looked at individually, these cells would show red flourescence with reduced green 
counter staining (figure 7.7). There were one or two COX negative cells in some o f  the 
control and patient cell samples, but there were no differences in the number o f  these 
seen between sample types.
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Figure 7.7 PA9 fibroblasts counterstained with Mitotracker, anti-COXI and DAPI, 
demonstrating a COX subunit I negative cell (arrowed) w hich has visible red staining 
from the Miotracker, but no green COX I staining.
7.5 D iscussion
The cytometric immunofluorescence technique used in this experiment has 
previously been shown to provide a useful assessment o f  deficiencies o f  mitochondrial 
protein expression (177) in terms o f  the individual subunits o f  the mitochondrial 
respiratory chain. As the subunit 1 o f  complex IV is encoded for by the mtDNA molecule, 
and this complex has previously been found to be deficient in muscle tissue (98) and 
central nervous tissue (178) o f  patients with ALS, the possible genetic origins o f  such a 
defect were investigated. Even without finding a discrete enzyme complex defect in 
homogenates o f cultured myoblasts and fibroblasts, it should be possible to demonstrate 
abnormalities in the mitochondrial expression o f  individual cells, where perhaps these are 
being masked by a large population o f  phenotypically normal cells without any 
deficiencies o f  protein expression below the threshold o f the expression o f  a mtDNA 
mutation.
The deletions and lower levels of mtDNA from patient muscle and spinal cord, as 
found in some studies (112,113,178), would suggest that these abnormalities produce a 
pathological effect through respiratory chain complex deficiencies (179), because these 
are partly encoded for by the mtDNA molecule (complexes I, II and IV). Although 
respiratory chain enzyme function abnormalities have been described in many tissues (sec 
above), there have been no hard correlations between mtDNA abnormalities and aberrant 
mitochondrial function in ALS. This is supported by the results as detailed.
Apart from 2 reported patients, one with a mitochondria tRNA(Ile) (4274T-»C) 
mutation(180), and one with a heteroplasmic 5-bp deletion in the 5’ end of the COX I 
gene (99), specific mitochondrial mutations have yet to be found in patients with ALS. 
The finding of lower levels of mtDNA in patient skeletal muscle (112) or higher levels 
of deletions (113) in central nervous system tissues without specific nuclear gene 
abnormalities, implies that various abnormalities of the mtDNA may be the primary 
cause of cellular abnormalities in the disease. In this respect, examination of the 
expression of subunit I of complex IV is likely to be of as much value in the assessment 
of mitochondrial protein expression as any of the other mtDNA-encoded proteins. These 
abnormalities are not found in all patients, however. A correlation has never been made 
between severity of disease and the extent of the mitochondrial genetic abnormalities 
described (115). Because mtDNA is susceptible to oxidative damage (26) and because the 
abnormalities of motor neurons in ALS may represent the result of oxidative damage 
(26,181), it would be difficult to state with certainty that the mtDNA abnormalities seen 
in the disease are not the secondary effects of oxidative damage rather than the cause per 
se.
The results from this single cell analysis are consistent with the finding of normal 
mitochondrial function from the patient cell lines analysed. It would be interesting to 
know whether mtDNA protein expression abnormalities were detected in the samples 
previously described where discrete respiratory chain enzyme deficiencies appear to 
occur. MtDNA analysis of the samples studied is described in the following chapter (8).
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8 Analysis of mtDNA from Controls and Patients with ALS
8.1 Aims
To analyse mtDNA fractions from patient and control tissue in order to determine 
whether there are different amounts or a greater frequency of deletions in patients with 
ALS compared with controls.
8.2 Introduction
Mitochondria have their own DNA molecules which contribute to the 
biosynthesis of four of the five OXPHOS complexes on the mitochondrial membrane (I, 
III, IV, V) (Figure 8.1).
It would be predicted that abnormalities of electron transport chain function or 
other mitochondrial processes may be due to an underlying abnormality of the mtDNA. 
As mtDNA is more sensitive to oxidative damage than nuclear DNA (25), a degenerative 
disease, such as ALS may be related to cumulative insults to the mtDNA which would 
then manifest as mitochondrial dysfunction, with resultant cell death. To this end, 
mtDNA was extracted and analysed from muscle biopsies of the patients and controls in 
our sample groups.
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Figure 8.1 A schematic of a mitochondrion showing the mtDNA encoding the 
mitochondrial OXPHOS complexes on the inner membrane o f the mitochondrion. 
Mitochondrial DNA encodes for subunits offour o f the five complexes.
Mitochondrial DNA analysis has previously revealed that patients with ALS have 
a greater level o f  the so-called “common” deletion (4977 bp) in their central nervous 
system (113) and skeletal muscle (115) than controls. This finding was thought to support 
the role o f mitochondria in the pathogenesis o f  ALS. mtDNA depletion has also been 
described in the skeletal muscle (112) o f  patients with ALS. Analysis o f  spinal cord (178) 
homogentate o f patients with ALS revealed increased levels o f  mtDNA point mutations. 
Further evidence to support the idea o f  mtDNA abnormalities being involved in the 
pathogenesis o f  ALS was provided by the description o f  a patient with a motor neuron 
disorder and a specific deletion o f  the mtDNA gene encoding for subunit I o f  respiratory 
complex IV (99), although this patient had an earlier age o f  onset and predominantly
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upper motor neuron involvement. Apart from this single case study, primary genetic 
causality of mtDNA abnormalities in ALS has not been convincingly demonstrated.
8.3 Approach
In the examination of mitochondrial abnormalities, total genomic DNA was 
extracted from whole muscle tissue (2.10.1) and subjected to restriction digest using 
PvuII enzyme in order to linearise the circular mtDNA molecules (2.10.2). Samples (3 
pg) were loaded onto an agarose gel based on spectrophotometric calculations of 
concentration of the DNA. The samples were electrophoretically separated and 
transferred to a membrane to make a Southern blot (2.10.3). This initial blot was probed 
for mtDNA using a radiolabelled mtDNA fragment (Figure 8.2) to detect mtDNA 
rearrangements. The picture of the ethidium bromide-stained gel from this experiment 
was used to determine the optimum loading of the DNA samples to give equivalence of 
loading amounts. The amount of staining was measured using the ImageQuant software 
package (Amersham). Based on these calculations, a second Southern blot was prepared 
and hybridised simultaneously with a radiolabelled mtDNA fragment and a radiolabelled 
fragment of the nuclear 18S RNA gene. The latter probe was used to allow corrections to 
made for DNA loading.
The nuclear and mtDNA signals were measured by phophoimaging and analysed 
with ImageQuant software to determine the relative mtDNA levels in the muscle samples.
The tissue aconitase levels determined previously for whole muscle (chapter 4) 
were correlated with mtDNA levels to determine whether there was a relationship 
between oxidative damage and mtDNA levels per se.
In order to control for variability in the number of mitochondria, the absolute 
mtDNA : nDNA ratios were plotted against tissue citrate synthase concentrations (as 
previously determined -  2.8.6), as this is a marker for total tissue mitochondrial 
concentration.
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To further investigate mtDNA rearrangements, the more sensitive long-range PCR 
(lrPCR) was used. In this procedure, deleted mtDNA molecules are preferentially 
amplified over full-length wild type species. The PCR was performed using with the 
Expand IrPCR kit (Roche), using the conditions and reagents described above (2.10.4). A 
9900-bp region of mtDNA (6222 -  16152) was amplified. The muscle DNA samples 
used in the PCR amplifications were the same as the samples used for the Southern blots. 
As a preliminary experiment, samples of patient (PA11) and control (C5) DNA were 
loaded onto a gel in 5 lanes (a-e) with different primer and nucleotide concentrations 
(a=l xprimer 1 xdNTP, b=2xprimer 1 xdNTP, c=l xprimer 2xdNTP, d=2xprimer 2xdNTP, 
e=2xprimer 1.5xdNTP) (figure 8.8).The test sample with optimum band visualisation 
was used to determine the primer and nucleotide concentrations which would be used in 
the lrPCR. In order to determine the levels of mtDNA deletions in the lrPCR experiment, 
the number of bands visible on an agarose gel, stained with ethidium bromide, was 
counted for each sample. The counting process was done in a “blinded” fashion, so that 
the experimenter did not know the identity of the samples for which the bands were being 
counted. This procedure has been performed in similar experiments using this method to 
look for deletions of the mtDNA (182).
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8.4 Results
8.4.1 Primary Southern Blot
The initial blot probed with a radiolabelled mtDNA fragment did not demonstrate 
large scale mtDNA rearrangements.(figure 8.2). The levels shown were used to determine 
optimal loading amounts for equivalence on a second sample.
C l C2 C4 C8 C9 CIO C l l  C12 C14 D1 D3 D4 D5 D6 D7 D ll  D12
D12 PA1 PA2 PA3 PA4 PA5 PA6 PA7 PAS PA9 PA10 PA11 PA12
Figure 8.2 Primary Southern blot probed with radiolabelled mtDNA to reveal possible 
mtDNA rearrangements.
8.4.2 MtDNA quantification
The amount o f mtDNA as determined by the mtDNA : n DNA ratio was the same 
in the patient (n=12), control (n=14) and disease control (n=4) muscle DNA samples as 
measured in the Southern blots (Figure 8.3, table 8.1).
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C17 C l 8 C19 C20 C21 PA7 PA8 PA9 PA10 PA11 PA12 D6 D7 C14 C18 PA4 U
Figure 8.3 Southern blots comparing amounts o f mitochondrial (upper band) and nuclear 
(lower band) DNA. U is sample from a known paediatric patient with mtDNA depletion. 
The other samples are labelled according to their allocated experimental code (table 2.1- 
2.3). Sample PA8 has an air bubble on the lower band. This sample was. therefore, not 
used for analysis.
Table 8.1 mtDNA:nuclear DNA ratios for muscle DNA
Sample Type Number of Samples Mean mtDNA : nuclear
DNA ratio
Patient 11* 1.09 + 0.407
Control 12 0.98 ±0.398
Disease Control 4 1.02 + 0.096
*  Sam ple P A S  w as not used due to the artifact described above (figure 8 .4 )
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No significant correlation was demonstrated between mtDNA concentration and citrate 
synthase concentration (figure 8.4), indicating, that variations in the levels o f  mtDNA 
observed are not due to variations in absolute mitochondrial number.
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Figure 8.4 mtDNA:nuclear DNA ratios against tissue citrate synthase activity 
(nmoles.min1 .m g1) demonstrating no difference in amount o f mtDNA per mitochondrial 
volume between patient and control samples. Disease and normal controls have been 
pooled. The SOD I mutant sample (PA11) has been arrowed.
8.4.3 MtDNA levels and tissue aconitase activity
There was a negative correlation between the levels o f  muscle aconitase 
determined by spectrophotometric analysis (chapter 5) and relative mtDNA levels 
determined by Southern blotting (Figure 8.5), although this did not reach significance 
(p=0.093).
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Figure 8.5 Correlation of tissue aconitase activity (nmoles, miri1 .m g1) and mtDNA levels 
in patient and control muscle samples. Disease and normal controls have been pooled. 
The SOD1 mutant sample (PA11) has been arrowed.
In order verify whether this relationship was true for other tissues, fibroblasts with a 
known single, large mitochondrial deletion, partial depletion (residual levels o f  mtDNA 
o f  25%) and normal levels o f mtDNA (provided courtesy o f  Dr J-W Taanman) were 
grown up and subjected to the same analyses. There was a difference in aconitase levels 
between theses three samples (table 8.2), but in contrast to the results for muscle, which 
suggested that low mtDNA levels are associated with relatively high aconitase activity 
levels, the mtDNA-depIeted fibroblasts showed a lower Aconitase activity the the two 
control fibroblast samples.
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Table 8.2 Aconitase activity in fibroblasts with different levels o f  mtDNA
Type of mtDNA abnormality Aconitase activity (U/mg)
None (control) 3.45
Deletion 2.32
Partial depletion 1.55
None (control) 2.49
8.4.4 Age and mtDNA levels in muscle tissue
There was no correlation between patient or control subject age and the absolute 
amount o f  mtDNA present (figure. 8.6).
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Figure 8.6 The relation between the amount o f mtDNA present in muscle tissue and 
subject age. The amount o f  mtDNA is given relative to citrate synthase (CS) activity to 
correct for a possible difference in amount o f  mitochondria present in the sample.
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8.4.5 Determination of Reagent Concentration for IrPCR
The Optimum concentration o f  primers and nucleotides required to visualise multiple 
bands using IrPCR were determined by the best visualised bands using the concentration 
o f primers and nucleotides as shown (figure 8.7)
a b c d e  a b c d e
Patient (PA 11) Control (C5)
Figure 8.7 Agarose gel o f  IrPCR products obtained using variable nucleotide and primer 
concentrations in order to determine the optimum concentrations fo r  visualization o f  
multiple bands.
The optimum absolute amounts o f  reagents for the IrPCR were determined to be;
DNA - 200 ng
dNTP (200 mM)- 350 pi
Forward primer- 300 nm
Reverse primer- 300 nm
8.4.6 Band quantification using IrPCR
Long-range PCR o f the mtDNA revealed multiple deletions, as indicated by the 
appearance o f  multiple bands in some o f  the patient samples as well as some o f  the 
control samples (figure 8.8). Long range PCR is able to detect low levels o f  mtDNA  
deletions that are not identified on by Southern blotting. The “normal” band o f  amplified 
mtDNA, without deletions, is visualised at around 8kb. Twelve patient samples and 
sixteen normal- and disease-controls were used. There was no increase in the number o f  
deletions present in patient samples as compared with controls (table 8.3).
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Figure 8.8 Agarose gels o f  IrPCR products stained with ethidium bromide. showing total 
number o f  bands o f  PCR-amplified mtDNA. norma I control P=patient D=disease 
control M=bacteriophage A DNA digested with Hindlll (DNA standard). The SOD1 
mutant sample (PA11) is underlined.
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Table 8.3 The mean number o f  bands seen on IrPCR analysis o f  mtDNA extracted from 
skeletal muscle
Sample Type Number o f  Samples Mean Number o f  Bands
Control 12 3.75
Disease Control 8 1.63
Patients 10 3.4
For patient, normal- and disease control mtDNA IrPCR here was a positive 
association between subject age and the number o f  bands present, although this did not 
reach statistical significance. (p=0.24 for all samples) (figure. 8.9).
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Figure 8.9 Association o f  age and number o f  bands visualised on IrPCR using pooled  
patient and control samples
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There was a negative association between the number o f  bands present on IrPCR and 
amount o f  mtDNA as measured by Southern blotting for each sample (p=.095) (figure. 
8.10). This finding may represent a reduction in the total amount o f  mtDNA present in 
the muscle as a cumulative effect o f  the multiple deletions present.
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Figure 8.10 Relationship between number o f  bands seen on IrPCR and relative amount o f  
mtDNA per tissue citrate synthase (CS) activity per mg o f  protein.
8.5 Discussion
Researchers have previously identified lower levels o f  mtDNA in the skeletal 
muscle o f  13 patients with ALS as compared with 17 controls using identical Southern 
blotting techniques (112). This study was performed using patients with spinal muscular 
atrophy as controls, and the differences in absolute mtDNA levels did not correct when 
controlled for citrate synthase concentration, indicating that differences were not due to 
differences in mitochondrial concentration per se. This finding o f  lower levels o f  mtDNA 
does not appear to correlate with increased levels o f  mtDNA deletions. In a study looking 
at levels o f the 4977-kb common deletion o f  mtDNA in single cell post mortem brain and 
spinal cord samples (116) spinal cord neurons showed slightly higher deletion detection
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rate in patients than controls (94% vs 75%). No significant differences were found 
between patients and controls for neurons derived from other motor or non-motor 
regions. The analysis of the mtDNA from the sites of “pathology” would suggest that 
mitochondrial deletions are not a significant contributory factor, and one would not 
expect to see large scale abnormalities in skeletal muscle on the basis of this result. A 
separate study of hospital inpatients with ALS (115), using primer-shift and quantitative 
PCR to determine the 4977-bp deleted mtDNA (the common deletion) in muscte 
specimens from 36 patients with sporadic ALS and 69 age-matched controls with other 
neuromuscular disorders, demonstrated increased levels of the common deletion hr 
muscle biopsies. The tissue specificity of mtDNA deletions in neurodegenerative diseases 
has recently been described for Parkinson’s disease (183), where mtDNA abnormalities 
were found to occur to a greater degree in the basal ganglia. This tissue specificity has 
not, as yet, been described for the motor cortex or motor neurons of patients with ALS. 
More recent Southern blot analysis studies of muscle tissue from patients with ALS and 
disease- and normal controls have shown slightly diminished levels of mtDNA relative to 
nDNA, but this was not significant (117).
Are measurements of the common deletion or of total mtDNA concentrations 
appropriate measures to look for mtDNA abnormalities in ALS? A patient with known 
autosomal dominant progressive external ophthalmoplegia was shown to have normal 
levels of mtDNA on Southern blotting, but multiple deletions on long-range PCR (184). 
The techniques available may not be specific or sensitive enough to detect very low 
levels of mtDNA deletions. It would appear from the assessment of mitochondrial protein 
expression (chapter 7), that there is no evidence of mtDNA abnormalities producing a 
deficiency in subunit 1 of complex IV expression in any of the thousands of cultured cells 
studied. This would lend support to the finding of normal levels of mtDNA in our patient 
and control muscle tissue samples, unless the mitochondrial damage was occuring at 
insufficient levels to result in abnormalities of protein expression in any of the cells 
studied. The finding of normal mtDNA levels is also consistent with the observation of 
normal respiratory chain activities in the tissue and cultured cell samples used in this 
study. Whether or not it is valid to make statements regarding mtDNA in muscle tissue
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on the basis of experiments conducted on cultured fibroblasts, there is a consistency in 
the pattern of results between tissues and cells studied.
It is interesting to note that in our sample group, increasing age did correlate with 
an increased level of mtDNA deletions as determined by IrPCR analysis, a feature which- 
has also been described for normal ageing (114,159,185). The accumulation of mtDNA 
deletions during ageing may be the result of oxidative damage sustained by the ageing- 
mtDNA molecules. The fact that the absolute levels of mtDNA, as determined by- 
Southern blotting, were not found to be diminished in association with aging in our 
sample, is consistent with published data (42). Increasing numbers of mtDNA deletions 
were statistically associated with lower total levels of mtDNA (8.10) which is, perhaps, 
surprising, given the small overall amounts of mtDNA lost in deletions.
There was a negative correlation between tissue aconitase levels and tissue 
mtDNA levels. This may imply that oxidative damage may not have a deleterious effect 
on mtDNA concentrations, although this does not appear to be a feature peculiar to ALS, 
being seen in all of the samples studied. The fibroblast cultures known to have mtDNA 
abnormalities (table 8.2) did not show any consistent relationship between mtDNA levels 
and cellular aconitase activity.
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9 Cellular Response to Oxidative Stress
9.1 Aims
To examine the apoptosis and oxidative damage profiles of patient and control 
cell cultures in response to exogenous oxidative stress.
9.2 Introduction
Cell dysfunction and death in response to oxidative stress is a well described 
model of neurodegenerative disease (186). It is thought that the generation of free 
radicals and their subsequent mishandling result in the death of neurons and the 
development of disease through the accumulation of oxidatively modified protein. As far 
as ALS is concerned, the discovery of mutated forms of SOD1, an antioxidant, in a sub­
group of familial cases has led to an increasing focus on the role of oxidative damage hr 
the pathogenesis of the disease. Although markers of oxidative damage have been shown 
to be elevated in the central nervous system tissue of patients with ALS (89), the time 
course and role in the aetiology of the disease has not been clearly delineated (181).
Increased vulnerability to injury of motor neurons in ALS has been described in 
the G93A transgenic SOD1 mouse model (187). In this study, injury to the sciatic nerve 
in S0D1(G93A) mice resulted in an acceleration in disease progression so that 90 day old 
mice show deficits that are only seen at the end stage in uninjured SODl(G93A)mice.
There is, however, no reason why the levels of oxidative stress to which patient 
nervous system tissues are subjected would be different to those of controls, and no clear 
relationship has been demonstrated between external factors and the aetiology of ALS 
(188).
Oxidative damage is not a phenomenon confined to the central nervous system of 
patients with ALS. Evidence of increased damage to muscle tissue of patients with ALS
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(depleted levels of ATP and elevated levels of mitochondrial uncoupling protein) has also 
been found, which is felt to be the result of specific metabolic impairments in the tissues 
studied (148).
In view of the mitochondrial focus of the study, paraquat was chosen as a modet 
of oxidative stress, as this is known to specifically affect mitochondrial respiratory 
function by the production of superoxide anions generated from paraquat radicals and by 
singlet oxygen derived from anions (189). This was felt to be a more quantifiable and 
reproducible model of oxidative stress than, for example, serum withdrawal from the 
growth media, which other researchers have used (80).
While there is an accumulating body of evidence that oxidative damage is 
involved in the pathogenesis of ALS, it is not clear by what mechanism this damage is 
having a deleterious effect on the tissues affected. In order to investigate the mechanisms 
by which cell death may occur, separate analyses were performed for apoptosis (caspase 
activation) and the total levels of oxidative damage sustained by the tissue (aconitase 
activity). These experiments were conducted on cybrids, myoblasts and fibroblasts.
Aconitase activity is a marker of oxidative damage because the enzyme is 
rendered inactive through oxidation of an iron-sulphur cluster (4FeS)2+->  (3FeS)+ . The 
enzyme is predominantly located intramitochondrially, although some aconitase is 
present in the cytosol. Glutamate has been shown to inhibit aconitase activity in rat 
neurones at low levels (190). Aconitase activity is also very sensitive to inhibition by 
peroxynitate, but not by its precursor, nitric oxide (191).
Work has been carried out looking at the mechanisms of cell death in ALS. Much 
of this has focussed on neuronal cell cultures (192) and cell models over-expressing 
SOD1 (193). In ALS, dying neurons undergo programmed cell death (PCD), rather than 
necrosis. Post mortem specimens and cell cultures exhibit features reminiscent of 
apoptosis, a prominent morphological form of PCD. In addition, many key molecular 
components of the PCD machinery are activated in ALS spinal cords (194). In order to 
analyse mechanisms of cell damage in response to oxidative stress, caspase (apoptosis) 
assays were performed on cultures treated with paraquat.
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9.3 Approach
Cell cultures of myoblasts, fibroblasts and cybrids were grown on cell culture 
plates as described (2.5). All cell cultures were examined at the same passage number and 
using the same experimental conditions. A stock solution of 100 mM paraquat in H2O  
was added to the cell culture medium of the growing cells to make concentrations of 0:1 
mM and 1 mM. Aconitase activity was measured 24 h later. These paraquat 
concentrations had been derived by assessing the response of a number of cell cultures ta  
increasing paraquat concentrations. Increasing the concentration of the paraquat much 
above 1 mM resulted in almost complete abolition of aconitase activity, while obvious 
effects on cell death were seen at concentrations as low as 0.1 mM, it was considered that 
growing cultures in normal media and these two paraquat concentrations would provide 
useful experimental comparison between patient and control cell samples. Further 
analysis was conducted on myoblast cultures with paraquat concentrations of 0.05 mM, 
0.1 mM and 1 mM. Aconitase activities were corrected for protein concentration of the 
cell homogenate under analysis.
In situ caspase 3 activity staining was used to measure the degree of apoptosis 
undergone by the cell cultures and was assessed using a fluorescent marker of activity 
(2.11.1) (figure 9.1). The cell cultures were grown in culture medium supplemented with 
the appropriate concentrations of paraquat as described, and the activity assayed 24 h 
later.
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Figure 9.1 Cultured fibroblasts under phase contrast (a) and viewed with a 
fluorescent microscope (b). Three cells out o f  the total fie ld  demonstrate caspase 3 
activation (arrowed).
9.4 Results
9.4.1 Oxidative Stress
There was a significantly greater fall in aconitase activity in patient myoblasts 
(p=0.04) and fibroblasts (p=0.02) cultured at a paraquat concentration o f  0.1 mM than 
controls (figure 9.2 -  9.4, table 9.1). This difference was not observed in platelet-derived 
cybrids or in myoblasts grown at concentrations o f  0.05 mM or 1 mM paraquat nor in 
fibroblasts grown in 1 mM paraquat. There is a relatively broad spread o f  results seen for 
all aconitase activity assays (figure 9.2 -  9.4)
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Figure 9.2 Percentage fa ll in aconitase activity o f  cybrid cell cultures grown in 
different concentrations ofparaquat showing spread o f  values, mean and SD. The 
values for the mutant SOD1 sample (PA 11) are arrowed.
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Figure 9.3 Percentage fa ll in aconitase activity o f  myoblast cell cultures grown in 
different concentrations o f  paraquat showing spread o f  values, mean and SD. The 
values fo r the mutant SOD1 sample (PA11) are arrowed.
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Figure 9.4 Percentage fa ll in aconitase activity> o f  fibroblast cell cultures grown in 
different concentrations o f  paraquat showing spread o f  values, mean and SD. The 
SOD1 mutant sample was not available fo r  analysis.
Table 9.1 Percentage decrease in mean aconitase activities fo r  cell lines grown in 
different concentrations o f  paraquat (absolute activity /  mg protein) + SD. Significant 
values are shown in bold.
Cell type Concentration Paraquat (mM)
0.05 0.1 1
Control Fibroblasts - 73.4 ± 17.0b 96.5 ± 3 .7
Patient Fibroblasts - 88.3 ± 10.2h 99 ±  1.6
Control Myoblasts 56.3 ± 2 1 .8 73.9 ± 20.7a 97.9 ± 5 .6
Patient Myoblasts 62.7 ±  20.4 90.8 ± 10.2a 95.1 ± 7 .2
Control Cybrids - 87.5 ± 6 .7 99.2 ± 2 .1
Patient Cybrids - 83.0 ±  13 1 0 0 .0 ± 0
“Significant difference (p=0.04) bSignificant difference (p=0.02)
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9.4.2 Apoptosis
Caspase 3 activation o f  the paraquat-treated cell cultures was compared to the 
untreated cell cultures. The increase in the ratio o f  cells demonstrating caspase 3 
activation to those not demonstrating caspase activation was significantly greater in 
patient fibroblasts and myoblasts than in control fibroblasts and myoblasts at paraquat 
concentrations o f  0.1 mM and 1 mM. Therefore, cultured fibroblast and myoblasts from 
patients underwent a greater degree o f  apoptosis than control cells. This effect was not 
seen in platelet-derived cybrid cultures (figures 9.5-9.8, table 9.2).
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Figure 9.5 Percentage change in ratio o f  apoptotic myoblasts to total cell 
number at different concentrations o f  paraquat showing spread o f  values, mean 
and SD. Values fo r the mutant SOD1 sample (PA11) are arrowed.
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at different concentrations o f  paraquat showing spread o f  values, mean and SD. 
Values for the mutant SOD1 sample (PA11) are shown (arrowed).
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Table 9.2 Percentage decrease in the ratio o f  apoptotic cells /  non-apoptotic cells o f cell 
cultures grown in different paraquat concentrations showing range o f results
Cell type Concentration Paraquat (mM)
0.1 1
Control Cybrids 42.2 ± 60 158± 160
Patient Cybrids 44.5 ± 62 107.2 ± 127
Control Myoblasts 72 ± 73a 88.5 ±72“
Patient Myoblasts 150 ±101a 250 ±115.8“
Control Fibroblasts 5.4 + 64 47.4 ±39“
Patient Fibroblasts 72.1 +76.5 162 ±67“
“Significant difference (p=0.048) bSignificant difference (p=0.003) Significant difference (p=0.003).
9.5 Discussion
Oxidative stress, as induced by paraquat, had a greater effect on primary cell 
cultures from patients with ALS than from controls. This effect was apparent witfr 
paraquat concentrations of 0.1 mM within the growth medium. This effect was 
demonstrated for fibroblasts and myoblasts but not for cybrids made with platelet-derived 
mtDNA. Cybrid cell lines do not contain patient or control nuclear DNA. This finding 
would suggest that the increased vulnerability of the patient cell lines to oxidative stress 
is mediated by a nuclear-encoded rather than a mitochondrial-encoded factor.
These results are supported by other work investigating the effects of oxidative 
stress on remote tissues of patients with ALS. A study using cultured fibroblasts (56) 
demonstrated that fibroblasts from patients with sporadic as well as familial ALS were 
more sensitive to oxidative stress from the free radical generating agent, SIN-1 but not ter 
serum withdrawal. Interestingly, addition of hydrogen peroxide induced greater levehr of 
oxidative damage in the fibroblasts from familial patients with known SOD1 mutations 
than sporadic patients (56).
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A neuronal cell model transfected with mutant SOD1 (79) showed increased celt 
death when exposed to oxidative stress by serum withdrawal, whereas the presence of 
normal human SOD1 exerted a protective effect. Under basal, unstressed culture 
conditions, no change in the ATP : ADP ratio was observed in the presence of mutant 
SOD1. These results support the assertion that neuronal damage is induced through" 
increased sensitivity to oxidative stress. Serum withdrawal, which will affect the growth 
and metabolism of cells, is a relatively non-specific condition by which to induce 
oxidative stress, especially in view of the different types of sera and growth media used 
by different researchers. Measurement of glutamate uptake in response to oxidative stress 
using paraquat with the SOD1 G93A neuronal cell model revealed increased sensitivity 
to the paraquat in transfected cells relative to control cultures (82).
The increased levels of oxidative damage occurring in SOD1 mouse model motor 
neurons have been attenuated by researchers using antioxidants (195), such as vitamin E 
and creatine. As has been stated earlier, antioxidants appear to have little effect on 
disease progression or severity in patients with the ALS (196,197), apart from a single 
unblinded, self report study demonstrating a lower risk of dying of ALS in individuals 
using regular vitamin E supplements (93).
The finding of an increased level of sensitivity to damage from oxidative stress in 
remote tissues, such as cultured fibroblasts and myoblasts is clearly of questionable 
relevance to the function and activity of motor neurons in situ. However, as mutant SOD1 
is expressed in every cell in the body, it would seem reasonable to extrapolate the 
influence of genetic factors to every cell where appropriate conditions have been met. 
Due to the obvious difficulties in the collection and analysis of such tissue, similar 
experiments in living motor neurons from affected patients would not be possible. 
Therefore, the finding of increased sensitivity to oxidative damage in remote tissues from 
patients with ALS is important in the consideration of the pathogenesis of the sporadic 
forms of the disease, where other cell models and transgenic mice are not available as 
experimental models.
The finding of an association between increased lactate production and free 
radical formation in the serum of ALS patients undergoing exercise (148) supports the
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concept of an enhanced systemic sensitivity to oxidative stress. The lack of systemic 
abnormalities in the vast majority of familial ALS patients suggests that the motor 
neurons are a vulnerable site of free radical damage resulting from their particular 
metabolic requirements.
Caspase activation has been reported in the spinal cords of transgenic mouse 
models of ALS (198). Caspase 3, 9 and 12 activation was studied and nitrotyrosine 
staining was utilised, as a marker of oxidative stress. There was an increased rate of 
caspase cleavage, indicative of apoptotic pathway activation, and levels of oxidative 
stress were found to be higher in the same tissues. These concur with the increase in 
markers of oxidative stress and apoptosis found in remote cell cultures of patients with 
ALS, implying that a common molecular mechanism may be responsible. Increased 
levels of caspase activation, and hence apoptosis, are found in cell cultures grown in the 
same concentration of paraquat which is shown to induce oxidative stress. Therefore, 
oxidative stress is a possible cause of apoptosis in these cultures, which would support 
the suggestion that increased sensitivity to oxidative stress is the cause of motor neuron 
death through apoptosis in ALS.
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10 Patterns of Inheritance in Familial ALS
10.1 Aims
To analyse patterns of inheritance in a large group of families with familial ALS. 
To determine whether the phenomenon of anticipation is demonstrated in inheritance. To 
determine whether there is a maternal pattern of inheritance in familial ALS.
10.2 Introduction
Sporadic and familial forms of ALS exist. The pattern of inheritance in familial 
ALS is usually autosomal dominant with age dependent penetrance (199). Mutations of 
the SOD1 gene, which encodes the enzyme copper/zinc superoxide dismutase, are found 
in approximately 20% of familial patients and occasional, apparently sporadic, patients 
(47). SOD1 mutations account for 1-2% of all patients with ALS (ALS1) (48). Other, 
rarer, genetic abnormalities have been detected in patients with ALS, including the alsin 
(53) and APEX (54) genes along with a number of other mutations (see table 1.1), but the 
significance of these is uncertain at the present time. The molecular and environmental 
causes of ALS otherwise remain undetermined.
Anticipation is the tendency for a disease to demonstrate an earlier age of onset or 
increasing severity of symptoms in successive generations. The concept was recognised 
over a century ago (200,201), and the term ’anticipation' was applied to observations of 
mental illness by Mott early in 1911 (202). A paper on myotonic dystrophy by Penrose 
in 1948 (203) suggested that the phenomenon was caused by several forms of bias. The 
discovery of a genetic basis for anticipation in some diseases was made in the early 
1990s. Trinucleotide repeat expansions were found to be the cause of several diseases 
with genetic anticipation (204).
Anticipation has been investigated in a range of diseases. Psychiatric illness has 
received particular attention with anticipation demonstrated in schizophrenia (205-207),
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panic disorder (208) and bipolar affective disorder (209). Other diseases have included 
inflammatory bowel disease (210-212), haematological malignancies (213-216), 
rheumatoid arthritis (217), familial cavernous angiomas (218) and polycystic kidney 
disease (219,220). Anticipation has been reported in a single Japanese family with the 
G93S mutation of SOD1 (221), as well as some Italian and American families with 
mutations at codon 84 of SOD1 (222).
ALS is a neurodegenerative disease, with some clinical and pathological 
similarities to conditions with demonstrated trinucleotide repeats, for example 
bulbospinal muscular atrophy, where the repeat is in the androgen receptor gene on the X 
chromosome (223). Functional and structural mitochondrial abnormalities have been 
demonstrated in different tissues of patients with ALS (164). Some researchers have 
identified mutations of the mtDNA in these tissues (112). The implication of 
mitochondrial genetic abnormalities in the pathogenesis of ALS suggests that these 
abnormalities may be reflected in a different mode of inheritance in SOD1 negative 
familial ALS. MtDNA disorders are maternally inherited (224) and one would, therefore, 
expect a sex effect in inheritance for SOD1 negative transmissions, if mtDNA mutations 
were causative.
Using the database of families with more than one individual affected by ALS, 
with the assistance of Professor deBelleroche from Imperial College London and Dr 
Marcus Bradley, the patterns of inheritance and ages of patients were examined to 
determine whether the phenomenon of anticipation occurs in families with ALS. 
Subgroup analysis was performed on known SOD1 negative and known SOD1 positive 
patients. The effect of sex on inheritance was analysed for SOD1 positive and SOD1 
negative transmissions, to determine if maternal inheritance occurred significantly more 
often than paternal.
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10.3 Approach
A total number of 185 families with two or more individuals affected by ALS 
were studied. These families are part of an ongoing study into the clinical and molecular 
genetics of ALS (199). Pedigree structure, age of onset of symptoms, duration of illness, 
and age of death of each individual was recorded. The superoxide dismutase-1 (SOD1) 
gene mutation status was recorded for each family.
Individual transmissions between generations were identified. Intergenerational 
values were compared between generation 1 (Gl) and generation 2 (G2) for each 
individual transmission. Gl comprised fathers, mothers, uncles and aunts. G2 comprised 
sons, daughters, nephews and nieces. The differences in age of onset, duration of disease 
and age at death between Gl and G2 were then calculated.
For first degree transmissions, the number of cases where maternal inheritance 
occurred was compared with those where paternal inheritance took place. The 
frequencies were analysed for the SOD1 positive and negative families.
Initially all subgroups were analysed together. To minimise bias, direct 
transmissions were those between first degree relatives (mother/father and son/daughter), 
and indirect transmissions were those between second degree relatives (uncle/aunt and 
nephew/niece). The analyses were also performed on those members of Gl below and 
above the median that is the lower and upper 50% of Gl. This was to identify the 
statistical phenomenon of regression to the mean, where anticipation may be 
demonstrated in the offspring of older parents (225). The following relationships were 
investigated:
1. The difference between each Gl and G2 pair was analysed. Tests for normality 
were performed (skewness and kurtosis) and confidence intervals were constructed 
around the median difference.
2. The median ages of Gl were compared to the median ages of G2. Medians rather 
than means were used and the Wilcoxon ranked sum test was preferred because the 
distributions of age of onset and death were non-Gaussian (206,207). The null hypothesis
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was that the median age of G2 would be the same as that of G l. If anticipation is present, 
the median age of G2 will be lower than that of G l.
3. The number of occasions when Gl was greater than G2, i.e. positive anticipation, 
was analysed using a %2 test.
4. The numbers of instances of maternal and paternal inheritance were compared, in 
SOD1 positive and negative families. Contingency tables were constructed, comparing 
the values in our sample with expected values where there was no sex effect on 
inheritance (i.e. the number of paternal and maternal transmissions were equal), using a 
X2 test to determine whether or not there was a significant difference.
10.4 Results
A total of 160 first degree intergenerational transmissions were identified (Table 
10.1). The mean age of death for all the individuals with ALS (n=503) was 55.2 years 
(95% confidence interval (Cl) 54.0-56.4 years) with a mean disease duration of 3.5 years 
(Cl 2.9-4.1). There was no significant difference (p>0.05) in age at death between 
patients with SOD1 mutations (53.9 years; Cl 51.4 -  56.4; n=114) and those with no 
SOD1 mutation (55.6 years; Cl 54.3 -  56.9; n=389). There was no significant difference 
(p>0.05) in duration of disease between patients with SOD1 mutations (4.9 years; Cl 3.4 
-  4.6; n=34) and those with no SOD1 mutation (3.3 years; Cl 2.7 3.9, n= 193).
Table 10.1 Number o f transmission for each relationship between Gl and G2 in families 
with ALS
Families Father Mother Aunt Uncle
All 123 149 124 108
SOD1 31 41 38 52
Non-SODl 92 108 86 56
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Age at death gave more complete data than age at onset or duration of disease, 
and was used for primary analysis. Three additional analyses were performed: 
comparisons were made between the different relationships of Gl to G2; comparisons 
were made between the upper, middle (i.e. between the 25 and 75 centiles) and lower 
50% of Gl and their G2 relatives; and the SOD1 families were compared to the non- 
SOD1 families.
The median age of death was compared between the two generations (Table 10.2). 
For all transmissions, the Wilcoxon ranked sum test demonstrated significant increase in 
median age at death in Gl (55 years) than G2 (48 years) (p<0.001). This was significant 
irrespective of the SOD1 status or relationship of Gl to G2. The significance was present 
when studying the upper (p<0.001) and middle (p<0.001) 50% of the Gl range. When 
the lower 50% of Gl were studied there was no significant difference (p>0.05). Within 
the lower 50% of Gl, there were 2 groups - indirect transmissions for all families and all 
transmissions for non-SODl families -  where the differences were reversed, such that G2 
was significantly older than Gl.
When comparing the difference in age at death between first degree Gl and G2 
pairs, the 95% confidence interval did not contain zero difference, indicating age of death 
in Gl was significantly older than G2 (Table 10.3), with the exception of all nonSODl 
individuals. Larger deviation from zero occurred when including only the older 50% of 
Gl, and smaller deviations with the younger 50% members of Gl.
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Table 10.2 Median values o f age at death for G1 and G2 in families with ALS with 
significance o f  difference between generations as determined by Wilcoxon ranked sum 
test.
n All samples Upper 50% of 
G1
Middle 50% of 
G1
Lower 50% of 
G1
G1 1 G2 G1 1 G2 G1 1 G2 G1 1 G2
All 29 55 | 48 63 54 55 48 45 45
families
MFAU
1 p<0.001 p<0.001 p<0.001 p>0.05*
All 16 56.5 52.5 64 54.5 56.5 53 49 48
families
MF
0 p<0.001 p<0.001 p<0.005 p>0.05*
All 13 53 46 62 48 53 45.5 42 43
families
AU
1 p<0.005 p<0.001 p<0.001 p<0.05*
All 90 55 48.5 61 53 55 52 48 43
families
M
p<0.005 p<0.001 p <0.05 p>0.05
All 70 58 56 66 58 58 56 50 53
families
F
p<.05 p<0.001 p <0.05 p>0.05*
Non- 18 55 48 62.5 58 55 49 42.5 47
SOD1
MFAU
4 p<0.01 p<0.001 p<0.05 p<0.005*
Non- 11 56.5 51.5 63 53 56 52 50 50
SOD1
MF
0 p<0.05 p<0.001 p<0.01 p>0.05*
SOD1 10 56 48 67 54.5 56 48 48 45
MFAU 7 p<0.001 p<0.001 p<0.001 p>0.05
SOD1 50 57 53.5 66 59.5 56 53.5 48 45
MF p<0.05 p <0.05 p>0.05 p>0.05
p  values for Wilcoxon ranked sum test are shown in bold where GJ significantly greater than G2 (P<0.05)
* G2>G1
mother; F=father; U=uncle; A =aunt.
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Table 10.3 Median difference in age at death between Gl and G2
n All samples Upper 50% of 
Gl
Middle 50% of 
Gl
Lower 50% of 
Gl
Media
n
Cl Media
n
Cl Media
n
Cl Media
n
Cl
All
families
MFAU
291 +5 1.8 + 12 2.3 +6 2.1 -2 2.3
All
families
MF
160 +6 2.3 +11 2.7 +6 2.9 -1 3.2
All
families
AU
131 +4.5 2.9 + 13 3.6 +5 3.1 -2.5 3.2
All
families
M
90 +6 2.9 +8.5 4 +6 4.5 0 4.3
All
families
F
70 +4 3.8 +12 3.7 +2 3.9 -2 5.3
Non-
SOD1
MFAU
184 +2 2.3 +13 2.7 +3.5 2.8 -4 2.8
Non-
SOD1
MF
110 +6 2.9 +13 3.1 +5 3.4 -2 3.9
SOD1
MFAU
107 +8.5 2.9 +12 4 +7 3.8 +2 3.7
SOD1
MF
50 +7 3.9 +8 5 +4 5 +3 5.8
Cl = 95% confidence interval. All samples testedfor normality conform to a normal distribution. 
M= mother; F=father; U=uncle; A = aunt.
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When both first degree (mother and father) and second degree (aunt and uncle) 
modes of transmission were studied together, there was evidence of significant 
anticipation in age at death for all ALS subgroups when SOD1 families were analysed, 
but in the non-SODl families the confidence interval for all transmissions overlapped 
zero.
Frequency of positive (anticipation) and negative intergenerational differences 
were compared using a %2 test (Table 10.4). This demonstrates the phenomenon of 
regression to the mean, i.e. the older the members of Gl, the more significant the 
tendency towards anticipation (Table 10.4). The expected result in a disease with no 
genetic anticipation would be equal numbers positive and negative results. %2 was 
positive for anticipation in all groups, with the exception of first degree intergenerational 
transfer in families with SOD1 mutations. The middle 50% of Gl in mothers, fathers and 
first degree SOD1 transmissions did not demonstrate a significant difference (p>0.05). 
When studying the younger 50% of Gl, there was no significant difference, with the 
exception of all transmission in non-SODl families, where the tendency was against 
anticipation.
The number of instances of maternal and paternal inheritance was compared, in 
SOD1 positive and negative families. A %2 test revealed no difference in SOD1 positive 
(p>0.1) and SOD1 negative (p>0.1) cases for first degree transmissions. This suggests 
that parental sex has no effect on inheritance.
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Table 10.4 Number o f occasions when the difference between Gl and G2 is positive 
(anticipation) and negative, f 2 andp values are given, for the null hypothesis that Gl = 
G2.
n All samples Top 50% of Gl Middle 50% of 
Gl
Bottom 50% of 
Gl
+ve -ve +ve | -ve +ve -ve +ve -ve
All 29 182 109 117.5 22.5 99.5 48.5 64.5 86.5
families 1 18.29 00 17.56 3.21
MFAU p<0.001 p<0.001 p<0.001 p>0.05
All 16 101 59 66.5 13.5 52.5 31.5 34.5 45.5
families 0 11.02 00 5.25 1.51
MF p<0.001 p<0.001 p<0.05 p>0.05
All 13 81 50 55.5 9.5 41 23 25.5 40.5
families 1 7.34 16.27 5.1 3.41
AU p<0.01 p<0.001 p<0.05 p>0.05
All 90 56 34 34 9 29 16 20 23
families 5.38 14.53 3.8 0.19
M p<0.05 p<0.001 p>.05 p>0.05
All 70 45 25 30.5 3.5 21 14 14.5 21.5
families 5.71 21.36 1.4 1.36
F p<0.05 p<0.001 p>.05 p>0.05
Non- 18 107.5 76.5 70 12 57.5 34.5 37.5 64.5
SODl 4 5.22 00 5.75 7.15
MFAU p<0.05 p<0.001 p<0.05 p<0.01
Non- 11 69.5 40.5 49 6 37.5 20.5 20.5 34.5
SODl 0 7.65 00 4.92 3.56
MF p<0.01 p<0.001 p<0.05 p>0.05
SOD1 10 74.5 32.5 45.5 8.5 45.5 18.5 29 25
MFAU 7 16.48 oo 11.39 0.296
p<0.001 p<0.001 p<0.001 p>0.05
SOD1 50 31.5 18.5 17.5 8.5 21.5 10.5 14 11
MF 3.38 4.00 3.78 0.36
p>0.05 p<0.05 p>0.05 p>0.05
Significantp values are shown in bold M=mother; F=father; U=uncle; Avaunt.
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10.5 Discussion
The median ages of death and disease duration were similar to other studies of 
ALS (3). The median age at death in patients with familial ALS was significantly lower 
in the second generation of patients, p<0.001 (figure 10.1, table 10.2). The mean 
difference in age at death between the 2 generations was positive (younger death in 
second generation) and the number of occasions that positive anticipation occurred was 
significantly more than would be expected if there was no anticipation, p<0.001 (table 
10.4).
All ages Gl 
Upper 50% Gl 
Middle 50% Gl 
Lower 50% Gl
-5  0  5  10 15
Age difference in years
Figure 10.1 Median difference in age o f death between Gl and G2 with 95% confidence 
interval for the upper, middle and lower 50% o f age o f Gl.
Significant differences were observed in median age at death, mean differences in 
age at death, and frequency of earlier age at death, between the generations. These 
support the concept of anticipation in patients with ALS. Similar findings were present in
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SOD1 and nonSODl groups (figure 10.2). It remains possible that a modifying gene may 
be active in both groups of patients, explaining variable penetrance in SOD1 and 
nonSODl families, and also possibly the occurrence of sporadic patients with SOD1 
mutations (46). There are occasional instances of nonsignificance, which may be 
explained by incomplete ascertainment or insufficient numbers.
All families 
Non-SODl families 
SOD1
-2 0 2 4 6 8 10 12
Age difference in years
Figure 10.2 Median difference in age o f death between Gl and G2 with 95% confidence 
interval for SOD1 and non-SODl families.
Ascertainment bias is recognised in studies of anticipation (226,227). Different 
key events have been used as the measured time point in studies of anticipation. 
Examples include age at onset in panic disorder (208) and schizophrenia (206), age at 
diagnosis in Crohn's disease (228) and age at onset of end stage renal failure in polycystic 
kidney disease (220). We used age at death as ALS is a rapidly progressive and fatal 
disease, and death is a definitive end-point. Death, for patients with ALS, occurs around 
3 years after the onset of symptoms and is caused by ALS in over 98% of cases (229).
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There is often incomplete information for age at onset, as it may be difficult for relatives 
and physicians to precisely recall or define the first feature of the disease. In some 
diseases, such as Crohn’s disease, age at death may be an unreliable marker of disease, as 
this may not be the primary determinant of death. Improvements in diagnostic capability 
and the increased family awareness of the illness once a parent is diagnosed, could lead 
the offspring to be diagnosed much earlier than the parent (210,211). These forms of 
bias, which tend to suggest genetic anticipation when it is not actually present, are 
avoided by using age of death in ALS. The major factor, which could delay death in 
patients with ALS, is long term respiratory support. In this study, only one patient was 
identified to have received aggressive ventilatory support.
For various reasons, patients with a genetic disease may not wish or may be 
unable to have children. This process may lead to bias being introduced because of the 
effect on fertility or fitness. An individual with disease onset at a young age may be less 
likely to have children, either due to a wish to prevent others suffering with a similar 
disease, or because they would be physically incapable of looking after children. In a 
genetic line ending with mostly young onset patients, this will bias towards anticipation 
by eliminating many putative transmissions from early onset parents to late onset 
children. Other studies have used the second degree relatives as a means of minimising 
this bias. For example, this has been used in schizophrenia (206). Our analysis of second 
degree relatives supported the presence of anticipation.
Ascertainment bias may occur if not all individuals in the study are interviewed at 
the same age. Anticipation may be introduced if offspring are interviewed at a younger 
age. This could be due to simultaneous onset in both generations attracting the differing 
attention of family members and their physicians. This would present as apparent later 
onset in parents and earlier onset in offspring. G2 would have an earlier onset than Gl 
and favour anticipation. This is further compounded, as any siblings of G2, who may 
eventually develop the disease, thus negating the effect of the perceived anticipation, 
would not be detected at the time of data collection.
Huntington's disease was found to have only weak evidence of anticipation in the 
female line (230). This finding was consistent with regression to the mean such that
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anticipation was only seen in the children of older mothers (231). Despite this weak 
association Huntington's disease was shown to be due to a trinucleotide repeat expansion, 
which could be transmitted by the female line (232). It has been reported that only 
around 70% of the variability of age at onset in Huntington’s disease is attributed to the 
CAG repeat size. A significant additional contribution to the variability is attributed to a 
TAA repeat polymorphism, related to the kainate receptor GluR6 on chromosome 6 
(227,233).
With no anticipation, the median value of Gl minus G2 will be close to zero, with 
confidence intervals crossing the zero axis. Regression to the mean is a phenomenon 
whereby higher values of Gl artificially increase the degree of perceived anticipation, 
and vice versa for lower values of Gl. Such a tendency causes the value to be positive 
when selecting the oldest 50% of Gl and negative when selecting the youngest 50% of 
Gl. This phenomenon was observed when the data were analysed in this way. This 
leads me to interpret the suggestion of anticipation in this analysis with caution. This 
does not however exclude anticipation or unstable DNA disease (207,225,231).
This study does not demonstrate maternal inheritance in familial ALS, even 
without attempted correction for potential disputes of paternity or families where paternal 
contact has been lost. The lack of a sex effect in inheritance occurs in SOD 1 positive and 
negative families, implying that mitochondrial transmission, alone, does not account for 
inheritance.
In conclusion, although there is apparent anticipation in age at death between 
generations in patients with familial ALS, there remains the difficulty of fully accounting 
for ascertainment bias, as illustrated by the failure to demonstrate anticipation in the 
offspring of the younger 50% of the patient population studied. The results may be 
important in pointing to underlying genetic mechanisms to explain the multifactorial 
predispositions, genetic and environmental, to developing ALS. There is no evidence of 
maternal inheritance in the sample studied. This would suggest that abnormalities in 
mtDNA are not inherited in familial ALS.
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11 Conclusions
11.1 Summary of Results
The findings of this study are, in summary:
1) There are no specific histological changes in the skeletal muscle of patients with 
ALS (chapter 4).
2) Mitochondrial respiratory chain activity is the same in the skeletal muscle 
homogenate of controls and patients with ALS (chapter 5).
3) Aconitase activity is the same in the skeletal muscle of controls and patients with 
ALS (chapter 5), suggesting that the levels of oxidative damage are the same 
(chapter 5).
4) Mitochondrial respiratory chain function is the same in cultured myoblasts, 
fibroblasts and platelet-derived cybrids from controls and patients with ALS 
(chapter 6).
5) The expression of the mitochondrially encoded protein, subunit I of complex IV is 
the same in fibroblasts from controls and patients with ALS (chapter 7).
6) Total levels of mtDNA, mtDNA deletions and rearrangements are the same in the 
skeletal muscle of controls and patients with ALS (chapter 8).
7) Aconitase activity is more affected by exposure to paraquat in fibroblast and 
myoblast cultures from patients with ALS than cell cultures from controls, 
suggesting that patient cultures are more susceptible to oxidative stress. This is 
not seen in cultures of platelet derived cybrids (chapter 9).
8) Caspase 3 activity is more stimulated by exposure to paraquat in fibroblast and 
myoblast cultures from patients with ALS than cell cultures from controls,
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suggesting that patient cultures are more susceptible to oxidative stress. This is 
not seen in cultures of platelet derived cybrids (chapter 9).
9) There is no convincing evidence for anticipation or sex-effect in the inheritance of 
familial ALS (chapter 10).
11.2 Discussion
The body of evidence implicating mitochondrial abnormalities in the remote 
tissues of patients with ALS is broad, inconsistent and sometimes contradictory. Most 
groups have tended to focus on one particular tissue or cell type in their analysis. Whole 
muscle analysis has been reported as showing mitochondrial abnormalities in terms of 
respiratory chain complex defects (98) and metabolic defects (91). Other groups report no 
differences in mitochondrial activities between controls and patients (104) when studying 
respiratory function and ATP synthesis. Analysis of platelet-derived cybrids was reported 
as demonstrating a difference in respiratory chain complex activity and calcium 
homeostasis by one group (120) but another group demonstrated that the mtDNA from 
ALS patients’ platelets restores normal respiratory function in p° cells (122). Fibroblast 
and myoblast cell culture analysis has generally not been carried out with the exception 
of a small study looking at the susceptibility of fibroblasts from ALS patients to oxidative 
stress (56). This study demonstrated that SOD1-FALS and SALS fibroblasts were 
significantly more sensitive than controls to the free radical generating agent, SIN-1 but 
not to serum withdrawal. SOD1-FALS fibroblasts were more sensitive to H2O2 than 
SALS fibroblasts and than control fibroblasts.
The analysis of mtDNA shows similar disparity. Whereas some groups have 
identified increased levels of deletions and lower total amounts of mtDNA in tissues 
taken from patients (112,115) others have shown no differences in mtDNA between 
patients and controls (116).
Even without consideration of the potential publication bias against “normative” 
data (234) in the study of mitochondria and ALS, there does not appear to be a clear
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consensus on the status of mitochondrial abnormalities in remote tissues. It was for this 
reason that this study sought to analyse a number of different tissues using different 
experimental paradigms across the same tissue and cell types.
Initial work, looking at the appearances of skeletal muscle from ALS patients on 
light microscopy (chapter 4) demonstrated that fibre changes consistent with a 
denervation -  reinervation pattern were the only changes positively associated with a 
diagnosis of ALS. There were no changes suggestive of classical mitochondrial disease 
(ragged-red fibres or COX negative fibres) and there was not a significant degree of 
inflammatory change.
Analysis of mitochondrial respiratory chain function was normal in muscle, 
platelet derived cybrids, fibroblasts and myoblasts from patients with ALS (Chapters 5 
and 6). There were no consistent significant differences between patients, controls or 
disease controls in any of the tissues studied. While this finding is at odds with some of 
the previously published work (103,120), it does confirm the conclusion of others 
(116,122). The possible reasons that these differences may have emerged is discussed 
below.
The single cell analysis of myoblast and fibroblast cultures from patients and 
controls demonstrated no mtDNA protein expression abnormalities in the cultures 
(Chapter 7). This is consistent with the finding of normal respiratory complex activity in 
the cells, and is also against the concept that random systemic mtDNA mutations occur 
with a higher frequency in patients with ALS. The relative lack of documented cases of 
ALS resulting from discrete mtDNA mutations would also support this (99). Invoking 
mtDNA abnormalities to explain the primary pathogenesis of ALS is not borne out by the 
analysis of the inheritance of non-SODl familial ALS (Chapter 10). If mitochondrial 
inheritance was responsible for even a portion of non-SODl cases, it would be expected 
that there would be a sex bias in inheritance, but this was not the case. Cellular 
mitochondrial abnormalities have been described in association with some of the 
trinucleotide repeat sequence disorders (106) which demonstrate anticipation. Analysis of 
familial ALS cases show that any perceived anticipation is likely to represent the 
statistical phenomenon of regression to the mean.
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The normal mitochondrial protein expression and normal respiratory chain 
function in the remote tissues of patients with ALS are found in association with normal 
total amounts and normal levels of deleted mtDNA in these tissues (chapter 8). The 
experimental findings are, therefore, consistently against a systemic primary mtDNA 
abnormality in ALS. The single patient that was included in the study with an SOD1 
mutation did not demonstrate different mitochondrial DNA expression or metabolic 
activity to the sporadic cell cultures and tissues which were analysed. Although this was a 
single patient, it does indicate that the metabolic profiles of systemic tissues may be the 
same for sporadic and familial patients, hence the similarities seen in the phenotypes of 
each disease.
There is the possibility that apparent mitochondrial abnormalities seen in SOD1 
transgenic mice, cell models and human tissues may represent secondary rather than 
primary manifestations of an underlying pathogenic process. This supposition is 
supported by a recent study which shows that motor neuron cells expressing low levels of 
mutant SOD1 are in a chronic state of oxidative stress and mitochondrial dysfunction (as 
measured by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) 
conversion rates (235). Given that studies on human tissues are generally performed on 
patients with established ALS, it is difficult to draw the conclusion that mitochondrial 
abnormalities are the primary pathogenic process in these individuals.
The finding that remote tissues from patients with ALS are more susceptible to 
experimental oxidative stress, in terms of apoptotic activity and aconitase inhibition, 
concurs with published work on the sensitivity of patient fibroblasts to oxidative stress 
(56), as well as studies which show a greater amount of apoptotic activity in response to 
oxidative stress in transgenic SOD1 mice (198). Neuronal cell models transfected with 
mutant SOD1 show a greater death rate in response to oxidative stress than cells 
transfected with normal SOD1 (79) as impairment of glutamate transport mechanisms 
(82). It would appear that the mutant SOD1 found in familial forms of ALS may exert its 
toxic effect by lowering the cell’s resistance to oxidative stress. By extension, the 
underlying pathological mechanism of neuronal death in sporadic ALS would involve a 
similar mechanism in view of the relative phenotypic homogeneity between the two
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diseases. The present study confirms that there is an increased sensitivity to oxidative 
stress in two different remote cell cultures from patients with the sporadic disease. 
Thorough analysis of mitochondrial function suggests that the cause of this increased 
sensitivity is not of mitochondrial origin, especially in view of the normal levels of 
oxidative stress and apoptosis seen in patient platelet-derived cybrid cell cultures.
It is of note that the tissue respiratory chain enzyme activities, mtDNA analysis 
and susceptibibilty to oxidative stress revealed no consistent differences between the 
tissue and cell samples taken from the patient with familial disease and those with 
sporadic ALS. Although this is a single case, it does indicate that there are unlikely to 
major differences in the cellular pathology of the sporadic and familial forms of ALS, 
further work with a greater number of defined familial samples would obviously be 
required to confirm this supposition.
Given that mtDNA is more sensitive to oxidative damage than nuclear DNA (26), 
the findings of abnormal mitochondrial activity in muscle (103) and cybrid cultures (120) 
of patients with ALS that other groups have identified may represent the secondary 
effects of oxidative damage rather than a primary pathological process. The conditions of 
cell culture and tissue analysis vary between centres, and if cell lines or tissue were 
grown or stored in conditions where higher levels of oxidative stress were encountered, 
detrimental effects on mitochondrial activity may occur. This would explain why other 
groups identify no abnormalities in remote tissues of patients with ALS (104,116,122). 
With the consistency of normal results through the range of different paradigms and 
different tissues that the present study has analysed for mitochondria, this appears a 
plausible theory. The supplementation of growth medium with foetal calf serum 
introduces another inter-centre variable, because the composition of the sera varies 
between manufacturers and batches. A study looking at mitochondrial enzyme activity, 
histochemical abnormalities and mtDNA levels identified no significant differences in 
muscle biopsies taken from patients with ALS, disease controls and normal controls 
(117). The findings from this comprehensive analysis are consistent with those from this 
study.
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Given the relative size and metabolic activity of motor neurons, such cells would 
be expected to sustain a greater degree of oxidative stress throughout life. With the poor 
regenerative potential of such tissues in adulthood, this stress would translate into 
oxidative damage more readily than for other tissues. The threshold effect for damage 
and the development of overt pathology would be lower in patients with ALS. The 
present study suggests that this is due to a systemic factor which increases susceptibility 
to such damage. These findings are potentially important for a number of reasons:
• The investigation of the pathogenesis of sporadic ALS may be possible by 
using remote cell cultures from living patients.
• A model of sporadic ALS may be developed using these cultures. This 
avoids the need to draw conclusions about the human disease from mouse 
or cell SOD1 transgenic models.
• The potential assessment of therapeutic agents in limiting oxidative stress 
in such cultures may be possible.
• The particular properties of remote cell cultures may be utilized to provide 
earlier diagnostic tools.
11.3 Further Work
The replication of these findings in cell cultures taken from transgenic mice, or 
from neuronal cultures would be a potentially valuable method of determining the 
common pathological pathways in familial and sporadic ALS. A larger study with a 
greater number of familial patients would also be an appropriate means of further 
investigating these ideas.
In order to confirm the possibility that mitochondrial abnormalities in the cell 
cultures of patients with ALS may be a secondary effect, there would be some value in 
carrying out respiratory chain assays and protein expression estimation in different cell 
cultures that had been subject to different levels of such stress.
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The analysis of primary tissue and cell cultures from large numbers of patients at 
different points of progression of the disease would also go some way to addressing the 
question of cellular abnormalities manifesting as a secondary effect of the disease 
process.
Carrying out experiments using these paradigms in patients with known 
mitochondrial diseases would allow comparisons to be made with neurodegenerative 
conditions where these experimental techniques have previously been utilised.
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Appendix 1 -  Media and buffer composition
Cvbrid medium
500ml Dulbecco’s Modified Eagle Medium 
50ml dialysed foetal calf serum (final cone: 10%)
2.5 ml 50 U/ml penicillin 2.5 ml 50 U/ml streptomycin (aliquoted together)
Denhardt’s Solution 
2% (w/v) BSA 
2% (w/v) Ficol 400
2% (w/v) polyvinyl pyrrolidone (PVP).
Fibroblast / p° medium
500 ml Dulbecco’s Modified Eagle Medium (Gibco)
50 ml foetal calf serum (Biosciences) (final cone: 10%)
1 ml 2 mM uridine 
5 ml 1 mM sodium pyruvate
2.5 ml 50 U/ml penicillin 2.5 ml 50 U/ml streptomycin (aliquoted together)
Homogenisation Buffer
0.25 M Sucrose
10 mM Tris.HCl (pH 7.4)
1 mM Potassium EDTA
Myoblast dissociation solution
10 ml Dulbecco’s Modified Eagle Medium
12000 U Collagenase (Sigma)
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3.2 ml of 0.1% trypsin in versene solution 
40 mg bovine serum albumin (Sigma)
- Dissolved and filtered through a 2 pm filter (Sarstedt).
Myoblast medium
500 ml Dulbecco’s Modified Eagle Medium 
100 ml foetal calf serum (final cone: 20%)
1 ml 2 mM uridine 
5 ml 1 mM sodium pyruvate
2.5 ml 50 U/ml penicillin 2.5 ml 50 U/ml streptomycin (aliquoted together) 
PBS
10 mM sodium phosphate 
0.9% NaCl 
pH 7.4
SSC Buffer 
0.15 M NaCl 
0.015 M sodium citrate 
pH 7.0
TAE Buffer 
20 mM Tris-acetate 
1 mM Sodium EDTA 
0.2 M Acetic Acid 
pH 7.4
2 1 2
TE Buffer 
10 mM Tris.HCl 
1 mM Sodium EDTA 
pH 7.4
Trypsin Solution (0.1%)
4ml 2.5% of trypsin stock solution (Gibco) in 100ml versene solution (1:5000; Gibco)
Tvrode’s Buffer 
150 mM NaCl 
5 mM HEPES 
0.55 mM NaH2P04 
7 mM NaHC03 
2.7 mM KC1
5.6 mM Glucose 
1 mM Potassium EDTA 
pH 7.4 
1 mM MgCl2
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Appendix 2 -  Data tables
Appendix 2(a) — Normal (control) muscle mitochondrial enzyme values for all samples 
assayed. Activities per citrate synthase activity, protein concentrations and activity as a 
ratio o f protein concentration are shown. There was insufficient material in samples 
(C6, C l5, Cl 7) to perform protein assays.
Activity I CS activity Protein Activity I Protein Concentration
ll/lll IV (mg/ml) I * IV
C2 0.361 0.064 0.076 2.440 27.800 44.822 10.805
C3 0.107 0.210 0.038 2.340 25.157 47.412 14.982
C5 0.158 0.259 0.023 1.520 36.670 19.003 22.566
C6 0.129 0.208 0.041
C7 0.100 0.073 0.043 3.880 59.485 15.025 6.260
C8 0.099 0.163 0.053 3.980 24.337 39.894 12.707
C9 0.113 0.259 0.018 1.490 22.873 31.371 10.645
C11 0.262 0.133 0.052 1.630 23.538 42.477 11.201
C12 0.120 0.120 0.033 3.880 35.920 26.222 15.446
C14 0.139 0.080 0.032 3.370 14.827 24.411 13.400
C15 0.053 0.250 0.011
C16 0.358 0.084 0.035 3.960 17.964 21.515 7.086
C17 0.087 0.157 0.041
C18 0.367 0.235 0.039 3.580 29.082 39.987 12.178
C19 0.164 0.204 0.032 1.850 48.900 31.312 5.196
C20 0.160 0.220 0.067 1.160 39.783 22.897 10.624
C21 0.119 0.143 0.047 1.700 58.046
* nmoles.min" .mg k.min
58.451
mg"1. X = insufficient sam ple to p rocess
11.813
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Appendix 2(b) -  Disease control muscle mitochondrial enzyme values for all samples 
assayed. Activities per citrate synthase activity, protein concentrations and activity as a 
ratio o f protein concentration are shown.
Activity / CS activity Protein Activity / Protein Concentration
I If/Ill IV (mg/ml) r ii/nr IV**
D1 0.263 0.190 0.063 2.410 44.087 44.522 7.102
D3 0.177 0.223 0.022 2.120 28.529 35.943 13.485
D4 0.109 0.308 0.034 1.900 47.323 40.260 11.963
D5 0.115 0.140 0.017 1.500 56.289 34.470 12.854
D6 0.202 0.132 0.016 2.600 47.815 24.274 17.691
D7 0.260 0.350 0.032 2.000 13.064 14.663 5.821
D8 0.234 0.226 0.033 3.700 26.060 39.680 16.463
D9 0.134 0.186 0.051 3.100 11.648 12.560 12.195
D10 0.268 0.180 0.026 5.200 11.223 13.620 5.253
D11 0.243 0.170 0.039 4.090 40.697 54.785 5.009
D12
* nmo
0.203
es.min'1.mg‘
0.205 
1 **k.min‘1.r
0.033
ig'1-
1.900 42.736 52.281 12.737
215
Appendix 2(c) -  Patient (disease) mitochondrial enzyme muscle values for all samples 
assayed. Activities per citrate synthase activity, protein concentrations and activity as a 
ratio o f protein concentration are shown.
Activity / CS activity Protein Activity / Protein Concentration
I ll/lll IV (mg/ml) I* ii/nr IV**
PA1 0.198 0.137 0.035 5.350 19.380 22.647 3.831
PA2 0.131 0.093 0.039 2.130 31.689 41.330 10.559
PA3 0.172 0.201 0.034 2.030 26.419 18.756 7.865
PA4 0.152 0.156 0.048 3.160 43.037 58.950 16.037
PA5 0.241 0.163 0.057 4.430 16.696 23.678 10.777
PA6 0.140 0.230 0.035 1.980 44.935 24.762 22.813
PA7 0.110 0.156 0.071 3.450 37.139 12.998 7.525
PA8 0.520 0.182 0.051 2.870 36.861 52.200 15.833
PA9 0.270 0.380 0.022 2.160 42.978 29.068 10.094
PA10 0.260 0.144 0.044 3.660 57.408 58.790 5.021
PA11 0.340 0.201 0.050 3.040 37.076 21.951 5.452
PA12 0.270 
.  .1  -1
0.237 
**. . -1
0.050
.1
1.840 44.814 40.663 X
* nmoles.min"1.mg'1 **k.min'1.mg"1. X = insufficient sample to process.
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Appendix 2(d) — Muscle absolute aconitase activities for all normal (control) samples
shown with corrected values for sample protein concentrations.
Sample Uncorrected 
Aconitase Activity 
(mmol/min/ml)
Protein Concentration 
(mg/ml)
Corrected
Activity
(mmol/min/mg)
C2 14.48 1.64 8.83
C3 29.70 3.88 7.66
C7 10.20 3.37 3.03
C8 60.72 3.96 15.33
C9 78.59 3.58 21.95
C11 2.37 1.84 1.29
C12 33.72 2.44 13.82
C14 12.91 1.15 11.23
C15 46.20 1.16 39.73
C18 15.18 2.34 6.49
C19 64.36 3.53 18.23
C20 37.94 3.98 9.53
C21 31.11 2.49 12.49
Appendix 2(e) -  Muscle absolute aconitase activities for all disease control samples 
shown with corrected values for sample protein concentrations.
Sample Uncorrected 
Aconitase Activity 
(mmol/min/mi)
Protein Concentration 
(mg/ml)
Corrected
Activity
(mmol/min/mg)
D1 6.61 2.40 2.75
D3 34.86 0.90 38.73
D4 21.60 2.12 10.19
D5 3.32 0.73 4.55
D6 36.49 1.50 24.32
D7 25.42 1.13 22.50
D12 48.05 5.00 9.61
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Appendix 2(f) -  Muscle absolute aconitase activities for all patient (ALS) samples shown
with corrected values for sample protein concentrations.
Sample Uncorrected 
Aconitase Activity 
(mmol/min/ml)
Protein Concentration 
(mg/ml)
Corrected Activity 
(mmol/min/mg)
PA1 24.24 5.35 4.53
PA2 63.75 3.40 18.75
PA4 35.46 3.04 11.66
PA5 21.09 0.62 34.02
PA7 13.52 4.50 3.00
PA8 27.63 1.12 24.67
PA9 24.54 4.43 5.54
PA10 9.89 3.48 2.84
PA11 17.10 1.10 15.55
PA12 31.72 2.16 14.67
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Appendix 2(g) -  Myoblast mitochondrial respiratory chain specific activities for control
(C), disease control (D) and patient (PA) samples.
Complex activities a s  a Ratio of Citrate Synthase Activity
Sample I ll/lll IV
C2 0.129 0.164 0.052
C4 0.160 0.259 0.072
C5 0.285 0.267 0.058
C6 0.086 0.297 0.025
C7 0.270 0.440 0.050
C12 0.185 0.228 0.056
C14 0.215 0.244 0.014
C15 0.138 0.212 0.042
C17 0.146 0.287 0.078
C19 0.104 0.307 0.046
C20 0.100 0.491 0.031
D3 0.142 0.228 0.040
D4 0.198 0.270 0.006
D5 0.100 0.278 0.030
D6 0.176 0.296 0.087
D7 0.080 0.328 0.029
D8 0.301 0.359 0.022
PA1 0.119 0.251 0.043
PA2 0.243 0.276 0.018
PA3 0.092 0.087 0.008
PA4 0.062 0.498 0.053
PA5 0.152 0.212 0.045
PA6 0.150 0.158 0.019
PA8 0.083 0.255 0.030
PA10 0.142 0.310 0.037
PA11 0.269 0.193 0.025
PA12 0.220 0.360 0.050
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Appendix 2(h) -  Fibroblast mitochondrial respiratory chain specific activities for control
(C), disease control (D) and patient (PA) samples.
Complex Activities a s  a Ratio of Citrate Synthase Activity
Sample I ll/lll IV
C2 0.149 0.157 0.042
C3 0.063 0.181 0.043
C4 0.174 0.120 0.026
C5 0.100 0.255 0.033
C6 0.263 0.157 0.028
C11 0.090 0.328 0.082
C12 0.262 0.202 0.056
C18 0.250 0.330 0.046
C19 0.093 0.324 0.014
D3 0.163 0.258 0.053
D5 0.386 0.200 0.009
D6 0.228 0.233 0.014
D7 0.170 0.316 0.058
D8 0.186 0.248 0.053
PA3 0.169 0.209 0.039
PA4 0.176 0.152 0.043
PA5 0.105 0.199 0.052
PA6 0.073 0.307 0.088
PA7 0.079 0.209 0.048
PA8 0.077 0.232 0.032
PA9 0.252 0.383 0.070
PA10 0.144 0.280 0.040
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Appendix 2(i) -  Platelet-derived cybrid mitochondrial respiratory chain specific activities
for control (C), disease control (D) and patient (PA) samples.
Complex Activities a s  a Ratio of Citrate Synthase Activity
Sample I ll/ill IV
C21 0.498 0.328 0.016
C9 0.283 0.193 0.073
C18 0.397 0.304 0.094
C19 0.275 0.296 0.074
C20 0.270 0.270 0.074
C14 0.151 0.407 0.055
D1 0.580 0.240 0.033
D6 0.254 0.286 0.034
D8 0.244 0.350 0.038
PA7 0.195 0.415 0.069
PA2 0.315 0.400 0.068
PA3 0.206 0.127 0.028
PA4 0.199 0.460 0.041
PA10 X 0.313 0.088
PA11 0.320 0.440 0.050
PA12 0.650 0.350 0.070
X = insufficient sam ple to process.
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Appendix 2(j) -  mtDNA and nDNA signals o f control (C), disease control (D) and patient 
(PA) skeletal muscle samples determined by phosphoimaging o f 32P-signals after 
Southern blot hybridiasation along with the number o f bands seen on IrPCR for each
sample.
Sample mtDNA Signal nDNA Signal Ratio
mtDNA/nNA
Number of 
Bands
C3 36354 26227 1.39 X
C4 X X X 6
C8 244884 255555 0.96 9
C9 X X X 6
C11 94612 62987 1.50 1
C12 57505 58408 0.98 1
C14 122132 230626 0.53 8
C14 180546 190867 0.95 8
C15 57983 112661 0.07 1
C16 X X X 1
C17 40425 43692 0.93 1
C18 54157 48044 1.13 1
C19 72320 54528 1.33 2
C20 58266 45533 1.28 X
C21 118319 154756 0.76 X
D1 X X X 1
D3 178898 103498 1.73 1
D4 X X X 1
D5 X X X 1
D6 119805 141568 0.85 5
D7 77262 74999 1.03 1
D11 X X X 2
D12 X X X 1
PA1 130592 114765 1.14 5
PA2 86744 167345 0.52 7
PA3 49381 33979 1.45 1
PA4 30427 53634 0.57 13
PA5 102651 81548 1.26 6
PA6 98523 111638 0.88 X
PA7 57430 44775 1.28 8
PA8 131555 Air bubble X 1
PA9 49781 38022 1.31 1
PA10 30038 32123 0.94 X
PA11 91209 47786 1.91 1
PA12 107055 129315 0.83 X
X = insufficient sam ple to process.
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Appendix 2(k) Absolute aconitase activity per mg o f protein measured in control (C), 
disease control (D) and patient (PA) cybrids grown at different paraquat concentrations. 
The percentage fall in aconitase activities between different concentrations is shown.
Aconitase Activity at Different Paraquat 
Concentrations (mmol.min'1.m g'1)
% Fall in Aconitase Activity
Sample 0 mM 0.1 mM 1 mM 0 versus 0.1 mM 0 versus 1 mM
C14 6.2 1.2 0.03 80.7 99.5
C18 4.6 1.0 0.3 79.1 94.1
C19 3.4 0.7 0 80.0 100
C20 12.7 1.6 0 87.4 100
C21 5.5 0.3 0 94.5 100
D1 9.4 0.4 0 95.4 100
D6 5.6 0.5 0 90.9 100
D8 10.9 0.9 0 92.1 100
PA2 7.9 0.2 0 97.6 100
PA3 13.0 4.1 0 68.5 100
PA4 5.9 0.5 0 91.5 100
PA7 3.7 0.6 0 84.1 100
PA10 3.0 0.1 0 97.0 100
PA11 6.2 1.5 0 75.8 100
PA12 13.5 4.5 0 66.7 100
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Appendix 2(1) Absolute aconitase activity per mg o f protein measured in control (C), 
disease control (D) and patient (PA) myoblasts grown at different paraquat 
concentrations. The percentage fall in aconitase activities between different 
concentrations is shown.
Aconitase Activity at Different 
Paraquat Concentrations 
(mmol.min'1.mg'1)
% Fall in Aconitase Activity
Sample OmM 0.05 mM 0.1 mM 1 mM 0 versus 
0.05 mM
0 versus 
0.1 mM
0 versus 
1 mM
C5 1.9 0.6 0.0 0.0 70.5 100 100
C6 1.5 1.0 1.0 0.3 33.3 34.0 80.7
C7 2.2 1.9 1.0 0 14.8 55.2 100
C8 6.0 2.9 1.2 0 50.6 79.8 100
C14 1.5 0.5 0.9 0 65.3 43.3 98.7
C17 3.7 0.8 0.2 0 77.4 95.4 100
C18 6.4 4.8 2.6 0 25.0 59.4 90.6
C21 1.9 1.0 0.6 0 47.4 69.5 100
D3 3.3 0.9 0.4 0 72.5 89.3 100
D4 7.2 3.3 0.7 0 54.0 89.8 100
D6 7.2 0.7 0.6 0.4 90.7 91.8 95.1
D7 5.7 2.1 1.5 1.0 63.2 73.3 82.5
D8 6.8 2.2 1.4 0.8 67.1 79.4 88.2
PA1 8.4 1.7 0.9 0 80.1 89.3 100
PA2 2.3 0.4 0.0 0 81.3 100 100
PA3 3.0 1.7 0.1 0 43.9 97.0 100
PA4 4.6 0.9 0.0 0 80.4 100 100
PA6 4.2 2.3 1.1 0.1 45.2 73.8 97.4
PA8 5.1 2.3 0.1 0 54.9 98.0 100
PA9 6.0 2.3 1.6 1.1 61.9 73.5 82.1
PA10 2.6 0.8 0.2 0 70.2 91.4 100
PA11 2.3 0.4 0.3 0 83.6 85.8 100
PA12 5.0 1.6 0.1 0 68.0 98.8 100
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Appendix 2(m) Absolute aconitase activity per mg o f  protein measured in control (C), 
disease control (D) and patient (PA) fibroblasts grown at different paraquat 
concentrations. The percentage fa ll in aconitase activities between different 
concentrations is shown.
Aconitase Activity a t Different Paraquat 
Concentrations (mmol.min'1.mg*1)
% Fall in Aconitase 
Activity
Sample OmM 0.1mM 1mM 0 versus 0.1 mM 0 versus 1 mM
C2 1.6 1.0 0.1 39.1 91.3
C3 1.2 0.2 0.0 81.1 97.1
C4 2.0 0.6 0.1 69.8 95.0
C5 2.1 1.1 0.1 47.9 94.2
C 2.0 0.2 0 89.3 100
C11 2.7 0.3 0.3 90.6 90.6
C18 2.6 0.8 0 69.2 100
D3 3.1 0.6 0.1 80.3 97.1
D5 0.7 0.3 0.1 56.9 92.2
D6 0.7 0.2 0 79.7 100
D7 1.2 0.1 0 90.0 100
D8 1.7 0.2 0 87.2 100
PA3 1.4 0.1 0 93.8 100
PA4 0.8 0.0 0 100.0 100
PA6 1.1 0.1 0 91.1 100
PA7 1.5 0.3 0.1 83.1 96.1
PA8 2.8 0.8 0 70.7 98.6
PA9 1.1 0.1 0 90.8 100
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Appendix 2(n) Relative proportions o f apoptotoic (caspase-activated) cells and 
unaffected cells in control (C), disease control (D) and patient (PA) cybrid cultures 
grown in different paraquat concentrations. The percentage change in the levels o f 
apoptosis seen between different concentrations o f paraquat is also shown.
Ratio of Apoptotic to  Non-apoptotic Cells 
Seen in Different Paraquat 
Concentrations
% Change in Apoptosis Levels
Sample 0 mM 0.1 mM 1 mM 0 versus 0.1 mM 0 versus 1 mM
C14 0.07 0.15 0.36 112.86 411.43
C18 0.00 0 0.17 0 165.00
C19 0.04 0.10 0.06 140.00 50.00
C20 0.01 0.01 0.01 14.29 28.57
C21 0.06 0.08 0.07 40.35 26.32
D1 0.03 0.04 0.09 61.54 242.31
D6 0.06 0.07 0.29 4.69 348.44
D8 0.17 0.11 0.16 -36.47 -5.88
PA2 0.05 0.06 0.08 11.11 44.44
PA3 0.07 0.17 0.25 142.86 251.43
PA4 0.02 0.04 0.03 100.00 50.00
PA7 0.00 0.01 0 7.00 37.00
PA10 0.06 0.09 0.12 50.00 100.00
PA11 0.01 0.01 0.04 44.00 311.00
PA12 0.04 0.02 0.02 -43.24 -43.24
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Appendix 2(o) Relative proportions o f apoptotoic (caspase-activated) cells and 
unaffected cells in control (C), disease control (D) and patient (PA) myoblast cultures 
grown in different paraquat concentrations. The percentage change in the levels o f 
apoptosis seen between different concentrations o f  paraquat is also shown.
Ratio of Apoptotic to Non-apoptotic Cells 
Seen in Different Paraquat C oncentrations
% Change in Apoptosis 
Levels
Sample 0 mM 0.1 mM 1mM 0 versus 0.1 mM 0 versus 1 mM
C2 0.08 0.09 0.10 14.63 17.07
C5 0.11 0.14 0.29 27.27 163.64
C6 0.06 0.11 0.10 96.43 78.57
C7 0.05 0.13 0.10 150.94 88.68
C16 0.06 0.18 0.14 195.08 129.51
C17 0.12 0.14 0.19 16.67 58.33
C18 0.17 0.20 0.13 17.65 -23.53
C20 0.11 0.16 0.29 45.45 163.64
C21 0.14 0.17 0.20 21.43 42.86
D5 0.07 0.11 0.15 57.14 114.29
D6 0.05 0.16 0.17 220.00 240.00
D7 0.13 0.13 0.17 3.17 34.92
D8 0.21 0.36 0.30 71.43 42.86
PA1 0.07 0.17 0.25 142.86 257.14
PA2 0.10 0.33 0.49 230.00 390.00
PA3 0.09 0.10 0.20 6.38 112.77
PA4 0.06 0.12 0.18 118.18 227.27
PA6 0.16 0.30 0.43 87.50 168.75
PA7 0.13 0.30 0.53 130.77 307.69
PA8 0.14 0.23 0.27 64.29 92.86
PA10 0.07 0.32 0.39 338.36 434.25
PA11 0.07 0.23 0.24 228.57 242.86
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Appendix 2(p) Relative proportions o f  apoptotoic (caspase-activated) cells and 
unaffected cells in control (C), disease control (D) and patient (PA) fibroblast cultures 
grown in different paraquat concentrations. The percentage change in the levels o f 
apoptosis seen between different concentrations o f  paraquat is also shown.
Ratio of Apoptotic to  Non-apoptotic Cells 
Seen in Different Paraquat Concentrations
% Change in Apoptosis 
Levels
Sample 0 mM 0.1 mM 1 mM 0 versus 0.1 mM 0 versus 1 mM
C2 0.25 0.30 0.40 20.00 60.00
C3 0.02 0.02 0.03 -21.26 42.86
C4 0.13 0.31 0.15 137.42 14.81
C5 0.04 0.02 0.06 -46.43 40.45
C6 0.05 0.07 0.06 27.71 4.04
C7 0.24 0.33 0.28 37.50 16.67
C11 0.12 0.13 0.15 9.17 25.00
C18 0.53 0.08 0.58 -84.91 9.43
C19 0.09 0.11 0.39 18.89 333.33
D3 0.06 0.02 0.08 -63.53 53.48
D5 0.09 0.14 0.15 55.56 66.67
D6 0.26 0.19 0.38 -26.92 46.15
D7 0.18 0.05 0.40 -71.43 128.57
D8 0.15 0.32 0.34 113.33 126.67
PA3 0.10 0.20 0.40 100.00 300.00
PA4 0.06 0.04 0.07 -28.57 24.62
PA7 0.06 0.04 0.12 -36.05 91.52
PA6 0.25 0.68 0.67 172.00 168.00
PA9 0.34 0.72 0.92 111.76 170.59
PA8 0.05 0.10 0.13 100.00 150.00
PA10 0.07 0.13 0.16 85.71 128.57
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